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ABSTRACT  
Diseased heart valves are commonly replaced by mechanical, bioprosthetic, or 
allograft heart valves. These replacements provide major improvements in cardiac 
function and quality of life, but have significant limitations and eventually require surgical 
replacement within 15-20 years. These risks are particularly prominent in pediatric 
patients and young adults. The field of tissue engineering and regenerative medicine, 
which combines scaffolds and cells, holds great promise in developing living replacement 
heart valves that would self-repair and grow in size along with the growing children. 
The long-term goal of this project is to generate living, tissue-engineered heart 
valves from biological scaffolds and autologous stem cells – a goal that hinges on our 
ability to create tissue devices that withstand mechanical stresses immediately upon 
implantation without posing risks of immunological rejection. We hypothesized that 
these valves can be generated by optimal integration of three main factors: acellular heart 
valve root scaffolds, autologous stem cells, and construct preconditioning in a bioreactor. 
Furthermore, we hypothesized that the valves would not be generated without advanced 
bioreactor systems for the development, conditioning, and translation to clinical practice. 
To reach this goal, we developed integrated platform technologies for complete 
aortic valve root (AVR) decellularization, stem cell seeding, and dynamic conditioning 
before implantation. Unique features include universal “no touch” valve-mounting devices, 
decellularization in a purpose-designed pulsatile perfusion system, and techniques for in 
vitro re-vitalization with adipose tissue-derived stem cells (hADSCs) followed by 
progressive conditioning in our heart valve bioreactors. Acellular porcine AVRs seeded 
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with autologous (sheep) ADSCs were implanted in 10 sheep as right ventricle to 
pulmonary artery shunts with complete clamping of the pulmonary aorta. 
Results showed perfect decellularization of the entire porcine AVR and almost 
complete seeding with ADSCs. Bioreactor studies revealed stem cell pre-differentiation 
into cells resembling valvular interstitial cells as a response to dynamic stimulation. 
Animal studies with follow-ups to 12 months are ongoing. 
Novel customized devices and bioreactor systems are vital to the successful 
development of tissue engineered heart valve products, especially in preparation for 
clinical translation. Herein is described some of the basic equipment and expertise 
necessary for the successful development of tissue-engineered cardiovascular products. 
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CHAPTER 1: BACKGROUND INFORMATION 
1.1 Anatomy and Physiology 
1.1.1 Cardiac Anatomy and Physiology 
The heart has two double-chambered pumps pictured in Figure 1-1, which 
demonstrates the pressures and flow through the chambers. The right pump pushes blood 
through the lungs, where waste gases are exchanged for nutritional gasses while the left 
pump propels blood through the peripheral organs. Within each pump, blood first enters 
the superior chamber, the atrium, which moves the blood through an atrioventricular 
valve into the ventricle, the inferior chamber. When these ventricles contract, blood 
propels through the pulmonary (right side) valve or ventricular (left side) valve and 
through the rest of the body. Following contraction, the pulmonary and aortic valves 
close to prevent blood flow back 
through the heart.[1]  
The pumping heart is a 
dynamic feedback system that 
changes its physical and chemical 
outputs according to the body’s 
needs. Under average normal 
resting conditions, the heart beats 
about 70 times per minute (bpm), 
ejecting 70 mL (stroke volume) of 
its left ventricular volume of 120 
 
Figure 1-1: Blood flow through the heart 
Normotensive blood pressures are given in the green boxes for 
each chamber or area of the heart. However, these values can 
vary greatly and still be considered normal.[1,180] 
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mL (end-diastolic volume) each beat.[2,3] This results in a total of about 4.9 liters of 
blood flow per minute. The ventricles’ cyclic contractions create pressures that drive the 
blood through the circulatory system. Upon contraction, the pressure in the left ventricle 
increases to approximately 120 mmHg. Almost simultaneously, the aortic valve snaps 
shut and blood flows away from the heart along the pressure gradient. As the pressure in 
the aorta drops toward 80 mmHg, the left ventricle has begun its contraction to pump 
another bolus of blood and return the pressure to 120 mmHg. Figure 1-2 shows the left 
ventricular volumes and pressures as described above.[1]  
 
Figure 1-2: The cardiac cycle for the left heart 
By studying the pressure and volume correlations with time, we can understand the function and 
performace features of the heart that allow it to perform incredibly over a person’s lifetime.[1] 
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1.1.2 Valvular and Cellular Anatomy 
Aortic Valves, Cusps, and Extracellular Matrix 
The heart valves are excellent examples of durability, design, and adaptability not 
found in man-made materials. The physiological composition of a human aortic heart 
valve is optimized to withstand rigorous physical stresses and to respond to  small 
pressure changes during the diastolic and systolic stages of the cardiac cycle. It is 
constructed with very strong, yet very pliable fibrous tissue with three heterogeneous 
cusps attached to an annular ring  and wall 
of the aorta (Figure 1-3a).[4] With every 
beat of the heart, the aortic valve, which 
acts as a one-way check valve, is opened to 
progressively move blood through the 
pulmonary and systemic circulation of the 
body and closed to prevent retrograde flow 
during diastole.[1,5] The continuous 
performance at 850 milliseconds per cycle 
leads to a lifetime average of more than 
three billion cycles.[6,7] Further, the 
trans-valvular pressures across the aortic 
valve change from roughly zero to 120 
mmHg in the course of only 17-20 
milliseconds that is required for the valves 
to close. This leads to a 13% 
 
Figure 1-3: Aortic valve anatomy 
a) Aortic valve dissected for viewing.[181] b) cross 
section of a cusp, showing the three layers.[182] 
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circumferential and a 24% radial cusp stretch.[7] As a result, the heart valves are 
unequivocally the most mechanically stressed tissues in the body.[8] 
The cusps themselves have almost no blood vessels, but are thin enough to be 
nourished predominately by diffusion from blood.[1] They also have no active part in 
opening and closing, but act solely in a passive manner in response to flow and pressure 
differentials. When they open during systole, they press against the aortic root wall and 
when they snap close at the start of diastole, they perfectly align to create a seal that can 
prevent backflow even with the 100 mmHg transvalvular pressure difference.[1] The 
free edge of each cusp attaches to the portion of the aortic root surrounding one of the 
three aortic sinuses. The indentations of these sinuses change the fluid dynamics of the 
valve and likely cause the formation of vortices that aid valve closure.[9] Two of the 
sinuses lead to coronary arteries and are therefore named the left coronary, right coronary, 
and noncoronary sinuses. 
The aortic valve cusps are comprised of three distinct layers: the ventricularis, 
spongiosa, and fibrosa. These layers contain valvular endothelial cells (VECs), valvular 
interstitial cells (VICs), collagen, elastin, and glycosaminoglycans (GAGs) in a formation 
that provide the necessary biomechanical properties to withstand the 40 million rigorous 
cycles of loading each year. Figure 1-3b shows a view of the aortic valve and a cross-
sectional view of a cusp. Error! Reference source not found. displays each component’s 
locations and major functions. Collagen gives the valve strength to withstand the 
pressures when closed while maintaining coaptation. Elastin extends and recoils in every 
valve cycle as the cusp moves. GAGs absorb the shear forces between the ventricularis 
and fibrosa layers.[10] 
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Valvular Endothelial Cells 
Although VECs are very similar to other endothelial cells at their basic structural 
and functional levels, they are phenotypically distinct from endothelial cells in various 
locations in the circulatory system, even in locations in close proximity, such as the 
adjacent aortic wall. Their differences possibly allow VECs to interact with VICs to 
mediate disease and maintain valve tissue integrity. An example of differences between 
VECs and other endothelial cells is their alignment perpendicular to flow while most 
endothelial cells align parallel to flow and their transcriptional gene expression profiles 
differ under the same mechanical environment. Differences even go so far as to distinguish 
between transcriptional profiles of endothelial cells on the aortic side versus the 
ventricular side of cusps.[10,11] 
Table 1-1: Key cellular and extracellular matrix components of the aortic valve 
Although not isolated in regions, many components of the aortic valve have primary locations and 
functions.[10,183,184] 
Component Location Putative Function Comments 
Endothelial 
cells (VECs) 







Role in transducing shear and 
modulating VIC function; Functional 
differences from vascular wall EC 
Interstitial 
cells (VICs) 






Currently considered the major 
modulator of long-term valve durability 





aligned in fibrosa 
layer. 
Provides strength and 
stiffness to maintain 
coaptation against the 
pressure gradient 
during diastole 
Likely the most important structural 
element; Crimp and alignment provide 
directional anisotropy of properties 








Absorb shear and 
cushion shock 
between ventricularis 
and fibrosa during 
cyclical valve motion 




radially aligned in 
ventricularis layer 
Maintains valve 
resilience and allows 
stretch in response to 
pressure changes 
Extend in diastole, recoil in systole 
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Valvular Interstitial Cells 
VICs are the most abundant type of cell in the heart valve. Under normal 
conditions, they synthesize extracellular matrix (ECM), and express matrix-degrading 
enzymes such as matrix metalloproteinases (MMPs) and MMP tissue inhibitors (TIMPs). 
These syntheses explain how VICs mediate the remodeling of the ECM structural 
components, thereby continuously repairing functional damage to collagen and other 
ECM components in the valve.[11] In all, five distinct phenotypes of VICs have been 
classified, providing a diverse and dynamic population of cells in the valve. They include 
embryonic progenitor endothelial/mesenchymal cells (eVICs), quiescent VICs (qVICs), 
activated VICs (aVICs), postdevelopmental/adult progenitor VICs (pVICs), and 
osteoblastic VICs (obVICs).[12] Error! Reference source not found. gives a brief 
overview of the characteristics of all five phenotypes of VICs. 
A vast majority of adult VICs in situ are qVICs, having characteristics of 
fibroblasts. qVICS phenotypically change into myofibroblast-like aVICs upon external 
Table 1-2: Characteristics of VIC phenotypes 
CD34 and CD133 are stem cell markers; S100 is an intracellular calcium-biniding protein.[11,12] 
Cell Type Location Function 
eVICs Embryonic cardiac cushions 
Give rise to resident qVICs, possibly through an activated 
stage; EMT can be detected by the loss of endothelial 
markers and gain of mesenchymal markers 
qVICs Heart valve leaflet Maintain physiological, normal valve structure and function and inhibit angiogenesis in the leaflets 
pVICs Bone marrow, circulation, and/or heart valve leaflet 
Enter valve or are resident in valve to provide aVICs to 
repair the heart valve, may express CD34, CD133, and/or 
S100 
aVICs Heart valve leaflet 
α-SMA containing VICs with activated cellular repair 
processes including proliferation, migration, and matrix 
remodeling; respond to valve injury caused by pathological 
conditions and abnormal hemodynamic/mechanical forces 
obVICs Heart valve leaflet 
Mediate calcification, chondrogenesis, and osteogenesis in 
the heart valve; secrete alkaline phosphatase, osteocalcin, 
osteopontin, bone sialoprotein 
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macroscopic stimuli such as alterations in the mechanical environment, certain chemical 
signals, or in response to injury. aVICs are characterized by an increase in stiffness, 
expression of alpha smooth muscle actin (α-SMA), and increased ECM biosynthesis.[13] 
This phenotypic change is healthy at a small scale for repair, but is widespread during 
development, after abrupt changes in the mechanical stress state of valves, and in disease 
states. 
In conditions that promote valve calcification, qVICs and possibly pVICs can 
differentiate into obVICs, which actively participate in the valve calcification process. 
There is currently no evidence that obVICs are a separate cell population from aVICs, 
but the osteoblastic differentiation and calcification promotion of VICs significantly 
differs from normal aVIC activity, thereby warranting its own category.[12] 
Summary of VIC Phenotype Markers 
eVICs are present in development. Similar processes are thought to be present in 
the initial stages of disease, but a distinct cell type is not anticipated in these mature 
sources.  
qVICs show two types of intercellular junctions: gap junctions and adhesion 
junctions, as seen by the expression of transmembrane gap junction proteins Connexin-
26 and -45. Cell-cell adhesion junctions are especially present between the long processes 
of adjacent cells as detected by small amounts of N-Cadherin and desmoglein.[12]  
pVICs are found as other cell types in the body such as endothelial progenitor cells 
(EPC) and dendritic cells (DC). EPCs can be identified by stem cell markers such as 
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CD133 and CD34, a high proliferative capacity, and the ability to form blood vessels. DCs 
are identified by an intracellular calcium binding protein, S100.[12] 
aVICs are most often characterized by expression of α-SMA, which is normally 
not found in qVICs. They also have the features of myofibroblasts: increased contraction, 
prominent stress fibers, and other contractile proteins. Activated VICs also increase the 
secretion of cytokines, such as TGF-β.[12] 
obVICs express markers that characterize osteoblasts in bone such as alkaline 
phosphatase, osteocalcin, and osteopontin. There is no clearly defined method of 
identifying a VIC in the osteoblastic state.[11] 
1.2 Aortic Valvular Disease 
1.2.1 Worldwide Prevalence 
Although most people’s heart valves will last their entire lifetime and cycle about 
3 billion times, about 2% of the American population will be affected by heart valve 
disease.[14] By 2011, it was estimated that roughly four million people in the United 
States were diagnosed annually with a heart valve disorder.[15] Worldwide, over 
300,000 heart valves are replaced every year.[15–17]  
However, this number is not representative of the actual number patients in need 
of valve replacements. Statistically, 80% of all cardiovascular disease occurs in developing 
countries,[18–20] but 85% of all open-heart procedures are performed in developed 
countries representing 11% of the world population.[21,22] In developing countries, 
economies cannot support the vast number of open heart surgeries or valve replacements 
that would actually help the population. Furthermore, in those developing countries, we 
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see that it is children and young adults[20,21] that are the demographic most affected, 
not the population over 65 as is seen in the United States.[23] 
While the majority of causes for heart valve diseases in industrialized nations is 
degenerative pathology, inhabitants of developing nations also often suffer from the 
persistent burden of rheumatic fever.[15,24] However, As the economies of these 
developing countries grow, so will healthcare. The cause of valve degeneration will  shift  
and cardiac surgery will become increasingly more accessible to potentially millions more 
who are in need of valve replacements.[21] 
1.2.2 Causes for Valve Disease 
In a normal heart valve, the cyclical stresses (which are often exacerbated in cases 
of genetically malformed valves) and other systemic conditions[20,25] damage the valve 
in the form of micro tears and calcific deposits that must be continuously repaired by the 
specialized valvular interstitial cells (VICs).[7,12,26–29] Mechanical cues play an 
important role in this delicate regulation.[30–33] When an imbalance occurs in this 
damage-repair cycle,[20,34,35] the valve can become diseased.[35–37]  
Valve disease most often occurs in the aortic valve and is commonly classified into 
two main types of abnormalities that disrupt blood flow: regurgitation and stenosis. In 
aortic stenosis, the left ventricle fails to empty adequately following contraction due to  
the aortic valve not opening properly This creates a reduction in the valvular orifice. In 
aortic regurgitation, blood flows backward into the left ventricle after contraction due to 
the aortic valve failing to close properly. This can be caused by stenosis as well as other 
factors.[1] 
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The most frequent cause for aortic regurgitation is stenosis, which occurs when 
the cusps thicken, stiffen, or fuse together, most often due to calcific nodule formation.[38] 
This is most often a result of many risk factors that increase with age, but can also be 
seen in younger patients, especially those with congenital defects such as improper valve 
size, malformed leaflets, or an irregularity in the way the leaflets are attached.[24,39,40] 
In fact, evidence of a high percentage of valve replacement surgery patients having 
congenital abnormalities[41] suggests that patients with a congenital valve defect are 
predisposed to valve disease.[14] Stenosis may also be caused by damage acquired after 
birth as described above such as calcific deposits, changes in the structure of the valve, or 
infections like infective endocarditis and rheumatic fever. 
While there are various causes for each of these problems, the final outcome is the 
same. Both stenosis and regurgitation lead to a reduction in the net stroke volume output 
of the heart, causing it to work harder to pump the same amount of blood through the 
body. Patients suffering from valvular heart disease will eventually need surgical 
intervention to repair or, more frequently, replace the damaged heart valve.[1] 
1.3 Valvular Interstitial Cell Contributions to Stenosis 
1.3.1 Curing Valve Stenosis 
The ability to stop progression, if not completely reverse calcification would be 
the optimal cure for stenotic valvular heart disease. This cure would help the roughly 
30% of patients[42] previously classified as untreatable because they were unable to 
undergo the necessary surgery due to their age, poor health, or immune compromised 
status. The option of a pharmaceutical approach instead of surgical treatment would 
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reduce the factors that often accompany surgery such as hospital recovery, infection, and 
anxiety of open heart surgery.  
This relatively new idea of medicinal treatment has developed in the last 10-15 
years as researchers have found evidence that valvular stenosis is not a passive deposition 
of calcium with degeneration, but is actually an active biological process involving 
endothelial dysfunction, lipid accumulation, inflammation, ostegenic processes, and 
multiple ubiquitous cellular pathways.[14,43,44] Some research in human aortic valves 
and in vivo animal models even suggest that degenerative valvular aortic stenosis is the 
result of active bone formation in the aortic valve that may be mediated by osteoblast-like 
differentiation processes.[45] 
As the evidence grows for an active process of calcification rather than a passive 
occurrence, novel areas are being investigated such as how to identify and classify the 
types of valvular interstitial cells (VICs), determining which exogenic factors contribute 
to calcium formation, and determining which endogenic pathways are involved in the 
pathology of this disease. 
1.3.2 Factors Contributing to VIC Phenotype Shifts and Calcification 
In normal valve function, the macroscopic mechanical stimuli like shear and solid 
stresses are translated into microscopic forces that impact VIC and VEC function. Sensing 
the local tissue microenvironment in response to the external factors, they transduce 
forces through cell-cell and cell-ECM interactions that mediate normal valve function 
and pathobiology. They also respond by transdifferentiating to perform phenotype-
specific duties of maintaining homeostasis, adapting to altered stress states, and repairing 
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ECM components.[10] This phenotypical shift in VICs is a normal occurrence under 
many circumstances. However, certain factors have been identified that excessively 
promote this effect and even cause the cells to start producing calcium, as in obVICs. The 
pathways of this transdifferentiation are shown in Figure 1-4, showing known and 
possible transitions. While there is not a complete knowledge base on every transition, 
some factors have been identified that contribute to certain changes in phenotype.[12] 
Embryonic Progenitor VICs (eVICs) 
eVICs are present during the developmental stages of life. Studies have shown 
that transforming growth factor beta (TGF-β), bone morphogenetic proteins (BMPs), 
Notch, and vascular endothelial growth factor (VEGF) have significant regulatory effects 
on eVICs becoming normal qVICs through the course of valve development. Correct 
levels of each are necessary to properly guide the differentiation.[12] 
Quiescent VICS (qVICs) 
Evidence shows that over several passages in cell culture, qVICs are activated and 
become aVICs, but these culturing conditions have not been deeply investigated in an 
isolated manner. Isolated 
factors that have been 
found to initiate this 
phenotypic shift in vitro 
include cyclic mechanical 
stretch and TGF-β  
Figure 1-4: Known and probable pathways of VIC transdifferentiation 
Hatched arrows depict possible transitions for which there is currently 
no solid evidence.[12] 
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treatment.[11] Moreover, these two factors are synergistic.[46] 
Post-developmental Progenitor VICs (pVICs) 
In response to injury, the number of VICs present increases quickly. This is now 
thought to be a result of pVICs from bone marrow-derived cells, circulating cells, and 
resident valvular progenitor cells being activated to become aVICs. It is not known 
whether pVICs go through the qVIC stage before becoming aVICs.[12] Two specific 
types of pVICs are the endothelial progenitor cell (EPC) and dendritic cell (DC). It is 
possible that these cells share a common circulating progenitor cell: the CD34+ 
hematopoietic stem cell. They have been shown to express mRNA for procollagen α1 and 
differentiate with morphological similarities to native VICs when engrafted into recipient 
heart valves.[47] Progenitor cells from the pulmonary valve have been isolated and 
shown to transition to VIC-like cells in response to TGF-β2. Interestingly, VEGF causes 
these same cells to become endothelium rather than mesenchymal VIC-like cells. 
Activated VICS (aVICs) 
aVICs are the master cells of valves. Under conditions of pathological injury or 
unusual hemodynamic or mechanical stress, qVICs become aVICs and take on the features 
of myofibroblasts. The characteristic marker for aVICs is α-SMA, which is normally not 
found in qVICs. In culture, many VICs may express α-SMA, while exhibiting a number 
of different morphologies. It is believed that under the exogenic factors of injury or 
unusual stress, VECs and macrophages/foam cells are activated, releasing chemokines 
and growth factors that stimulate qVIC activation.[12] The process surrounding aVIC 
activation and leading to valvular heart disease can be seen in Figure 1-5.  
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The normal adult heart valve is well adapted to its physiological environment, 
able to withstand the unique hemodynamic/mechanical stresses under standard 
conditions. Under conditions of pathological injury or abnormal 
hemodynamic/mechanical stresses, VICs become activated through activation of VECs 
and by inflammation and associated cytokine and chemokine signals. Macrophages will 
also be activated. aVICs increase matrix synthesis, up-regulate expression of matrix-
remodeling enzymes, migrate, proliferate and undergo apoptosis, and undergo osteoblast 
transformation. These processes are regulated by a variety of factors, several secreted by 
 
Figure 1-5: Pathways of clinical valve disease 
Pathological injury or abnormal hemodynamic/mechanical stresses can facilitate VICs activation through 
activation of VECs and by inflammation and associated cytokin and chemokine signals, which will also lead 
to macrophage activation. As a result, aVICS increase matrix synthesis, up-regulate expression of matrix-
remodeling enzymes, migrate, proliferate and undergo apoptosis, and undergo osteoblast transformation 
. under the regulation of a variety of factors including those secreted by the aVIC. Progressive clinical valve 
disease can then result from these cellular processes, angiogenesis, chronic inflammation, fibrosis, and 
calcification.[12] 
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the aVIC. If the aVICs continue to promote these cellular processes, angiogenesis, chronic 
inflammation, fibrosis, and calcification result, leading to progressive clinical valve 
disease.[12] 
Osteoblastic VICs (obVICs) 
Currently, there is no evidence that obVICs are a separate cell population from 
aVICs, but they can be classified as VICs that undergo osteoblastic differentiation and 
promote calcification as seen when VICs are cultured in osteogenic and chondrogenic 
culture medium. This classification is useful when considering the evidence of 
cartilaginous nodule and mature lamellar bone presence in explanted valves. Associated 
proteins such as osteopontin, bone sialoprotein, alkaline phosphatase, and BMP-2 and -4 
have also been found. 
Numerous factors have been identified that promote the active calcifying action of 
VICs: TFG-β, 25-hydroxycholesterol, and BMP-2 increased the rate of nodule formation 
when cultured in growth medium supplemented with organic phosphate; Oxidized 
cholesterol stimulates calcified nodule formation; BMPs and TGF-β caused osteoblastic 
differentiation of VICs; VIC calcification and ECM degradation is induced by MMPs and 
may be promoted by Tenascin and early growth response-1 (Egr-1); Oxidized lipids, 
tumor necrosis factor-α (TNF- α), and hyperglycemia may all mediate osteoblast 
differentiation and thus, valvular calcification through pathways activated by BMP2; and 
VECs may transduce external signals to VICs, regulating the aVIC or obVIC 
function.[12] 
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1.3.3 Pathology and Pathways 
Along with factors that affect the individual VIC phenotype and actions, there are 
many larger-scaled factors that contribute to VIC phenotype shifts and calcification. 
General risk factors include age, male gender, hypertension, diabetes mellitus, smoking, 
renal disease, hypercholesterolemia, hyperparathyroidism, and decreased bone mineral 
density.[45] Some literature suggests that the molecular mechanism resembles that of 
atherosclerosis[48] with hypercholesterolemia playing a role in this calcification,[45] 
but statin treatments have had mixed results. Therefore, the overall valvular tissue 
response to disease, which further exacerbates the problem, can be characterized by four 
major processes: 1) accumulation of VICs and inflammatory cells, 2) neovascularization 
or angiogenesis, 3) increased matrix production, and eventually 4) fibrosis and 
calcification.[12] Figure 1-6 shows some of the factors and mechanisms that will be 
discussed. 
Cells 
In response to injury, the number of VICs present increases quickly. This process 
is discussed above. Under normal conditions, when valve repair is complete, excess cells 
undergo apoptosis to restore the balance of cells in the valve. However, in α-actin-positive 
cells, mRNA and protein levels of the G1 and G2 cell cycle checkpoint genes 
p21WAF1/CIP1 and 14-3-3 sigma are down regulated several-fold, possibly giving rise 
to the observed increase in cellular density.[12,48] 
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Angiogenesis 
Normal valves are avascular, but a dramatic increase of angiogenesis in diseased 
conditions has been reported in a close association with valvular stenosis and 
inflammation. Endothelial cells in stenotic valves exhibit CEACAM1, a cell adhesion 
molecule involved in angiogenesis expressed in angiogenic but not quiescent endothelial 
cells. Angiogenic factors, VEGF and MMPs, have also been shown to play a role in valve 
pathology.[45] While the presence of these factors contribute to angiongenesis, down 
regulation of the angioinhibitory factor, chondromodulin-I (chm-I) has been seen to 
permit pathologic angiogenesis in coronary artery endothelial cells. The work partly 
described in Figure 1-6 is the basis for a newly proposed mechanism for the onset of aortic 
valve degeneration where angiogenesis is the main contributing factor.[48] 
ECM 
Certain proteins have been found in the matrix of cardiovascular calcifications that 
are not present in normal cardiovascular tissue. These include osteocalcin, osteopontin, 
osteonectin, TNF-α, BMPs, and many MMPs. Some components, such as the 
extracellular proteins tenascin C and cystatin C, alkaline phosphatase, Egr-1 (induces 
tenascin-C), are present in low levels in normal tissues, but have been found in higher 










Figure 1-6: Degenerative mechanisms in the cardiac valve 
The putative degenerative mechanisms for superficial endothelial cells, valvular interstitial cells, and 
extracellular matrices are shown (A–E). The table is a summary of several factors, including the function, 
mechanism (corresponding to A–E above), and effect on degeneration of the cardiac valve.[48] 
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obVIC Differentiation 
Some work has been done to identify which genes are expressed in obVICs. 
Characteristic gene expression includes those encoding osteocalcin, Sox9, Cbfa-1, Runx2, 
Osterix, Msx2 oteopontin, and bone sialoprotein. Additional genes that have been studied 
are receptor activator of nuclear factor kB ligand (RANKL) and osteoprotegerin (OPG). 
RANKL promotes matrix calcification and induces the expression of osteoblast-
associated genes, transitioning VICs toward an osteogenic phenotype. OPG is present in 
normal valves, but without it, calcification occurs.[14,45] 
Many signals present for cardiac valvulogenesis during development are also 
reported to be present in valve degradation. These include Wnt, TGF-β1, BMP, and 
Notch. In general, the overexpression of these signals results in valve disease and 
calcification.[48] 
1.3.4 Current State 
New observations in human aortic valves support the hypothesis that 
degenerative valvular aortic stenosis is the result of active bone formation in the aortic 
valve, which may be mediated through a process of osteoblast-like differentiation in these 
tissues.[45] 
Some underlying mechanisms have been demonstrated including TGF-β1, 
tenascin-C, VEGF, angiogenesis, inflammation, and MMPs. However, a defining 
molecular target for heart valve disease has not been defined and significant gaps in this 
knowledge still exist. At this time, suppressing inflammation and preventing obVIC 
differentiation appear to be the best ways to prevent calcific progression in valves. 
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Progress needs to be made in the areas of VIC activation, valve stem cell contributions, 
initiation of an osteogenetic gene expression profile, aggravators and inhibitors of valve 
degeneration, what steps precede end-stage stenosis and calcification, and how valve 
calcification can be lessened or reversed. Measures to identify AoV disease earlier and 
treat AoV disease pharmacologically or with less invasive approaches would be a 
significant improvement over the current standard of care. These advances will only be 
possible with a better understanding of the molecular mechanisms underlying valve 
development and disease.[14,45,48] 
1.4 Current Treatments 
1.4.1 Pharmacological 
Once diagnosed with aortic stenosis, there is currently little one can do to reverse 
the damage done to their valve. In the early stages, drugs can be used to ease the pain and 
treat the symptoms, thereby attempting to stop progression of the disease. Examples 
include diuretics to decrease the heart’s workload, beta-blockers to control the heart rate 
and decrease blood pressure, and anticoagulants to decrease the risk of clots forming on 
the diseased heart valve.[38,49] Studies have investigated using statin treatment to treat 
stenotic aortic valves because many of the same processes are characteristic of 
atherosclerosis.[44,45,48] However, there have been mixed results with some showing 
that the use of a statin stopped progression of aortic stenosis[50] while others have 
shown no effect on stenotic progression.[51,52] 
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1.4.2 Replacement Heart Valves 
Ultimately, the only current treatment available for aortic valve stenosis is to 
repair[53,54] or replace the valve, leading to the second most common type of open heart 
surgery in the western world. Without this surgery to replace the valve, 50% of patients 
with aortic stenosis die within two or three years of diagnosis.[42] Repair may involve 
removing calcium deposits, reinforcing a valve that does not close properly, or 
mechanically altering a congenitally defected valve.[38]  
Most diseased valves cannot be repaired. Instead, they are replaced by mechanical 
heart valves (general practice for younger patients), bioprosthetic heart valves (general 
practice for older patients), or allograft heart valves (special cases when available). 
However, these treatments each have major drawbacks (see Figure 1-7). 
Thrombogenicity of the artificial surfaces and induced turbulent flow regimes necessitate 
lifelong antithrombotic therapy for patients with mechanical valves.[55,56] The reliance 
upon an expensive drug therapy 
and the necessity of close patient 
monitoring is undesirable and the 
main factor that has kept 
mechanical valve replacement out 
of developing countries. 
Additionally, pregnancy and 
surgical procedures may require 
temporary suspension of this 
antithrombotic treatment. A 
 
Figure 1-7: Complications with current valve replacements 
Mechanical valves have a very low risk of reoperation, but 
carry a high risk of a major bleeding event that increases with 
implant age. Bioprosthetic valves last a limited amount of 
time, so are the choice for older patients who will likely die of 
other causes before the valve implant fails.[62] 
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solution to the thrombogenicity of 
mechanical valves was the advent 
of bioprosthetic valves (BHVs) that 
are made from either porcine aortic 
valves or bovine pericardium that 
has been chemically fixed to cross-
link the tissue and mask the 
antigens present in the xenogeneic 
materials. These devices do not 
require the anticoagulation drug 
regimen, but are predicted to last 
only about 15-20 years due to calcific degeneration[57,58] and even less in younger 
patients.[11] Allograft or homograft valves are good choices for valve replacements, but 
they also suffer from degradation, chance of rejection, and general lack of availability.[59] 
With these severe limitations, the current treatments have high risk of 
complications (Figure 1-8Figure 1-7)  and are not ideal procedures.[60–64] Furthermore, 
they are sub-par solutions for young adults and children needing valve replacements 
because of infections or birth defects.[24,39,40] In this demographic, multiple revision 
surgeries will be necessary to accommodate the increased degradation rate seen in 
younger patients and lack of device growth along with a growing child,[14,39,40,65] 
which is still a very frequent need in less developed nations.[66,67] 
 
Figure 1-8: Patient survival after valve replacement 
Long term survival rate for patients receiving either type of 
replacement valve is less than 50% after 25 years. While 
mechanical valves can last well beyond that point, they often 
lead to other adverse events.[63] 
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1.4.3 Valve Replacement in Children 
The general drawbacks of current heart valve replacements are accentuated when 
considering that, in contrast to the United States, children and young adults in developing 
nations are the most affected demographic.[20,21,23]  
Current methods of non-replacement treatment for children include repair of the 
valve, reconstruction of the aortic valve with autologous pericardium, or the Ross 
procedure, whereby the patient’s pulmonary valve is moved to the aortic position and 
replaced with a pulmonary homograft.[39,40] This is usually a sufficient short-term 
solution; the pulmonary valve does not have the robustness of an aortic valve, and as such, 
will eventually need replacing with a more traditional option. In recent trials, 
decellularized xenograft valves have even been used in the pulmonary position, 
demonstrating a preliminary shift toward a tissue engineering approach. However, none 
of these solutions are ideal.  
Alternatively, the field of tissue engineering and regenerative medicine holds 
great promise[15,20,68] in developing replacement heart valves that would function just 
as native, healthy valves: not requiring antithrombotic or other pharmacological therapy, 
repairing themselves as micro-damages are incurred, and growing in size along with a 
growing child. As has been eloquently said,[40] “future advances with tissue-engineered 
heart valves […] may change the landscape for valve repair in the paediatric population.” 
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1.5 Heart Valve Tissue Engineering 
1.5.1 Long-Term Goal  
Tissue engineering approaches are being developed that seek to make curative 
solutions for patients in need of long-term treatment of disease and tissue degeneration.  
The constructs that are being researched and tested will not simply compensate for the 
damaged tissue, but rather create living tissue that can be implanted into a human that 
would function just as a native, healthy valve: not requiring antithrombotic or other 
pharmacological therapy, repairing itself as micro-damages are incurred, and growing in 
size along with a growing child.  
Ideally, a tissue engineered heart valve will resemble both the size and shape of 
the native valve, be durable and fully functioning with good hemodynamics, be non-
immunogenic, non-inflammatory, non-thrombogenic, and non-obstructive, respond to 
mechanical and biological cues appropriately, grow in size with the recipient, and adapt 
to changing conditions throughout the life of the recipient and valve. A valve such as this 
would dramatically change the way we treat heart valve disease in children and young 
adults all over the world.  
1.5.2 Valve materials & various approaches 
Multiple methods of creating the above valves are foreseeable and many are being 
thoroughly investigated and developed, such as decellularized animal valves,[69–73] 
polymers,[15,74,75] layered composites,[76–78] and 3D printing.[79,80] Among the 
most researched and advanced methods are those that utilize a decellularized xenographic 
aortic valve as a scaffold.[20,68,81] Combining those easily accessible scaffolds with the 
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patient’s own stem cells before conditioning in a bioreactor and implanting would provide 
a replacement that is fully functional from initial implantation while able to maintain 
matrix homeostasis and reduce valve thrombogenicity for the lifetime of the patient.  
Current progress of xenographic valve preparation has been widely successful in 
decellularizing pulmonary and aortic valve cusps.[82–87] However, when reported, 
investigators note that the aortic wall and sinus wall have not been completely 
decellularized[84] or they do not give definitive proof of complete decellularization.[88] 
1.6 Valve Seeding and Animal Implantations 
The key to achieving an implant capable of repairing itself in response to micro 
tears is the presence of cells to remodel the matrix as necessary.[35,37] In cases where 
the valve implant does not have the adequate mechanical properties to function properly 
upon implantation, in vitro cellular remodeling must prepare the valve scaffold prior to 
implanting.[89–91] Multiple groups have demonstrated cell seeding on the exterior 
surface of valve cusps and some have even achieved some interstitial seeding, though full 
revitalization has not been realized.[92–94] The surfaces of some valves have even been 
repopulated after implantation in animal models,[95,96] but the same is not guaranteed 
in the human system. Even if the valve can be initially covered with cells,[73,97,98] it is 
likely that these cells will need some sort of progressive conditioning to remain attached 
after implantation since application of sudden shear forces can detach cells. Overall, more 
progress is needed to achieve full and consistent external and internal recellularization of 
the cusps and to determine what methods are needed to allow the cells to remain, but 
autologous adult stem cells provide a promising source for this application.[99,100] 
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1.7 Heart Valve Bioreactors 
Another major obstacle to the creation of such tissue engineered heart valves seen 
in many experimental approaches of biodegradable polymer scaffolding[4] is inadequate 
mechanical properties to withstand in vivo forces after implantation.[69] Conversely, 
many stabilized tissues have more than adequate mechanical properties, but are unable to 
degrade appropriately to facilitate the formation of a natural valve or have chemical 
properties that do not facilitate cellular in-growth.[101] As a result, research is being 
focused on decellularized valves that will allow the recipient patient’s cells to infiltrate 
the extra-cellular matrix, repopulate the valve, and eventually replace the slowly 
degrading donor scaffold with newly fabricated extra-cellular matrix.[11,13,57,102,103]  
Bioreactors can be generally defined “as devices in which biological and/or 
biochemical processes develop under closely monitored and tightly controlled 
environmental and operating conditions” such as pH, temperature, pressure, nutrient 
supply, and waste removal.”[104] Bioreactors for heart valves can use these monitored 
and controlled conditions to help develop well-functioning valves.[105] Requirements 
for such bioreactors and examples of previous aortic valve bioreactors are discussed below. 
1.7.1 Bioreactor Requirements 
Freed[106] says that a bioreactor must be able to perform at least one of the 
following five functions: 
(1) Establish a uniform distribution of cells on a three-dimensional scaffold 
(2) Maintain the desired concentration of gases and nutrients in the culture 
medium 
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(3) Provide efficient mass transfer to the growing tissue 
(4) Expose developing tissue to physical stimuli 
(5) Provide information regarding the formation process of 3D tissues, which 
originate from the isolated cells. 
One of the most important controls of a bioreactor is to supply an adequate 
amount of oxygen to a 3D tissue construct. Other biochemical factors, such as carbon 
dioxide and wastes also require adequate transport. In conventional cell culture, this is 
most often done by creating a large liquid to sterile air interface to facilitate the diffusive 
transport of oxygen. In a bioreactor, where the volume of culture medium present is much 
larger than in standard cell culture, additional methods must be used. These methods 
range from a sterile filter open to the external environment in combination with flow of 
the culture medium[107] to coiling gas-permeable tubing inside a culture medium 
reservoir.[108] 
Physical stimuli such as tension, compression, shear stresses, pressure, 
temperature, and pulsatile flow of culture medium improve the structure and mechanical 
properties of engineered tissues.[109,110] These mechanical forces have an integral part 
in regulation of cell phenotype and growth and the repair or degradation of tissues.[109] 
Control of trans-valvular pressure, pulsatile forces, flow rate, frequency, stroke rate, and 
stroke volume are all important design parameters of bioreactor to ensure that the 
necessary physical stimuli are integrated into the design.[110]  
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1.7.2 Current Bioreactors 
Many bioreactor systems have been developed[94,107,111–118] to test and 
precondition valvular constructs prior to implantation. Although they vary in design, 
footprint, capabilities, and valve-holding mechanisms, they each share common attributes 
to be functional.  
Current heart valve bioreactors are designed to test a single valve in vitro at 
different levels of pulsatile flow under controlled conditions in a standard humidified 
incubator at 37°C and 5% CO2. Figure 1-9 shows the common main components of aortic 
valve bioreactors, which include the fundamental components of a driving force to move 
the fluid, a reservoir, a valve holder, a capacitance chamber, a resistive element following 
the capacitance chamber, and a method of gas exchange.[118]  
This schematic gives one representative layout of these components, but many 
bioreactors in use today have variations on placement, type, and extent of use of these 
components. Most bioreactors have control over parameters such as flow, pH, and stroke 
volume and can change those parameters as desired to create varying environments for 
the valves. One use of the controllable parameters is progressive adaptation, where 
increasing amounts of mechanical stimuli are applied to aid strengthening of the tissue 
construct and prevent immediate failure upon implantation.  
There are currently numerous individual laboratories across the country using 
heart valve bioreactors. Many reviews[8,104,106,109,110,119,120] contain extensive 
comparison and assessment of the variations between them. The bioreactors range in 
design, complexity, and function, performing at various levels and accuracy. Valve 
mounting methods and modes of assembly vary, often with little options or ability to 
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accommodate abnormal valve shapes.[8] While many bioreactors are very powerful and 
can achieve high pressurization, few are able to simultaneously subject valves to actual 
physiological conditions of flow and pressure.[108,113,121] Those that can are very 
cumbersome to set up and operate for the duration of an experiment, especially while 
maintaining sterile conditions. Furthermore, independent control of those physiological 
conditions is elusive.[122] Overall, much progress has been made in the area of heart 
valve bioreactors. However, there is still room for improvement. 
 
Figure 1-9: Schematic diagram of a model pulsatile flow bioreactor 
Pulsatile flow loops for heart valve bioreactors all contain these minimum components. However, the form 
and means of use they take may vary from system to system.[110] 
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CHAPTER 2: PROJECT RATIONALE 
2.1 Introduction to Project 
Most diseased heart valves cannot be repaired. Instead, they are replaced by 
mechanical, bioprosthetic, or allograft heart valves. These treatments each have major 
drawbacks and none are ideal for a growing child or young adult. The field of tissue 
engineering & regenerative medicine holds great promise in developing replacement 
heart valves that would function just as native, healthy valves: not requiring 
antithrombotic or other pharmacological therapy, repairing themselves as micro-
damages are incurred, and growing in size along with a growing child. We hypothesized 
that implantable tissue engineered heart valves can be generated by optimal integration 
of three main factors: acellular heart valve root scaffolds, autologous stem cells, and 
construct preconditioning in a bioreactor.  
In our preliminary studies we have developed a heart valve bioreactor and tested 
it with a variety of valves[117] under physiological pressures, but flow rates and shear 
stresses were suboptimal. We have successfully decellularized cusps by simple immersion, 
but not the aortic and sinus walls. We have experimented with interstitial and external 
stem cell seeding followed by dynamic preconditioning, but the surface cells were not well 
retained under flow. Planning for large animal studies has revealed multiple 
translational challenges.  
To address these shortcomings, we proposed to optimize the bioreactor 
performance through engineering design improvements, to achieve full decellularization 
of valve roots by novel, perfusion, pressure, and decellularization methods and devices, 
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and to mechanically precondition stem cell seeded roots under optimal adaptation 
conditions before implantation in large animals. Furthermore, we aimed to demonstrate 
that translational regenerative medicine is feasible with autologous stem cells for tissue 
engineering replacement therapy – a vital stage in the ability to remove barriers in 
commercializing tissue engineered products.[68,123–125] 
2.2 Specific Aims 
2.2.1 Aim 1: Heart Valve Bioreactor Optimization  
Goal 
To modify the heart valve bioreactor system to achieve physiological levels of flow, 
pressure, and shear stresses. 
Approach 
Alternative components (compliance chambers, reservoirs, restrictor valves, etc) 
were developed to allow for physiological levels of flow at pulmonic pressure conditions. 
Shear stresses were increased by adding dextran to the culture media. The controlling 
hardware and software was upgraded to allow simultaneous and independent operation 
of multiple bioreactors and accurate monitoring of the flow and pressure conditions.  
Novelty & Innovation 
Multiple heart valve bioreactors were simultaneously run under physiologic 
conditions with independent controls. 
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2.2.2 Aim 2: Aortic Heart Valve Root Scaffold Preparation 
Goal 
To decellularize all areas of the aortic valve roots (cusps, sinuses, ascending aorta, 
and muscular tissue near cusps). 
Approach 
Cusps were subjected to immersion conditions. The sinuses and ascending aortas 
were subjected to a transmural pressure gradient and cyclical mechanical stretching. 
Muscular areas were subjected to a pressure gradient and large flow through their tissues. 
This variety of techniques was simultaneously applied to the individual areas of the valve 
using a custom-built decellularization device. Histology and DNA analysis was used 
to evaluate the removal of cellular components. Mechanical tests were used to compare 
the valve scaffold with native tissue.  
Novelty & Innovation 
A novel device was designed, manufactured, and used to apply individualized 
conditions to multiple areas of the valve roots. We revealed, for the first time, fully 
acellular aortic valve root scaffolds. 
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2.2.3 Aim 3: Dynamic Conditioning of Cell-seeded Heart Valve Scaffolds 
Hypothesis 
Progressively pre-conditioning stem cell seeded acellular valve scaffolds in the 
improved bioreactor will allow internally seeded cells to migrate within the cusps and 
externally seeded cells to maintain confluent coverage. 
Approach 
Adipose-derived stem cells were manually injected directly and after pre-
inflation into multiple areas of each cusp. Valves were rotated in a cell suspension for 
external coverage. Valves were placed in the bioreactors and flow, pressure, and viscosity 
conditions slowly increased until physiologic levels were reached. Recellularization, cellular 
migration, and cell retention were evaluated using histological and surface microscopy 
techniques.  
Novelty & Innovation 
A novel rotational device was used for external cell seeding of all valve surfaces. 
For the first time, heart valves revitalized with cells adapted to physiologic conditions 
were prepared for implantation. 
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2.2.4 Aim 4: Translation to Pre-Clinical Large Animal Testing 
Goal 
To overcome hurdles encountered while translating tissue engineered heart 
valves into clinically relevant products. 
Approach 
Acellular valve scaffolds were prepared, seeded with autologous adipose-derived 
stem cells and pre-conditioned using the bioreactor. Valves were implanted in young 
adult sheep in a right ventricle to pulmonary artery shunt position. A valve mounting system 
was modified to allow for integrated exchanges between decellularization, sterilization, 
cell seeding, and valve conditioning steps before implantation with minimal handling of 
the valve itself. Methods of aims 2-3 were continuously adjusted as necessary and re-
verified to accommodate the clinical situation. 
Novelty & Innovation 
Stem cell seeded heart valves were implanted in an animal model. Products created 
in labs were effectively translated from bench to bedside, demonstrating translational 
feasibility with autologous stem cells. 
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PART 2: PLATFORM TECHNOLOGIES AND DEVICES 
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CHAPTER 3: A SELF-ADJUSTING, NO-TOUCH DEVICE FOR 
INTEGRATED PROCESSING AND HANDLING OF 
HEART VALVES 
3.1 Introduction to Need 
Advances in replacement heart valves available on the market have been relatively 
stagnant since the introduction of bioprosthetic heart valves in the 1970s. Although 
mechanical valves typically last a patient’s lifetime and bioprosthetic valves do very well 
for a limited time in patients who cannot be on anticoagulants, there is still a need for a 
tissue-engineered valve that can repair itself to last the lifetime of a young adult and grow 
along with a growing child.  
Whether for study or implantation, natural and synthetic heart valve tissue is 
generally subjected to multiple treatment regimes. For instance, xenograft valve tissue 
must be decellularized to remove the native cells prior to either testing or implantation 
and it is common for some of the tissues to become thinner and drastically reduce in 
strength during these processes. In addition, mechanical testing by use of a conditioning 
system can be carried out to examine and alter tissue strength or to ensure suitable 
strength prior to implant.  
Some researchers believe the key to a lasting tissue-engineered heart valve 
replacement lies not only in a mechanically durable scaffold that will function immediately 
upon implantation, but also requires the presence of cells. While some researchers are 
leaving recellularization until after implantation in large animals, others are revitalizing 
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natural or synthetic scaffolds with various cell types in vitro. These cells must not be 
removed through the normal handling of the valve tissue. 
When these products reach the market or even clinical trials, they will also 
undergo the scrutiny of physicians needing a product that will hold up to the conditions 
required for implantation. Whether 
transcatheter deployment or open-heart 
surgery is the route of implantation, 
clinicians often desire a “no-touch” 
product. These products are held by 
external objects up-to and sometimes 
during implantation. 
It has been common to secure valve 
tissue during the various treatment 
regimens by temporarily suturing or 
clipping the tissue to mounting rings 
(Figure 3-1). Unfortunately, physically 
attaching the tissue to the holding device 
can damage the tissue and cause 
mechanical weakening or physical change 
of the tissue. Moreover, securement 
systems generally do not provide a method 
for securing the tissue with a tight seal and 
fluid leakage around the tissue during the 
 
Figure 3-1: Valve holder requiring intense suturing 
Diagram (A) and picture (B) of an example valve 
holder requiring many sutures in standard locations 
to hold a heart valve during testing.[113] (C) A second 
example of a common valve tissue holder.[185] 
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treatment protocols can prevent effective conditioning and/or testing. For instance 
decellularization can lead to a loss of tissue volume, and presently known systems do not 
account for the physical changes of the tissue associated with a volume loss. Thus, with 
present systems, the tissue can become loose in/on the holder and/or leaks can form 
between the tissue and the holder as decellularization takes place. 
Regardless of the stage of the valve replacement technology, researchers and 
clinicians are in need of a device that can effectively grip a heart valve root through the 
entire process of valve preparation, testing, and implantation to prevent damage and 
facilitate easier product development and use. We have developed a device that provides 
for a totally no-touch procedure after initial mounting, secure retention during multiple 
treatment regimens, and self-adjustment to accommodate natural changes in tissue 
volumes. This device is of great benefit for natural or synthetic heart valve tissues alike. 
3.2 Device Materials and Resulting Benefits 
Initially, multiple valve bracing ring designs (Figure 3-2) were used for each of 
various valve preparation devices. Although the initial bracing rings share common sizes 
and some design features, they require constant user intervention when installing or 
transferring valves between devices. Furthermore, the purpose of certain devices required 
some bracing rings to have features that are incompatible with use in other devices. For 
instance, during recellularization, it is necessary to allow flow across the rings outside of 
the valve, but during bioreactor testing, this allows flow to bypass the lumen of the aortic 
root, thereby nullifying the purpose of the bioreactor. 
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3.2.1 Initial Bracing Rings 
Figure 3-2A shows the initial bracing rings with offset ridges to clasp the tissue. 
These are held in place by the initial bioreactor pieces with six bolts (Figure 3-3) and 
require delicate maneuvering to install in place. These are used after tissue 
decellularization and subsequent recellularization and require significant manipulation of 
the tissue to function, thereby risking the sloughing of cells from the tissue surfaces. 
Furthermore, the tissue is at risk of drying out during the valve mounting and assembly 
of the bioreactor that follows. With the development of a larger bioreactor for potential 
use with cow heart valves, larger bracing rings (Figure 3-2C) were created that allowed 
for valves up to 60 mm in outer diameter to be tested, but these pose the same problems 
as the smaller rings. 
 
Figure 3-2: Bracing rings for heart valves 
Multiple sizes, styles, and holding techniques are used for the various bracing rings. (A) and (B) were 
designed initially with various internal diamters and two external diameters for various bioreactors and 
testers. (C) was designed explicitly for the seeding chambers. (D) was designed to be used in the self-
adjusting device for aortic valves while (E) and (F) (courtesy of Chris deBorde) were designed for use in the 
self-adjusting device with mitral valves. 
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3.2.2 Bracing Rings for Cell Seeding 
When a device was developed to aid external cell seeding of heart valves[126] by 
a master’s student in the lab (see section 5.2.3), additional bracing rings were designed. 
These bracing rings contain holes around the outside of the center hole to allow a cell 
suspension to flow around the external surfaces of the valve roots and through the valves 
during rotation of the 
seeding chamber (Figure 
3-2C). After cell seeding, 
the bracing rings are 
replaced by new bracing 
rings not containing 
additional holes before 
placing the valve into the 
bioreactor as above. While 
the transfer of the valve 
from one set of rings to 
another is easier because of 
the indentations made in 
the tissue, it still requires 
handling of the valve that 
contributes to the removal 
of cells from the external 
tissue surfaces. 
 
Figure 3-3: Valve mounting procedure with initial bracing rings 
Details of mounting procedures for stented valves, mechanical valves 
and un-stented valves are shown. e) The basic valve holder, f) holder 
with one o-ring placed in the machined groove (arrow), g) bottom 
mounting ring placed on top of the o-ring (arrow). h) A stented valve 
was placed on top of the bottom mounting ring (arrow), i) a second 
mounting ring placed and o-ring over it and j) pushed slowly. k) Shows 
a mechanical valve (arrow) after mounting between the two rings. l) 
Porcine aortic valve root ready for mounting in bioreactor; m-o) valve 
mounted into a silicone root using 6-10 bottom sutures and 3-6 upper 
sutures (arrows). p) The valve was placed on the holder prepared as 
shown in (g); q) a second ring slid onto the root (arrow), r) a second o-
ring added on top and s) the entire mount inserted into the aortic 
chamber (arrow).[117] 
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3.2.3 Heart Valve Quick-Tester 
Even with these slight improvements, the process of tightly clamping a heart 
valve root between the bracing rings and mounting them in the bioreactor for testing is 
complicated, difficult, and time-consuming. While it was necessary for work with sterile 
valves, a faster and simpler method was desired for testing iterations of synthetic and 
alternative valve designs under non-sterile conditions. 
A novel tester was designed and built in cooperation with an undergraduate 
student for quick assembly and testing to assess integrity and function of valves. As 
shown in Figure 3-4, the primary components in the design are a ventricular chamber, 
bracing rings, an aortic chamber, and a cap. The tester is made from clear acrylic, allowing 
a clear view from all angles of the valve being tested. To manipulate the valve, the user 
operates two bellows so that when the ventricular bellow is squeezed (collapsed), fluid 
moves through the valve into the aortic chamber and the valve opens. The user then 
squeezes the aortic bellow to shut 
the valve and the fluid travels 
through the external tubing to 
return to the ventricular chamber. 
The aortic chamber is attached to 
the ventricular chamber via three 
adjustable draw latches that can 
quickly secure the two chambers 
while allowing for adjustments in 
height for different valve designs. 
 
Figure 3-4: Manual heart valve tester 
This tester can be very quickly assembled and is used for quick 
valve testing. Valves are placed between the bracing rings and 
the metal latched hold all other components together with a 
quick latch. The two rubber bellows are used to pump fluid 
through the valve to evaluate opening and closing. 
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Three screws are used to ensure the cap stays in the correct position and a seal is 
maintained. The tester utilizes the same set of bracing rings as previously described, 
which are placed between the two chambers and held in place by o-ring tension instead 
of bolts. Thus, this heart valve quick-tester results in faster and fewer steps to assemble 
than the bioreactor and thereby provides a faster alternative than previously possible 
when evaluating new valve designs. 
3.2.4 Self-Adjusting, No-Touch Valve-Mounting Device 
While the quick-tester decreased the time and work necessary to test iterations of 
non-sterile valves, there was still a need for a device that would clasp a valve for mounting 
without damaging it, adjust to maintain a constant holding force on the valve tissue, and 
allow for no-touch manipulation and transfer of the valve between devices. A valve-
holding device was designed (Figure 3-5) from the ground up that meets these desires. 
While the bracing rings operate 
under the same clamping principal 
as the above bracing rings, their 
clasping mechanism was 
redesigned to improve hold during 
assembly, eliminate slip during use, 
and provide a better seal around 
the tissue in all processes.  
The rings for this quick-
mount (Figure 3-2D) can be 
 
Figure 3-5: Self-adjusting, no-touch valve mountng device 
Photograph (A), isometric (B), and blow-out (C) views of the 
new device to quickly mount heart valves and provide no-
touch handling throught the preparation process. 
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created in multiple sizes and shapes to hold various heart valve sizes and even types, such 
as the mitral valve (Figure 3-2E&F). In the current configuration, an angled series of 
ledges match together with a precise gap between the two bracing rings to clasp the final 
thickness of the tissue that remains after decellularization. The series of ledges create a 
clasping force that adequately seals around the tissue base. Grooves on the lower bracing 
ring are engaged by co-radial bumps on the upper bracing ring. Those bumps help 
prevent the tissue from slipping during processing as well as during mounting of the 
valve in the mounting device. They puncture the surface of the tissue and prevent slippage 
even when the lower bracing ring is not engaged, as seen in Figure 3-7G, which 
demonstrates the stepwise assembly of an aortic valve into the mounting device. 
After clasping of the tissue, the bracing rings are held in place between two 
interacting threaded casing rings and a spring. The threaded casing rings can be adjusted 
to apply the desired initial amount of force on the clamped tissue. The spring allows that 
force to remain relatively constant during decellularization and the resulting dramatic 
thinning of the clamped tissue. The threaded casing rings contain holes around the 
outside of the center hole. The external ring of holes are used to engage with the 
tightening tools during assembly. The tightening tools have teeth with the appropriate 
heights to rotate the tissue and both bracing rings while not interfering with the 
tightening of the casing rings. In addition to facilitating the tightening of the casing rings, 
the holes can be aligned with one another. In this configuration, the holes allow a cell 
suspension to flow around the external surfaces of the valve roots and through the valves 
during rotation of the seeding chamber, just as with the bracing rings for cell seeding. If 
the external flow is not desired, an o-ring can be placed under the lower external casing 
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ring to prevent passage of fluid from the internal hole to the external series of holes. This 
is beneficial during decellularization to create a pressure differential between the inside 
and outside of the aortic root and during conditioning to cause the culturing medium to 
flow through the valve instead of around it. 
3.2.5 Distal Aortic Root Constrictor and Stabilizer 
When the pressure differential between the inside and outside of the aortic root is 
desired, a plug with a controlled outflow (Figure 3-6A) can be inserted into the distal 
portion of the aortic root and secured with cable ties. This outflow plug has a groove near 
its base in which the tissue and cable ties are seated to prevent tissue slippage. The 
outflow portion of the plug has a barbed fitting that is connected to tubing and can be 
constricted as desired by using external clamps. 
While culturing the aortic root in a bioreactor setting, this plug is replaced by a 
two-piece stand (Figure 3-6B) to keep the valve root from collapsing under the 
backpressure applied during the bioreactor functioning. The first part of the stand 
consists of a ring with holes or grooves 
that is placed around the exterior of the 
aorta. It is attached to the most distal 
portion of the aorta via suturing or an 
internal retaining ring spring. The second 
part of the stand is the supporting ring 
with feet that surround the aortic root, yet 
do not interfere with the coronary arteries. 
 
Figure 3-6: Distal aortic root constrictor and stand 
The aortic flow constrictor (A) has a groove around 
which the aorta and cable ties can be tightened to 
hold the aorta in place for internal pressurization of 
the aortic root. The support stand (B) attaches an 
upper ring to the distal aortic root and uses a support 
stand to prevent the root from collapsing inward 
from the back pressure in the bioreactor. 
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The ledge on the first part of the stand rests on the top of the second part and by turning 
the first part “upside down,” it can accommodate longer or shorter aortic roots without 
the need for a larger or an alternative piece. 
3.3 Method of Device Assembly and Mounting of Fresh Valves 
The method of mounting an aortic heart valve into the self-adjusting, no-touch 
valve-mounting device is described below. While the description uses the most up to date 
bracing rings, it should be noted that the small initial bracing rings, large initial bracing 
rings, and cell seeding rings could all be used in their place. The upper casing ring 
contains counterbore cutouts corresponding to each size. It should also be noted that in 
certain designs, the upper and lower bracing rings may be combined with the upper and 
lower casing rings. 
3.3.1 Tissue Cleaning and Preparation 
Fresh porcine aortic valve roots with ascending aorta up to the branching of the 
brachiocephalic artery were collected from adult pigs at the local abattoir (Snow Creek 
Meat Processing Center; Seneca, SC) and transported to the lab in ddH2O over ice. Aortic 
roots were further dissected to include 6-8 cm of intact aorta, 5-10 mm long coronaries, 
and about 3 cm of mitral valve leaflet and ventricular endocardium tissue with an intact 
mitral-myocardial junction. The valve roots were cleaned of fat and other extraneous 
tissues while maintaining a thin muscular shelf under the muscular cusp and a thin 
muscular layer all around the valve 360° with a thickness matching that of the mitral 
valve leaflet (about 1-3 mm). The coronaries were sutured shut and the valve roots were 
rinsed with ddH2O. 
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3.3.2 Valve Mounting 
The process of assembling the valve-mounting device can be seen in Figure 3-7. 
First, the tightening tool with short teeth is placed on the counter and the upper casing 
ring, spring, and upper bracing ring are placed, upside down, onto the tightening tool. 
 
Figure 3-7: Assembly and mounting of an aortic root in the quick-mount device 
Components of valve mounting device including upper and lower casing rings, upper and lower bracing 
rings, spring, distal root constrictor, and distal root stabilizer ring and stand (A). To assemble, support 
“tower” (B) is placed on the counter and the upper casing ring (C) is placed on the support tower followed 
by the spring and upper bracing ring (D). A fresh aortic root (E) is cleaned and the root is mounted inside 
the support system (F), spread out and temporarily attached (G), and secured in place by the threaded 
outside casing ring using a second tightening tower tool (H). The valve root is then adapted with a fitting 
connector to the aorta (K). 
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The height of the tightening tool allows the valve root to rest on the upper bracing ring 
without touching the countertop below. A prepared valve root is then placed, upside down, 
through the center hole of the upper bracing ring and the mitral valve leaflet and thinned 
endocardium are spread around the surface of the upper bracing ring. The appropriate 
vertical location is achieved by ensuring that the base of each cusp is about 2 mm beyond 
the reach of the upper bracing ring. Any excess muscle or mitral valve that proceeds 
radially to cover the external holes can be trimmed and the tissue pressed into the bumps 
on the upper bracing ring, providing a temporary hold until the lower bracing ring is 
placed onto the assembly. Following the lower bracing ring, the lower casing ring is 
placed, the external holes are aligned, and a second tightening tool with long teeth is 
placed onto the assembly, all while maintaining an exertion of force onto the assembly to 
prevent slippage of the tissue. Following placement of all pieces, the tools can be picked 
up or kept on the counter and used to twist the casing rings and engage the threading. 
The threading should be tightened until the top of the upper casing ring is flush or below 
the top of the lower casing ring. In cases where the tissue is extremely thick or alternative 
bracing rings/devices are used, the upper casing ring can extend above the lower casing 
ring, but should always have at least two full threads engaged. After this initial tightening, 
the spring will provide a relatively constant force on the tissue during any subsequent 
decellularization and processing. 
3.3.3 Distal Aortic Root Stabilization 
In preparation for decellularization, the distal ascending aorta is trimmed flat and 
the outflow plug is inserted into the aorta and secured with cable ties. This plug has a 
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groove near its base and when cable ties are secured around the external diameter of the 
aorta, the tissue and cable ties are held in place within this groove (Figure 3-6A). This 
plug is used to create a pressure differential between the interior and exterior of the valve 
root during further processing. 
When the valve is fully decellularized and any subsequently desired sterilization 
and crosslinking is completed, the aorta can be cut just below the plug to remove any 
unwanted tissue that was clamped. Alternatively, the plug can remain in place to allow 
for more directed cell seeding to the interior of the heart valve during further processing. 
Prior to bioreactor conditioning of the valve root, the two-piece aortic stand 
(Figure 3-6B) is placed around the exterior of the aorta and secured to the tissue via 
suturing or an internal retaining ring. This stand does not interfere with the valve and 
will prevent the root from collapsing during the backpressure created from bioreactor 
functioning.  
3.4 Discussion of Integration into Valve Preparation Process 
With the self-adjusting mounting device, a researcher can mount a fresh valve and 
transfer the valve between processing stages all the way to implantation without 
removing the valve from the mounting device or even touching the valve directly. One 
benefit that is highly desired by clinicians is the “no-touch” aspect. In the operating room 
and when dealing with living tissue, direct handling of the tissue can be damaging. By 
using external tools and manipulating only the portions of the aortic root that are not 
vital, inherent tissue integrity is not altered. 
This device contains many pieces and performs multiple functions. However, 
during any given stage of processing, it is possible to remove or disable the aspects that 
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are either undesired or unneeded. At the same time, the valve is securely housed in one 
piece of equipment that can be transferred between processing devices. Furthermore, the 
features not currently in use do not interfere with the purpose or function of the 
immediate device. 
Use of this device has truly streamlined the development of tissue engineered 
heart valves, especially in the context of transferring the valves between systems having 
a distinct purpose and design. It is the key to fast transfers between systems and as well 
as appropriate care of the living tissue. Although currently fabricated in stainless steel 
and ABS-like material, it could easily be made of ceramics or other plastics to facilitate 
magnetic imaging techniques, cost-effectiveness, or other desired properties to further 
expand its uses in additional systems. 
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CHAPTER 4: A CYCLICAL PERFUSION DEVICE FOR 
DECELLULARIZING WHOLE AORTIC VALVE 
ROOTS 
4.1 Introduction to Need 
Multiple methods of creating tissue engineered heart valves are foreseeable and 
many are being thoroughly investigated and developed. Among the most researched and 
advanced methods are those that utilize a decellularized xenographic aortic valve as a 
scaffold.[20,68,81] Combining those easily accessible scaffolds with the patient’s own 
stem cells before conditioning in a bioreactor and implanting would provide a 
replacement that is fully functional from initial implantation while able to maintain matrix 
homeostasis and reduce valve thrombogenicity for the lifetime of the patient. 
While alternative ground up approaches have also been researched, a native 
scaffold gives the best mechanical properties and structural functionality to withstand the 
rigorous conditions of a replacement valve in the aortic position. Current progress of 
xenographic valve preparation has been widely successful in decellularizing pulmonary 
and aortic valve cusps.[82–87,117] Even attempts at decellularizing whole pulmonary 
artery roots has been adequately demonstrated.[82] Our own investigations with 
decellularizing aortic valve cusps has also been successful.[117] 
However, if an entire aortic root is to be used as a tissue engineered heart valve 
replacement, it is vital that the entire tissue be free of native cells to reduce or eliminate 
chances of immune rejection and subsequent failure. The most severe example, wherein 
all native porcine cells were not removed from implanted tissue, resulted in the death of 
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three children due to severe inflammation, degeneration, and structural failure.[127] The 
removal of all foreign cells from the cusps, sinuses, ascending aorta, and muscular regions 
of an aortic root must be clearly demonstrated. 
In some applications immersion decellularization techniques are frequently 
replaced with perfusion techniques for tissues that are difficult to decellularize.[86,128] 
When examining the properties of the aortic root tissues, it can be inferred that 
procedures that are more rigorous will be necessary to decellularize those portions than 
the procedures used to decellularize the cusps. However, the balance must be made to 
retain the structural integrity of the cusps while providing conditions harsh enough to 
decellularize the aortic wall. In this way, the entire aortic root would be prepared for 
recellularization with patient cells without the fear of an immune response caused by 
remnant xenogenic cells. 
During perfusion decellularization, tissue is generally subjected to multiple 
treatment regimens including various chemicals, detergents, enzymes, and pressure 
profiles. What is needed in the art of 
decellularizing whole aortic heart valve roots 
is a system and method for decellularizing 
tissue that can provide independent conditions 
of immersion, pressure, and stretch to the 
cusp, sinus, aorta, and muscular portions of the 
aortic root. These areas are mapped visually in 
Figure 4-1. 
 
Figure 4-1: Mapping of tissues in the aortic root 
Main anatomical coordinates of the aortic root 
are displayed. Each component has different 
physical characteristics and function.[105] 
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4.2 Materials and Methods 
Inadequate decellularization of entire aortic roots necessitated the creation of a 
perfusion decellularization system for aortic valve roots. Decellularized tissue samples 
from the cusp, sinus, aorta, and muscle were compared to fresh regions for DNA presence, 
matrix stability, and mechanical properties. 
4.2.1 Perfusion Device Components and Assembly 
Cleaned and prepared aortic valve roots were mounted in custom mounting rings 
as previously described (sections 3.3.1 and 3.3.2) and the distal portion stabilized with an 
outflow plug as previously described (section 3.3.3). If less than five valve roots were 
available for decellularization, acrylic cylinders having the outer dimensions of the lower 
casing rings were used as space holders. Figure 4-2D shows the assembled perfusion 
decellularization system. A brief overview of the process of assembly follows. All custom 
components were manufactured from stainless steel, acrylic, or polycarbonate materials 
by Clemson University Machining and Technical Services. Materials were chosen to 
provide strength in thin areas or transparency for visualization of aortas and cusps. 
Phase 1: Attaching Through-Wall Fittings 
Custom through-wall fittings (Figure 4-2A) were designed and manufactured that 
would protrude through the wall thickness while maintaining a seal, attaching to tubes, 
and not slip from their placement. Depending on need fittings either act as plugs or have 
barbed attachments on one or both ends. O-rings on either side of the fittings provide 
stabilization and a seal across the wall. A shoulder on one side of the fittings prevents the 
fitting from advancing through the wall in one direction while an external retaining ring 
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and groove prevents the fitting from reversing back through the wall. All fittings are 
pushed from the interior areas of the device through the wall and the retaining ring is 
attached on the portion of the fitting advancing on the outer portion of the wall. Fittings 
are attached to the lids for inflow and outflow and to appropriate areas in each other layer 
to provide the necessary circulation of fluid through the system 
 
 
Figure 4-2: Perfusion decellularization system for heart valves 
The flow diagram (C) illustrates the main system components comprising a valve (v), peristaltic pump, pulse 
dampener (d), valves (c) and pressure transducers (p). The working setup is shown in (D). Direction of flow, 
indicated by arrows is as follows: from the pump through the dampener (D) enters the bottom of the system 
and pushes fluid through the valves. Fluid then collects via a manifold (white arrows) into a single line which 
feeds the system again and bathes the valves from the outside. 
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Phase 2: Valve Clamping 
The next step of device assembly is to clamp the self-adjusting, no-touch valve 
holders in place between the three layers of the device that create a common solution 
chamber  (between layers 1 and 2) and do the holding of the valves in the holders (between 
layers 2 and 3). The valves are placed in the circular grooves of plate 3 before plate 2 is 
lowered around them and plate 1 above that. The three layers are bolted together to 
create a seal that forces fluid from the solution chamber into the inflow side of the valve 
lumens. 
Phase 3: Chamber Assembly 
After the valve holders are clamped between the three plates, the next layer is 
placed onto the root side of the plate assembly to create the main chamber. The outflow 
plugs of each valve root are connected to the through-wall fittings of the main chamber 
and the final layer, the outflow lid, is placed on top of the main chamber. Layers, 3, 4, and 
5 are then bolted together to create a sealed chamber around the valves.  
Phase 4: Flow Loop Assembly 
A five-port luer manifold with on/off valves is used to direct flow between the 
interior of the valves and the main chamber, where the solution bathes the tissues before 
exiting the system. This manifold and main chamber contain pressure transducers and a 
constriction valve between them to measure and control the pressure differential between 
the interior and exterior of the aortic roots. 500 mL bottles with glass-blown barbed 
attachments are used as reservoirs and pulse dampeners between the system and a 
peristaltic pump to create pressures and flow through the system. 
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Phase 5: Device Filling, Description of Flow, and Emptying 
Four liters of solution are used to fill the system. The pressures during filling 
should never exceed the running pressures of the desired protocol (described below) and 
after filling, any air bubbles are removed component by component in the direction of 
fluid travel. Once full, the system can be subjected to the desired protocol. Pressures are 
monitored with the transducers and a custom LabView program (Figure 4-3) the proper 
flow protocol is set in the menu of the peristaltic pump. Pressure and flow are controlled 
by adjusting the speed of the peristaltic pump and the constricting valve coming from the 
outflow of the manifold. 
4.2.2 Decellularization by Immersion 
Aortic roots were cleaned and 
prepared as previously described (section 
3.3.1), then decellularized in containers on 
an orbital shaker (immersion technique) at 
a ratio of 500 mL solution for 5 aortic 
roots. Decellularization steps consisted of 
hypotonic shock (ddH2O, 24 h, 4°C), 
loosening of extracellular matrix and 
initialization of cell removal (0.1 M NaOH, 
2 h, 22°C), decellularization solution (1% 
Sodium Dodecyl Sulfate, 1% Triton X-100, 
1% Na-Deoxycholate, and 0.2% EDTA 
 
Figure 4-3: Monitoring of decellularization system 
(A) The main decellularization system is comprised of 
5 layers which help direct flow through, then around 
the aortic roots. (B) The LabView software reads 
direct pressure inside and outside of the aortic roots, 
conditions it to achieve steady values, then gives a 
direct output of the differential of pressure. 
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acid in 50 mM TRIS, pH 7.5, 8 days with fresh solution every 2 days, 22°C), and removal 
of nucleic acid remnants (720 mU/mL deoxyribonuclease & 720 mU/mL ribonuclease in 
5mM Magnesium Chloride in 1xDPBS, 24 hours, 37°C). To reduce bio-burden, each 
extraction step was preceded by a 15-minute 70% ethanol treatment and appropriate 
rinsing. The roots were incubated in 70% ethanol (24 hours, 22°C) and sterilized[129] in 
0.1% peracetic acid (2 hours, 22°C). 
4.2.3 Decellularization by Perfusion 
Aortic roots were assembled into the perfusion system as described above for 
decellularization. Perfusion decellularization steps were performed with a cyclic 
transmural pressure gradient of about 52±2 mmHg and mechanical stretching for 3 
minutes on and 30 seconds off. Cyclical pressure steps were followed by rinsing with 
water, ethanol, or 1xDPBS as appropriate and consisted of hypotonic shock (ddH2O, 24 
hours, 22°C), loosening of the extracellular matrix and initialization of cell removal (0.1M 
NaOH, 2 hours, 22°C), detergent decellularization (1% sodium dodecyl sulfate, 1% Triton 
X-100, 1% sodium deoxycholate, and 0.2% EDTA in 50mM TRIS, pH 7.5, 16 days with 
fresh solution every 4 days, 22°C), enzymatic removal of nucleic acids (720 mU/mL 
deoxyribonuclease & 720 mU/mL ribonuclease in 5mM Magnesium Chloride in 1xDPBS, 
4 days with fresh solution every 2 days, 37°C), and initial sterilization (0.1% peracetic 
acid, 1 hour, 22°C). Immediately following, the distal root outflow constrictors were 
removed with sterile tools and the mounted valve roots were transferred to individual 
300 mL wide mouth glass containers with silicone membrane sealing lids on an orbital 
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shaker instead of the perfusion system for final sterilization (0.1% peracetic acid, 1 hour, 
22°C). 
Additionally, one group of aortic roots underwent the above protocol, but for 8 
days instead of 16 days in the detergent decellularization step. Another group underwent 
16 days of detergent decellularization, but was stopped immediately prior to enzymatic 
removal of nucleic acids. 
4.2.4 PGG Crosslinking Treatment 
High purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (penta-galloyl glucose, 
PGG) was a generous gift from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium 
(www.omnichem.be). Acellular valve scaffolds were rinsed in sterile PBS and then treated 
with sterile 0.15% PGG in 50 mM dibasic sodium phosphate buffer in saline containing 
20% isopropanol, pH 5.5. Treatment occurred at 22°C on an orbital shaker for 21±1 hours. 
At the onset of fixation, cusps were lightly stuffed with sterile cotton balls pre-soaked in 
PGG solution to preserve the valve conformation in ‘‘closed’’ position. After treatment, 
the cotton balls were removed and the scaffolds were rinsed then stored in sterile 1xDPBS 
solution at 4°C. 
4.2.5 RapidGlut Crosslinking Treatment 
Valves were treated with 0.7% Glutaraldehyde (Polysciences, Inc) at 22°C on an 
orbital shaker for 15 minutes. Valves were rinsed with sterile 1xDPBS for 15 minutes 
then incubated in two rounds of 1% Glycine (Fisher Scientific) solution for 15 minutes 
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each. After overnight rinsing in 1xDPBS, valve scaffolds were stored in sterile 1xDPBS 
solution at 4°C. 
4.2.6 DNA Analysis 
DNA was extracted from aorta, sinus, cusp and muscle tissue samples (n=4) and 
purified with the DNeasy Blood & Tissue Kit (Qiagen), then analyzed by Ethidium 
Bromide agarose gel electrophoresis. Samples were also quantified by reading absorbance 
at 260nm on a NanoDrop 2000c (Thermo Scientific). Quantities of DNA were normalized 
to dry tissue weight and expressed as ng/mg dry tissue.  
4.2.7 Histology and Immunohistochemistry 
For histology studies, samples collected from the aortic wall, sinus, cusp and 
muscle were fixed in 10% formalin, embedded in paraffin, sectioned at 5 µm (3 µm for the 
aorta), and stained with DAPI for nuclei, Hematoxylin & Eosin (H&E), and Movat’s 
Pentachrome.  
Immunohistochemistry (IHC) was performed to detect remaining components 
after decellularization. Biotinylated Griffonia simplicifolia (GS) lectin was used to detect 
Gala1–3Gal (a-Gal), the main porcine antigen responsible for acute rejection of 
xenotransplants. IHC for laminin, and type IV collagen was also performed. Tissue 
samples were rinsed with 1X PBS fixed at room temperature in 4% formaldehyde (BDH 
Chemicals). Following rinsing samples were blocked using 5% Bovine Serum Albumin 
(Rockland Immunochemicals, Gilbertsville, PA) with 0.05% Triton (BDH Chemicals) in 
1X PBS for 2 hours at room temperature. The blocking solution was removed and 250 
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μL primary CD-31/PECAM1 Antibody (VM64) (NBP1-42152; Novus Biologicals, 
Littleton, CO) in blocking solution (1:2 dilution) was added for 1.5 hours at room 
temperature. The primary antibody was removed before rinsing 4 times with 1X PBS. 
The secondary antibody, Alexa Fluor® 594 Donkey Anti-Mouse IgG (Invitrogen, Grand 
Island, NY) diluted in blocking solution (1:2 dilution) was added for 1 hour at room 
temperature in the dark followed by 4 rinses with 1X PBS. Finally, 500 μL DAPI stain 
(Sigma-Aldrich) was added to each slide for 5 minutes at room temperature in the dark 
before fluorescent imaging. Primary antibody was omitted for staining negative controls. 
4.2.8 Biaxial Mechanical Testing 
Samples were prepared from native (fresh) aortic valve leaflets and the PGG 
treated decellularized aortic valve leaflets (N = 6 for each group) using the methodology 
previously reported.[87,103] Square-shaped samples (~ 12 mm × 12 mm) were dissected 
from the belly region of the aortic valve leaflet, with one edge aligned with the leaflet 
circumferential direction and the other edge aligned with the leaflet radial direction. 
Thickness of each sample was measured in triplicate using digital calipers. Four dark 
markers were placed in the center region of the square sample (pasted on the ventricularis 
side of the leaflet). Samples were mounted onto the biaxial testing system via stainless 
steel hooks attached to 8 loops of 000 polyester suture of equal length (2 suture loops per 
sample edge). Membrane tensions (force/unit length) were applied to the circumferential 
direction and radial direction of the leaflet sample. A pre-load of 0.5 N/m was used during 
the biaxial mechanical testing. After 10 cycle preconditioning, the leaflet sample was 
loaded to an equbiaxial tension of 60 N/m. The leaflet extensibility was characterized by 
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the maximum stretch ratio along the circumferential direction (λcirc) and the maximum 
stretch ratio along the radial direction (λrad). Biaxial testing was carried out with the 
samples submerged in in PBS bath (pH 7.4) at 37˚C.  
4.2.9 Bending Mechanical Testing 
Bending tests were performed by following a previously reported protocol.[87] 
The bending tests were carried out in a bath chamber with PBS. Aortic valve samples, 
both native and PGG treated decellularized valve groups, were dissected out of the belly 
region of the valve leaflet (N = 5 each group). These samples were further trimmed to 
tissue strips (~8 mm long by ~4 mm wide) in both the circumferential and radial 
directions. Two hollow posts (~4mm) were attached to each end of the tissue strip for 
mounting purpose. One end of the tissue strips were attached to a post that was fixed on 
the inside wall of the bath chamber and the other end was mounted onto the bending bar. 
Each strip was mounted and subjected to simple bending testing with the ventricularis 
side up and the fibrosa side down. Five dark contrast markers used for tracking the leaflet 
strip curvature, i.e., marker 1 was pasted on the fixed post, marker 2 to 4 pasted along the 
edge of the tissue strip, and marker 5 pasted on the end of the bending bar (Figure 4-8D). 
The bending movement was tracked using a Firewire camera (DMK21AF04 model, The 
Imaging Source).   
Due to the previously reported variation in material stiffness between the native 
and PGG treated samples,[130] two different sizes of Titanium bending bars (grade 23, 
Small Parts Inc.), one with a diameter of 0.38 mm and the other with a diameter of 0.71 
mm, were used for testing the native leaflets and the PGG treated leaflets, respectively.  
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Both bending bars a length of 14 cm. The bending movement in the tissue strip was 
produced by moving the bath chamber toward the bending bar by a linear positioner 
controlled by a Velmex stepper motor (Velmex  Inc., Bloomfield, NY). The corresponding 
change in bending bar deflection was recorded by tracking marker pasted on the end of 
the bending bar, and the force was calculated by reference to the bending bar calibration 
curve. Both the Velmex motor and Firewire camera were controlled by a custom written 
Labview program (version 2000, National Instruments).  
In addition to circumferential and radial directions, each leaflet strip was tested 
by flexing the strip with the natural curvature (WC) and against the natural curvature 
(AC). The WC tests result in the ventricularis layer being in tension and the fibrosa layer 
being in compression, while the AC tests result in the ventricularis layer being in 
compression and the fibrosa layer being in tension. 
4.2.10 Statistical Analysis 
Results are represented as means ± standard deviation. Statistical analysis was 
performed with one way analysis of variances (ANOVA) and results were considered 
significantly different at p<0.05.  
4.3 Results 
4.3.1 Cyclical Perfusion Decellularization Device 
The novel device for decellularizing a whole aortic root can fully decellularize up 
to five aortic roots by circulating 4 liters of solutions through the system under a cyclical 
pressure regime that creates a transmural pressure gradient of about 52 mmHg. Utilizing 
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a peristaltic pump to create flow, the system (Figure 4-2D) incorporates a pulse dampener, 
reservoir, constrictor valve to build pressure, and a series of plates and chambers to 
appropriately direct flow through and around an aortic root. A simplified cross section of 
the fluid flow path is shown in Figure 4-2C. Fluid flows from the pump and through the 
dampener into the lower level of the chambers. It is directed into each of the valves 
mounted in the system where it can build pressure due to the downstream constriction 
created by the manifold and outflow constricting valve. From the manifold, it circulates 
back into the system to bathe the outside of the tissue in solution at a low pressure. From 
there, the fluid freely flows out of the chamber and into a reservoir for recirculation. 
Pressure is measured in lines communicating with the outside as well as the inside of the 
aortic roots by transducers controlled by custom LabView software, which displays inner, 
outer, and differential pressures (Figure 4-3B). 
4.3.2 DNA and Cellular Content  
Figure 4-1 and Figure 4-5 show a mapping of each portion of tissue in the aortic 
root. While it is clear that the aorta, muscle, and cusp are different tissues, it should also 
be noted that the sinus is a different tissue than the aorta, with a different structure and 
function. 
H&E and DAPI analysis for the 8-day immersion-decellularized valves revealed 
complete cellular removal from valve cusps (Figure 4-4A&B), which was confirmed with 
Nanodrop data (not shown). However, the sinus, aorta, and muscle were not completely 
decellularized using this immersion technique (Figure 4-4D).  
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While 8 days of perfusion 
treatment was sufficient to remove cells 
from the muscle and sinus as well as the 
cusp (Figure 4-5), a longer time was 
needed to decellularize the full thickness of 
the aorta. In unsuccessful attempts, cells 
remained in the central layers of the aorta, 
but were removed near the media and 
adventitia. Agarose gel imaging (Figure 
4-5A), Nanodrop (Figure 4-5B), H&E 
(Figure 4-7), and DAPI (Figure 4-5) show 
that 16 days of decellularization treatment 
was adequate to remove sufficient amounts of DNA from all aortic root areas. Notably, 
the use of DNase and RNase enzymes were vitally necessary to remove cellular content 
from the aorta after 16 days as well as from the sinus at the 8 day time point as seen in 
the agarose gel images (Figure 4-6). Nanodrop analysis (Figure 4-6) confirmed the drastic 
reduction in DNA content after the full 16 day perfusion decellularization protocol.  
4.3.3 Extracellular Matrix Components 
Examination of the H&E and Movat’s Pentachrome staining, as in Figure 4-7, 
revealed an intact matrix primarily comprised of collagen and elastin. As expected, 
glycosaminoglycans were not seen after any decellularization steps.  
 
 
Figure 4-4: Immersion decellularization is 
incomplete for all valve root areas 
Fresh (left) and immersion decellularized (right) H&E 
staining of the cusp (A&B) and H&E and DAPI staining 
of the aorta (C&D) with elastin autofluorescence. 




Figure 4-5: Decellularization results of immersion and perfusion methods 
(A) Representative histology images of fresh aortic root sections stained for nuclei with DAPI (blue) before 
(Fresh) and after immersion decellularization (Decell). Arrow points to DAPI stained cell remnants after 
immersion decellularization. (B) Representative DAPI stained sections of aortic valve root areas after 8 and 
16 days of perfusion decellularization. Arrow points to DAPI stained cell remnants. (C) Macroscopic images 
showing a fresh intact aortic root (1) and a root cut open with one cusp removed to reveal the main 
anatomical coordinates (2). A fully decellularized aortic root is shown in top view (3) and cut open (4). 
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4.3.4 Cusp Mechanical Testing 
Biaxial 
The biaxial data obtained (Figure 4-8A) for both groups (native leaflets and PGG-
treated leaflets) showed that the PGG-treated leaflets preserved the anisotropy of aortic 
valve leaflet tissue, i.e., a 
stiffer circumferential 
direction and more 
extensible radial direction. 
Moreover, the current 
PGG-treatment protocol 
generated leaflet tissue 
with extensibility very 
close to the native leaflets. 
We found that λcirc and λrad of 
the native leaflets were 
1.0193 ± 0.0108 and 1.2110 
± 0.0504, respectively; and 
λcirc and λrad of the PGG-
treated leaflets were 1.0245 
± 0.01507 and 1.2191 ± 
0.0509, respectively. 
However, we noticed that 
the tension-stretch curve of 
 
Figure 4-6: DNA analysis by agarose gel electrophoresis and 
nanodrop UV spectrophotometery 
(A) Ethidium bromide agarose gel electrophoresis of genomic DNA 
extracted from fresh aortic root tissues (F) and tissues collected after 8 
days (D8) and 16 days (D16) of perfusion decellularization. Samples 
were also collected before the nuclease treatment step from the 16 
days groups (D16 -). S = DNA standards consisting of whole genomic 
DNA (*) and DNA ladder (#). (B) Nanodrop UV analysis of DNA extracted 
from fresh aortic root tissues and tissues collected after 16 days of 
perfusion decellularization (Decell). 
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the PGG-treated leaflets showed a much stiffer toe region in the radial direction when 
compared with the native leaflets.  
Bending 
The native aortic valve leaflets followed a similar trend as we observed in our 
previous study.[87]  The moment-curvature curves (Figure 4-8B) showed that AC 
bending was stiffer than the WC bending, and the circumferential direction bending is 
stiffer than radial direction. After PGG treatment, the aortic valve leaflets showed a large 
increase in overall bending stiffness. In PGG-treated leaflets, we still observed that AC 
bending is stiffer than WC bending, and circumferential is stiffer than radial. Moreover, 
the degree of nonlinearity increases after PGG treatment, exhibiting a very stiff response 
when the bending curvature is small, but the increasing trend of the moment-curvature 
curve greatly slowed down after the bending curvature passed ~0.04 mm-1.  
4.4 Discussion 
4.4.1 Perfusion Decellularization Device  
Although widely used because of its simplicity to operate, immersion 
decellularization techniques are inadequate for decellularizing whole aortic roots. We see 
their successful utilization for tissues that are thin or relatively more porous than the 
aorta, which contains hundreds of layers of elastin that are difficult for solutions to 
penetrate. When considering the function of the aorta, to contain the pressurized blood 
within, it becomes apparent that simple immersion will not be adequate for solutions to 
reach all layers of this remarkable structure. Even the pulmonary artery is thinner and 
more porous than the aorta, resulting it its relative ease to decellularize. 




Figure 4-7: Histology of decellularized root tissues 
Representative images of H&E stained (A) and Movat’s pentachrome stained (B) sections showing fresh 
aortic root tissues before (Fresh) and after 8 and 16 days of perfusion decellularization. Arrows point to 
stained cell remnants. H&E stain shows nuclei in blue and cytoplasm and matrix in pink. Movat’s 
pentachrome stain reveals collagen (yellow), elastin (dark brown) and muscle cells (red). 
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A device and method of use was created for decellularizing the thick portions of 
the aortic root as well as the more fragile cusp portions. The cusps were subjected only 
to immersion conditions, the aorta and sinus were subjected to a cyclical transmural 
pressure gradient and resultant stretch, and the muscular regions were subjected to a 
transmural pressure gradient and increased perfusion. This combination of isolated 
conditions resulted in an aortic root that was overall, decellularized, yet maintained 
structural integrity in the most fragile and vital areas. 
4.4.2 Decellularized Aortic Root 
Upon initial evaluation of an immersion-decellularized aortic root, it was quickly 
apparent that the aorta regions of the root were not fully decellularized using our 
detergent and immersion method of decellularizing valve cusps. Further examination of 
the literature revealed a lack of evidence supporting full decellularization of the aortic 
roots. If an entire aortic root is to be used as a tissue engineered heart valve replacement, 
it is vital that the entire tissue be free of native cells to reduce or eliminate chances of 
immune rejection and subsequent failure.[127] The removal of all foreign cells from the 
cusps, sinuses, ascending aorta, and even muscular regions of an aortic root must be 
clearly and satisfactorily demonstrated and the aforementioned reports of decellularized 
aortic roots are inadequate in their descriptions. 
Our own experience indicates that cell removal must be evaluated by a variety of 
methods rather than one sole method of analysis. It can sometimes be difficult to classify 
an object as a cell or not in histological images. NanoDrop analysis is not as accurate at 
near-zero levels of dna, as evidenced by numerous negative readings, despite routine and 
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normal reads of our blanking solution. Perhaps the most identifying single analysis is the 
agarose gel. However, even that analysis is subject to human interpretation. Our 
demonstration of the necessity to utilize a perfusion system for decellularizing aortic 
roots reveals that many previously published methods should verify the cellular content 
of all areas of tissue to be used for implantation. Furthermore, the innermost portions of 
the aortic tissues should be verified to be free of cells and shown in publications. For the 
reasons stated above, multiple methods of analysis should be shown to demonstrate 
complete removal of cellular content. 
4.4.3 Mechanical Analysis 
The current protocol includes the step of leaflet decellularization followed by 
PGG treatment. It is well known that for most decellularization protocols, the aortic 
valve leaflets experience an increase in overall tissue extensibility due to the 
microstructural disruptions (e.g., disruption of collagen network and elastin fibers).[87] 
On the other hand, PGG treatment generates crosslinking at molecular level, which has 
a stiffening effects on collagenous tissues.[78,103,131] The treatment of PGG on the 
decellularized leaflets causes tissue crosslinking and stiffening, and hence the extensibility 
of the decellularized leaflets could be reduced accordingly. Interestingly, we found that 
the current protocol generated PGG-treated leaflets with an overall tissue extensibility 
comparable to the native leaflets. However, as we pointed out, the biaxial behavior of the 
PGG treated leaflets was not exactly the same as the native leaflets. The tension-stretch 
curves showed that the toe region of the radial direction is much stiffer than that of the 
native leaflets. The loss of a relatively flat toe region after PGG-treatment demonstrated 
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that the PGG-treated leaflet picked up mechanical load much quicker in the deformation 
initiation region.  
We found that the PGG treated aortic valve leaflets had a much stiffer bending 
moment-curvature relationship than the native aortic leaflets. This reflected the fact that 
the crosslinking took place at the molecular level after PGG treatment. Tissue bending 
stiffness seemed to be more sensitive to this molecular level crosslinking, and the order 
of change we observed is very high (Figure 4-8). Interestingly, the subtle variations of 
leaflet flexure, in terms of AC vs. WC bending and circumferential vs. radial bending, 
were all preserved after PGG treatment. This observation implied that the PGG 
treatment still preserved the ultrastructural level subtlety while in overall increasing the 
tissue bending stiffness. The increase of the degree of nonlinearity after PGG treatment 
is another interesting finding. As we notice, the stiffening effect was more in the range of 
small bending curvature, and this observation echoed with the biaxial testing, which 
showed the toe region of the radial direction curve turned into much stiffer after PGG 
treatment. All the biomechanical observations seemly hinted that the mechanical effect of 
PGG treatment on tissue behavior was more noticeable in the deformation initiation 
range. 
 




Figure 4-8: Mechanical properties of decellularized cusps 
(A) Biaxial stress-strain analysis of fresh cusps and cusps which underwent decellularization and PGG 
stabilization, tested in both circumferential and radial directions. (B) Bending test results for fresh and PGG-
treated decellularized cusps tested with curvature and against curvature. 
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CHAPTER 5: TECHNIQUES AND DEVICES FOR CELL SEEDING 
OF HEART VALVES 
5.1 Introduction to Need 
Cell seeding plays an integral role in the production of a tissue-engineered implant. 
Regardless of the target tissue, the idea of adding cells to a scaffold is a fundamental part 
of tissue engineering. Literature demonstrated numerous methods of adding cells to a 
scaffold, but no method has been deemed to work far better than any other does. 
Optimization of this process is considered to be an important aspect in the paradigm of 
tissue engineering.[65] Overall, seeding techniques can be categorized into three areas: 
static, dynamic, and perfusion.[65,132] 
Static seeding methods (Figure 5-1A) usually involve manually pipetting a cellular 
suspension directly on the scaffold and re-pipetting the solution back onto the scaffold as 
necessary. After a specified amount of time of pipetting, the scaffolds are kept static to 
allow for strong attachment of cells. This is by far the simplest and most widely used 
method of seeding, but complex geometries of scaffolds often make uniform and 
repeatable results impossible.[133] Additionally, this method often results in low seeding 
efficiencies. 
Dynamic seeding methods (Figure 5-1B) utilize fluid motion to maintain cells in 
a state of constant suspension around a tissue so they can contact many portions of the 
tissue evenly as they move. An example of this type of seeding is a commonly used spinner 
flask whereby the scaffold is placed inside the flask and the stir bar agitates the liquid to 
maintain cellular suspension. Although this constant mixing will provide cell contact to 
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many areas of the tissue, it can also cause the cells to detach and even cause cell death if 
shear forces are too high.[132,134] Another approach to dynamic seeding involves 
creating random fluid motions by 
randomly rotating a sealed container with 
the scaffold housed within.[65,135,136] 
This random cell movement increases the 
probability of cells attaching to multiple 
surfaces, but can sometimes require a more 
difficult method of mounting the scaffold. 
However, these methods can combine 
gravitational force to cause cells to fall and 
attach to specific portions of tissue when 
rotations are paused for a limited amount 
of time. 
Perfusion seeding methods (Figure 
5-1C) rely on hydrostatic pressure, 
magnetism, or electrostatic forces to move 
cells onto or into scaffolds.[132,137–139] 
Hydrostatic pressure utilizes a pressure 
gradient to force seeding solutions into a 
scaffold by increasing internal pressures or 
pulling an external vacuum. Magnetic 
nanoparticles bound to cell surfaces can 
 
Figure 5-1: General methods of cell seeding 
Static (A), dynamic (B), and perfusion (C) methods of 
seeding cells on a scaffold.Static methods rely on re-
pipeting the cell suspension over the tissue. Dynamic 
methods use fluid movement to keep cells in 
suspension so they can contact and attach to many 
areas of the tissue. Perfusion methods use forces to 
drive cells deep into the tissue rather than relying on 
cellular migration alone.[65] 
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allow the cells to be manipulated through precise use of magnets to direct cells onto 
specific surfaces of a scaffold. Electrostatic force methods involve inducing a positive 
surface charge on a scaffold to attract the negatively charged cells onto the scaffold. These 
methods are usually utilized in flat or tubular structures and could be difficult to apply to 
the complex geometry of a heart valve root. Additionally, they often involve complex 
equipment that makes maintaining sterility difficult. 
The methods developed here serve to combine the advantages of multiple methods 
of seeding to achieve optimal results for heart valve and aortic root scaffolds. They utilize 
other devices created in the lab that eliminate some of the difficulties previously 
mentioned. They also seek to take into consideration the complex geometry of the 
scaffolds and do not rely on cellular migration, which has been shown to be extremely 
slow and not far enough into the tissue in our previous work. 
5.2 Materials & Methods 
Cell seeding methods were developed in close collaboration with other students 
and improved or modified as needed. Notably, internal cellular seeding protocols were 
initially developed by Jordan Maivelett and improved in collaboration with Allison 
Kennamer.[140] External seeding devices and protocols were developed by Richard 
Pascal[126] and underwent design improvements described herein. 
5.2.1 Valve Scaffold Preparation 
Fresh porcine aortic valve roots were collected, cleaned, and prepared as described 
in section 3.3.1. Aortic roots were decellularized by either the immersion (section 4.2.2)  
then mounted in the valve mounting rings as in section 3.3.1 or decellularized by 16-day 
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perfusion (section 4.2.3) techniques. Following decellularization, roots were crosslinked 
with PGG as in section 4.2.4 and neutralized for 18-24 hours in DMEM with 50% FBS 
and 1% Antibiotics/Antimycotics at 37°C. 
5.2.2 Stem Cell Culturing 
Human adipose-derived stem cells (hADSC; Invitrogen, Eugene, Oregon) were 
cultured on cell-culture flasks at initial densities of 5000 cells per cm2. Cell culturing 
media consisted of Complete MesenPRO RSTM Medium (Invitrogen, Eugene, Oregon) 
with 1% Antibiotic/Antimycotic (Mediatech, Manassas, VA), and 0.36 g/L of L-
Glutamine (Fisher Scientific). Passaging occurred at 75-85% confluence and, unless 
otherwise noted, hADSCs were not used beyond passage 6. 
5.2.3 Rotational Seeding Device Design, Components, and Assembly 
A LabView-controlled dynamic seeding device (Figure 5-2) was developed using 
SolidWorks software and engineering design techniques and manufactured out of acrylic 
and aluminum. The device was designed around the aortic root characteristics and with 
the intention of easily integrating into the overall valve preparation process. A 
combination of static and rotational seeding methods were deemed the best fit for this 
tissue and integration into the valve preparation process. 
Initial methods of holding the aortic root involved previously used bracing rings 
described in section 3.2.2. These bracing rings contain holes around the outside of the 
center hole to allow a cell suspension to flow around the external surfaces of the valve 
roots and through the valves during rotation of the seeding chamber. Further 
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developments led to the improved method of mounting the aortic roots described in 
section 3.2.4. Utilizing these self-adjusting, no-touch valve mounting devices allowed an 
easier transition between devices and improved the retention of structural integrity of the 
tissue since no further handling was necessary. The improved valve mounting devices 
contain the same holes to allow fluid movement around the valve and fit well into the rest 
of the seeding device (Figure 5-2C) and methods. 
 
Figure 5-2: External seeding device 
Six chambers (B) can be held in the frame connected to the shaker plate (A) for cell seeding with agitation 
and pause cycles. The valve quick mount fits inside the chamber and allows flow to pass around the valve 
(C). The chambers are assembled and set into the chamber holder plates according to specific protocols 
that maintain consistency and ability to track valves (D). During rotation, cells are resuspended and during 
pausing at each angle, cells are allowed to fall to a valve surface and attach (E). During chamber assembly 
and placement into the chamber holder plates, the thumbscrews, degree marks, and ports must be 
alighned with specific characteristics in relation to each other and the set line or axial chamber holder plate. 
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The chambers (Figure 5-2B&C) to hold the valves were designed to use as little 
seeding solution as possible and reduce violent flow patterns that could cause cell removal 
from the scaffold or cell death. Rounded edges that fit closely to the outline of the aortic 
root were designed with dimensions that would cause the fluid to flow smoothly through 
the slits in the mounting device as well as the valve itself. The lid of the chamber contains 
two ports (Figure 5-2D) to allow pressure equalization and media or gas exchange as 
necessary. During end-over-end rotation, needleless ports can be added to the luer ports, 
but during axial rotation, luer plugs must be used for three chambers to fit into one 
chamber holder plate. It utilizes an o-ring seal to maintain sterility and slides into the 
outer chamber, thereby clamping the mounting device and holding it in place. The 
pressure of the o-ring seal provides temporary closure until the seeding chamber is 
mounted to the chamber holders described below. The chamber and lid was manufactured 
from acrylic material to allow visualization of flow and sterilization via ethylene oxide-
gas treatment. 
After or during attachment of the lids, each set of three lids should be lined up in 
relation to the chamber body so that each degree mark (0, 120, and 240) is each 1) aligned 
with both luer ports and 2) between two bolts. For example, on the first chamber, the 0° 
mark should be in line with both luer ports and also between two bolts; on the second 
chamber, the 120° mark should be in line with both luer ports and also between two bolts; 
and on the third chamber, the 240° mark should be in line with both luer ports and also 
between two bolts. This can be achieved by rotating the lid in relation to the chamber 
body and will be important when using the axially rotating chamber holder plate. 
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Up to three seeding chambers are mounted into aluminum chamber-holder plates 
by hand-tightened bolts between the lid and threaded portions of the chamber holder. 
These holders are mounted onto a frame containing a stepper-motor controlled by custom 
LabView software that provides rotation of the holders. The upgraded frame can hold 
two chamber-holder plates, resulting in the processing of up to six heart valves at one 
time. The frame can be mounted onto an orbital shaker that provides and additional 
direction of motion to help maintain suspension of the cells and create random fluid 
movement within the chamber (Figure 5-2A). The entire assembly of chambers, holders, 
frames, motors, and orbital shaker can fit into a standard cell culture incubator or heating 
oven to provide physiological temperature during seeding. 
Two versions of chamber holder plates were designed that can be exchanged with 
by loosening set screws on either end of the plates. One chamber holder holds the seeding 
chambers so they rotate in an end-over-end fashion around the point directly in the center 
of each heart valve (Figure 5-2 – upper plate) while the second chamber holder holds the 
seeding chambers so they rotate around their natural axis (Figure 5-2A – lower plate). 
The end-over-end rotation and pauses at specific orientations will ensure that cells flow 
through the valve scaffold and contact multiple areas of the valve when they fall due to 
gravitational forces during the static phases. The axially rotating chamber holder will 
ensure cell contact with all interior surfaces of the valve root and may provide additional 
coverage over the alternative chamber holder. 
Several marking systems (Figure 5-2D) were used to ensure uniform conditions 
between valve root samples and track areas already seeded with cells when performing 
multiple seeding steps. Each seeding chamber and lid set was labeled with a unique 
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number from 1 to 6 to identify and track each valve. The seeding chambers were also 
marked between each bolt with the degree marks of 0, 120, and 240. With three bolts, 
three degree marks, and by ensuring the non-coronary sinus was aligned with the 0° mark, 
we could ensure all three cusps and sinuses were treated equally as long as we performed 
three repetitions with 1/3 rotation between each repetition. A simple dash mark was made 
on the end-over-end rotating chamber holder that would align with one of the three 
degree markings on the seeding chamber. When using the axially rotating chamber 
holder, the degree markings would be referenced to the location between the two bolts 
that hold the chamber to the chamber holder. 
The LabView software allows the chamber holders to be programed and rotated 
automatically. The hardware interfaces included the National Instruments cDAQ-9171 
chassis and cDAQ-9401 module. Controllable parameters include rotation direction, 
rotation time, rotation pause time, orbital shaking speed, orbital shaking time, orbital 
shaking pause time, and number of repetitions. By using a finely-controlled stepper motor 
and calculating rotations per minute by time rotated, the final resting degree of rotation 
can also be controlled.  
5.2.4 Changing Media and Gas Exchange in the Seeding Chambers 
The needleless ports attached to the lid of the seeding chambers can be used for 
changing media, adding cells, cycling the gas content, or any other access necessary. To 
change media, the seeding chamber is removed from the A-frame and transferred to the 
cell culture hood. The chamber is drained by vacuum through a needleless port with an 
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empty 50 mL syringe attached to 
the other port to allow sterile air 
into the system (Figure 5-3). 
Following removal of all liquid, 
media is added to the chamber 
through the 50 mL syringe until 
the media just covered the stainless 
steel mounting rings (about 120 
mL). The attached vacuum will pull 
the media from the syringe into the 
chamber, but is not necessary for the chamber to fill. If additional gas exchange is 
necessary, sterile filters can be attached to each needleless port and vacuum applied to 
one port. This will draw CO2 rich air into the seeding chamber. It should be noted that 
compressed CO2-rich air can be used, but only when chambers are securely latched to the 
holding plate. If the lid is not attached, the pressurized air will force the lid out of the 
system. 
5.2.5 Internal Cellular Seeding via Injection 
Valve scaffolds were prepared as above and seeded with cells as in Figure 5-4.[140] 
Following neutralization, the base and free edge of all cusps in the valve were inflated 
with sterile compressed air (15-20 psi) attached to a sterile 33G x 1.25 inch needle. A 
sterile pipet was used to stabilize the tissue and the needle was inserted into the middle 
layer of the cusp, causing the fibrosa and ventricularis layers of the cusps to delaminate. 
 
Figure 5-3: Media and gas exchange in seeding chambers 
(A) Media can be changed without opeing the lid by aspirating 
through needleless ports. (B) If necessary, CO2-rich gas can be 
cycled through the chambers via sterile filters and vacuum 
pressure.[140] 
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Immediately after mixing, 4 million hADSCs in 1 mL were loaded into a 1mL syringe 
and manually injected into the free edges of the cusps in multiple areas and in the base of 
the cusp through a 33G x 1.25 inch needle. Injection was repeated for each cusp for a total 
of 12 million cells into the interstitial cusp area of each valve.  
Valves were then placed into a seeding chamber with the non-coronary sinus 
aligning with the 0° mark on the chamber. The chamber was filled with enough cell 
culture media (DMEM with 10% FBS, 1% Antibiotic/Antimycotic) to cover the stainless 
steel mounting rings (about 120 mL). The chamber was closed as described above and 
 
Figure 5-4: Internal cell seeding of valve cusps 
(A) Internal cell seeding was performed after mounting into the valve quick mount to assist in stabilization. 
(B) The bulb of a sterile pipet was inserted into the valve root to (C) hold the cusp in place. Compressed air 
(15-20 psi) was (D) pushed through a filter to sterilized the air before (E) injecting the base and free edges 
of the cusps with air. (F) After air injection, cusp layers delaminated and usually maintained pocket of air 
after needle removal. (G) Cell culture media was drawn into a syringe prior to (H) attaching a needle to the 
syringe. (I) Cells were injected into the previously delaminated cusps at the base and free edge.[140] 
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placed into the end-over-end chamber holder on the A-frame with the 0° chamber mark 
aligning to the corresponding mark on the end-over-end chamber holder. 
After placing all the valves into the chamber holder, the shaker was set to speed 
20%. The LabView program was set with the rotator at 5.0 RPM with a rotating time of 
300 seconds and pause time of 300 seconds. Rotations alternated direction each time and 
the seeding chambers were rotated for 18-24 hours at 37°C at those conditions to improve 
cell attachment to the valve scaffolds. 
5.2.6 External Cell Seeding via Rotational Device 
One day prior to internal seeding (the same night as the neutralization step), the 
seeding chambers were assembled and filled with sterile 5% BSA in 1xDPBS to block 
attachment to the container and localize the future fibronectin/pronectin attachment to 
the valve. The next night, the freshly internally injected valve scaffolds were coated with 
4 µg/cm2 (approximately 4 µg/mL in this application) fibronectin (Sigma) or pronectin 
(Sigma) by adding the correct volume of fibronectin/pronectin to the culture media. 
Following interstitial cell seeding and coating with 4µg/cm2 fibronectin or pronectin, the 
exterior surfaces of the valves were seeded by one or a combination of the methods 
described below.  
External Seeding Method 1 
In the first method, 16-24 million hADSCs were seeded in one night using end-
over-end rotation of the valves. For this method, the seeding chamber was removed from 
the A-frame and drained as described in section 5.2.4. 16-24 million hADSCs (as 
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determined by the experiment trial) were resuspended in 35 mL cell culture medium and 
added to the seeding chamber through the syringe, followed by about 90 mL of additional 
cell culture media to fill the chamber. 
The chamber was placed into the end-over-end holder on the A-frame with the 0° 
chamber mark aligning to the corresponding mark on the end-over-end chamber holder 
(position B in Table 5-1) and the rotational regimen in Table 5-1 was followed overnight. 
External Seeding Method 2 
For the second method, 30 million hADSCs were seeded over the course of three 
nights using end-over-end rotation of the valves. For this method, the seeding chamber 
was removed from the A-frame and drained as described in section 5.2.4. 10 million 
hADSCs were resuspended in 35 mL cell culture medium and added to the seeding 
chamber through the syringe, followed by about 90 mL of additional cell culture media 
to fill the chamber. 
The chamber was placed into the end-over-end holder on the A-frame with the 0° 
chamber mark aligning to the corresponding mark on the end-over-end chamber holder 
Table 5-1: External seeding method 1 dynamic regimen 
In one trial, the root was positioned down for only 5 minutes. 
Position A  
(holder orientation) 
Position B  














Rotating 0° on set mark 30 30% 5.00 30 0 
Root Up 0° on set mark 200 Off    
Rotating 120° on set mark 20 20% 0.75 60 0 
Root Up + 180 degrees 120° on set mark 90 or 5 Off    
Rotating 240° on set mark 20 20% 0.75 60 0 
Root Up + 30 degrees 240° on set mark 90 Off 0   
Rotating 240° on set mark 1000 Off 0.01 1800 7200 
Run the above until next seeding day. Can leave shaker off if needed.  
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(position B in Table 5-2). The chamber holder was positioned with the root up (position 
A in Table 5-2) and the rotational regimen in Table 5-2 was followed overnight. 
On the second day of seeding, the media was aspirated and another 10 million 
hADSCs were added to the chamber in 120 mL media through the needleless ports as 
described above. The seeding chamber was then placed back into the end-over-end holder 
on the A-frame with the 120° chamber mark aligning to the corresponding mark on the 
end-over-end chamber holder (position B). The chamber holder was positioned with the 
root up (position A) and the rotational regimen in Table 5-2 was followed overnight with 
the only change being position B was at 120° on the set mark. 
On the third day of seeding, the media was aspirated and another 10 million 
hADSCs were added to the chamber in 120 mL media through the needleless ports as 
described above. The seeding chamber was then placed back into the end-over-end holder 
on the A-frame with the 240° chamber mark aligning to the corresponding mark on the 
Table 5-2: External seeding method 2 dynamic regimen 

















Pre-Setting: Root Up 0° on set mark  00.13 Off 5.00 11 300 1 
Run for 12-15 seconds, then hit circular stop button during the first pause time. 
Rotating 0° on set mark 30.05 20% 
2.00 1805 5400 1 
Root Up + 30 degrees 0° on set mark 90.00 Off 
Rotating 0° on set mark 30.05 20% 
Root Up + 330 degrees 0° on set mark 90.00 Off 
Run the above for 1 cycle = 4 hours. Be sure to turn shaker off/on as appropriate. 
Second pre-Setting 0° on set mark  00.03 Off 5.00 1 5400 1 
Run for 2-5 seconds, then hit circular stop button during the first pause time. 
Rotating 0° on set mark 15.30 20% 
1.00 930 6300 100 
Root Up + 180 degrees 0° on set mark 105.00 Off 
Rotating 0° on set mark 15.30 20% 
Root Up 0° on set mark 105.00 Off 
Run the above until next seeding day. Can leave shaker off if needed. 
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end-over-end chamber holder (position B). The chamber holder was positioned with the 
root up (position A) and the rotational regimen in Table 5-2 was followed overnight with 
the only change being position B was at 240° on the set mark. 
External Seeding Method 3 
For the third method, 30 million hADSCs were seeded over the course of three 
nights using axial rotation of the valves. After removing the seeding chambers from the 
A-frame, the end-over-end chamber holder was replaced with the axial chamber holder 
on the A-frame. For this method, needleless ports were replaced with luer plugs before 
the first media aspiration to allow three chambers to fit into the axial chamber holder. 
The seeding chamber was drained as described in section 5.2.4.. 10 million hADSCs were 
resuspended in 35 mL cell culture medium and added to the seeding chamber through the 
syringe, followed by about 90 mL of additional cell culture media to fill the chamber.. 
Following the additional media, luer plug caps were place onto the luer fittings. 
The chamber was placed into the axial holder on the A-frame with the 0° chamber 
mark being set between the bolts holding the seeding chamber to the chamber holder 
(position B in Table 5-3). The chamber holder was positioned with the bolts up (position 
A in Table 5-3) and the rotational regimen in Table 5-3 was followed overnight. 
On the second day of seeding, the media was aspirated and another 10 million 
hADSCs were added to the chamber in 120 mL media through the luer ports as described 
above. The seeding chamber was then placed back into the axial holder on the A-frame 
with the 120° chamber being set between the bolts holding the seeding chamber to the 
chamber holder (position B). The chamber holder was positioned with the bolts up 
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(position A) and the rotational regimen in Table 5-3 was followed overnight with the only 
change being position B was at 120° between the bolts. 
On the third day of seeding, the media was aspirated and another 10 million 
hADSCs were added to the chamber in 120 mL media through the luer ports as described 
above. The seeding chamber was then placed back into the axial holder on the A-frame 
with the 240° chamber being set between the bolts holding the seeding chamber to the 
chamber holder (position B). The chamber holder was positioned with the bolts up 
(position A) and the rotational regimen in Table 5-3 was followed overnight with the only 
change being position B was at 240° between the bolts. 
5.2.7 Live/DEAD® Imaging 
Presence of live cells on tissue surfaces was analyzed using Live/DEAD® stain 
(Invitrogen, Eugene, Oregon) according to manufacturers’ directions, using 20 µL of 
EthD-1 and 5 µL of Calcein-AM in 10 mL of 1X PBS. The Live/DEAD® solution was 
Table 5-3: External seeding method 3 dynamic regimen 



















Bolts Up 0° between bolts       
Rotating 0° between bolts 30.15 20% 
2.00 1815 5400 1 
Bolts Down 0° between bolts 90.00 Off 
Rotating 0° between bolts 30.15 20% 
Bolts Up 0° between bolts 90.00 Off 
Run the above for 1 cycle = 4 hours. Be sure to turn shaker off/on as appropriate. 
Rotating 0° between bolts 15.30 20% 
1.00 930 6300 100 Bolts Down 0° between bolts 105.00 Off 
Rotating 0° between bolts 15.30 20% 
Bolts Up 0° between bolts 105.00 Off 
Run the above until next seeding day. Can leave shaker off if needed. 
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added to cover each sample and covered with foil at 37°C for 20 minutes before fluorescent 
imaging with an inverted microscope. 
5.2.8 SEM Analysis 
Scanning electron microscopy (SEM) was used to visualize the 3-D morphology 
of cells on the cusp surfaces. After rinsing in 1xDPBS, the cusps were fixed in Karnovsky’s 
fixative (2.5% glutaraldehyde, 2% formaldehyde in 0.1 M cacodylate buffer, pH 7.4) for at 
least 24 h. Samples were dehydrated in increasing ethanol concentrations until absolute 
alcohol was reached, then stored in 100% ethanol for up to 12 hours. Following immersion 
in hexamethyldisilazane (Polysciences, Inc., Warrington, PA) for 15 min, samples were 
left to air dry. Samples were then coated with platinum for 2 min (Hummer 6.2, Anatech 
LTD, Union City, CA) before imaging with a Hitachi S4800 or TM3000 Tabletop 
scanning electron microscope (Clemson University Electron Microscope Facility, 
Anderson, SC). 
5.2.9 Histology 
For histology studies, samples collected from the cusp were fixed in 10% formalin, 
embedded in paraffin, sectioned at 5 µm and stained with DAPI for nuclei and 
Hematoxylin & Eosin (H&E). 
5.3 Results and Discussion 
5.3.1 Injection Seeding 
Several trials of injecting cells into the cusps were used to determine the best sizes 
of needles and other tools to use during inflation and injection. Initial trials using carbon 
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particles were helpful in tracking 
where the injected media traveled, 
but did not travel in the same 
manner as the cell suspension. 
Figure 5-5B shows the route of 
needle injection into the central 
layer of the cusp where a bolus of 
localized carbon particles can be 
seen in black. 
Initial placement of cells by 
injection yielded similar boluses of 
cells in the free edges of the cusps 
(Figure 5-5D). The base of the cusp (Figure 5-5C) yielded the most complete air inflation. 
This allowed the injected cells to spread through the tissue more than in the free edges 
of the cusps. Overall, our method of injecting cells into the central layers of aortic cusps 
yields an initial distribution of cells that is concentrated in boluses in various locations of 
the cusp. We will rely on cell migration and dynamic forces to cause these cells to spread 
throughout the tissue during culture. 
Other trials using static seeding and relying on cellular migration to repopulate 
the scaffolds are clearly inadequate up to six weeks when using hADSCs (Figure 5-6). 
Briefly, hADSCs were seeded onto 1 cm2 scaffolds with dropwise methods in 12-well 
plates and kept in static conditions for 6 weeks with media changes every 2-3 days. We 
saw complete cell coverage by the 2-week time point with apparent proliferation beyond 
 
Figure 5-5: Mapping and repopulation after injection 
 (A) Carbon particles (black) were injected into the base and 
free edge of the cusps. (B) Area of carbon injection in the free 
edge of a cusp immediately after injection. Pre-inflation areas 
(C) and direct-inject areas (D) near the free edges are both 
repopulated with cells after injection. The air pockets created 
by inflation can be seen clearly in the base  as shown in the left 
image. The blue line indicates where the cusp was cut from the 
valve root.[140] 
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that, but extremely few cells penetrated the surface of the scaffolds. Although not ideal, 
the injection method of recellularizing the internal layers of the valve cusps holds promise. 
While other methods of achieving a uniform repopulation of the cusp layers are being 
developed, this method is substantially faster and more effective than current methods 
available. 
5.3.2 Rotational Seeding 
Following rotational seeding with method 1, valves were analyzed immediately 
for cellular attachment, spreading, and alignment in comparison to fresh valve cusps 
(Figure 5-7). Analysis using Live/DEAD® imaging and scanning electron microscopy for 
the cusps revealed substantial recellularization. Many surfaces appeared to have as many 
cells present as the native cusps. The exception to this is seen in Figure 5-7K, where fewer 
cells are covering the ventricularis side of the cusp. However, during this trial of cell 
seeding, the rotational regimen was varied and the valve rested in the “root down” 
position for 5 minutes instead of 90. Since this is the position in which the ventricularis 












Figure 5-6: hADSC migration into valve root scaffolds 
hADSCs seeded onto the surfaces (Live/DEAD images) of each type of scaffold proliferated, but did not 
penetrate the surface except in a few instances (C,G,H). The brightness/contrast settings in the DAPI images  
have been artificially increased to enable visualization. 
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Overall, initial cell repopulation was very successful with this method. However, 
the aortic wall and sinus are not as well covered as the cusp (data not shown). Data is not 
available for initial seeding using methods 2 and 3, but analysis of the surfaces after 
further conditioning suggests that these methods are equally or more effective at 
recellularizing the sinus and aorta portions of the valve root than method 1 (see Chapter 
8: for details). One drawback to these methods is the large number of cells to be used at 
one time. For example, a study recellularizing five heart valves by injection and a 
combination of methods 2 and 3 for full surface revitalization would use over 360 million 
cells. As demonstrated in Figure 5-7, fewer cells can achieve excellent results, but 
modifications to the rotational protocol and alternative chamber holders may be 
necessary to accomplish similar seeding densities on the sinus and aorta luminal surfaces. 
 
Figure 5-7: Initial cell coverage of valve cusps 
Fresh cusp surfaces (A-D) are compared with recellularized surfaces (E-L). External seeding method 1 was 
used for these valves. I-L show external seeding method 1 with very limited time resting in the root down 
position, resulting in fewer cells attached to the ventricularis surface.  
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5.3.3 Rotational Device 
Improvements to the previously developed seeding device allow for a semi-
automated process. Minimal user intervention is necessary, but observation during active 
phases of seeding is recommended to prevent unintended scenarios of rotation until the 
software and hardware can be further developed. By calculating the speed and time in 
relation to the physical parameters of the stepper motor, a stopping angle can be 
determined and set by the software and timing. Software and hardware is being developed 
that can control the speed of the shaker plate. 
The additional seeding chamber holding plate to provide an axis of rotation along 
the axis of the valve root was important in achieving full recellularization of all surfaces 
of the valve root. Furthermore, capabilities to seed up to six valves on the same system 
will improve future experiments by allowing for higher sample size. Overall, the 




Page | 93  
 
CHAPTER 6: A PLATFORM HEART VALVE BIOREACTOR 
6.1 Introduction and Background 
Bioreactors have many applications from the bioreactors used for microbial 
expansion to those intended to prepare a tissue for implantation. In the realm of tissue 
engineered heart valves, they have two main purposes: 1) to elucidate the mechanisms  
that influence interactions between cell types or cells and scaffolds and 2) to prepare a 
tissue engineered construct for implantation into a living animal.[118] However, even 
within the application of preparing or testing valve constructs, many various functions 
are performed by bioreactors. From seeding cells, to testing cell retention, to developing 
new extracellular matrix, bioreactors fulfill many purposes that are otherwise unavailable 
with conventional 2D or even some 3D methods. 
6.1.1 Previous Bioreactor Systems 
Many bioreactors focus on subjecting valves, cusps, or cells to stretch, flexure, 
flow, or a combination therof. Commercial systems such as Flexcell (Flexcell 
International, Hillsborough, NC) and other noncommercial systems[141,142] can 
subject cells or small pieces of tissue to various physiological levels of stretch. Flexure 
bioreactors have been created[143] to test the effects of bending on isolated segments of 
scaffolds with or without cells. Flow systems[144,145] have frequently been used in 
many applications to explore the effects of sheer stress on cellular function. Furthermore, 
many systems have been created[146–148] to combine the effects of various conditions 
for the purpose of studying independent vs synergistic effects of those conditions. 
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Despite the wide array of bioreactors present, relatively few are capable of 
preparing a tissue engineered construct for implantation. However, it is in this final area, 
that the most complicated of systems are necessary. They must be capable of subjecting 
the replacement to a gradually increasing set of physiological conditions until the final 
conditions that represent or exceed those seen in the body are reached. Furthermore, 
these types of bioreactor systems must keep the environment sterile and allow for other 
complications seen in the laboratory environment such as limited space, assembly 
techniques, and general lack of ready to use equipment for such purposes. 
The requirements for a heart valve bioreactor system have been discussed in 
previous sections. Although not the most sophisticated system in the literature, 
understanding the function of our previously published version will provide the 
foundational exposure necessary to see the further advances described herein. 
6.1.2 Previous Clemson Heart Valve Bioreactor 
The first edition Clemson heart valve bioreactor was developed to test and 
condition all types of tissue engineered, replacement, and native aortic and pulmonary 
heart valves under adjustable physical stimuli similar to those experienced in 
vivo.[117,149] It was designed with the following 10 important considerations:  
1) To allow mounting of various sizes and shapes of free-standing (“stentless”) 
and stented valve designs into the bioreactor. 
2) To ensure that the valve opens and closes cyclically due to measurable 
changes in trans-valvular pressure. 
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3) To maintain the desired concentration of gases and nutrients and waste 
removal in/from the culture medium. 
4) To expose cell-seeded tissue engineered scaffolds to physical stimuli 
similar to in vivo, including trans-valvular pressures, pulsatile forces, flow 
rate, frequency, stroke rate, stroke volume and sheer stresses on the valve 
surfaces. 
5) To allow full control over parameters and to allow for implementation of 
progressive adaptation protocols. 
6) To ensure maximum visibility and the ability to continuously and remotely 
monitor and record valve function. 
7) To use materials which are non-toxic, non-degradable, and easy to sterilize, 
8) To ensure reasonable durability, easy setup, and compact size to fit in 
standard cell culture incubators. 
8) To maintain the system at 37oC, 5% CO2, and 95% humidity in sterile 
conditions. 
9) To yield repeatable results while fulfilling all of the above conditions. 
The  valve bioreactor is based on a functional principle proposed by Hoerstrup et 
al[111] with numerous modifications. The pneumatic-driven conditioning system 
(Figure 6-1C) consists of a three-chambered heart valve bioreactor (1), an optional 
pressurized compliance tank (2), a res ervoir tank (3) with sterile filter (4) for gas 
exchange, one-way valves (5), resistance valves  (6), pressure transducers, a webcam (7), 
and a ventilator pump routinely used in clinics for intensive care and anesthesia (Siemens 
900E, Soma Technology, Bloomfield, CT). The entire system (except ventilator) can be 
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sterilized using conventional methods (ethylene oxide gas for the acrylic and high-density 
polyethylene components and autoclave for the silicone, PVDF,  and stainless steel 
components) and accommodates all clinically relevant sizes of stented or stentless 
biological, mechanical, or tissue engineered valve substitutes. The valve bioreactor is 
made of acrylic, composed of three compartments and measures 6 inches in diameter and 
8.5 inches in height and is completely transparent (Figure 6-1A). The three parts of the 
bioreactor are held together by stainless steel screws.  
The air chamber is connected to the external pump and is the only chamber not 
filled with culture medium. It is separated from the ventricular chamber by a clear silicone 
rubber membrane. During the inspiration phase of the ventilator (ventilator causing the 
patient to breath air in), air is pushed from the ventilator into the air chamber, the 
membrane bulges into the ventricular chamber, and the residing media is pushed through 
the heart valve into the aortic chamber, opening the valve. Once completed, the exhalation 
phase of the ventilator begins (ventilator relaxes pressure to allow the natural patient 
exhalation) and the ventilator releases pressure in the air chamber, allowing the 
hydrostatic pressure of the remaining fluid in the ventricular chamber to push down on 
the silicone membrane, creating vacuum pressure inside the ventricular chamber. The 
resultant pressure gradient between the ventricular chamber and the reservoir causes 
culture medium to flow from the reservoir tank, through the one-way valves, and into the 








Figure 6-1: First edition heart valve bioreactor and conditioning system 
a) CAD designs (left) and manufactured heart valve bioreactor (right) showing the four main components. 
A transparent silicone membrane diaphragm is mounted between the air chamber and the ventricular 
chamber. b) Air and media flow through the system during systole (left) and diastole (right). Color coding 
aids identification of the components and black arrows indicate direction of air and media flow. c) 
Schematic overview of the entire conditioning system: a three-chambered heart valve bioreactor (1), an 
optional pressurized compliance chamber (2), a reservoir tank (3) with sterile filter (4) for gas exchange, 
one-way valve (5), pressure-retaining valve (6), a webcam (7), and a ventilator pump (air pump). The entire 
setup fits within a standard cell culture incubator. d) Two identical bioreactor systems (Br 1 and Br 2) with 
endothelial cell-seeded, functioning valves inside an incubator; the bioreactors are in the front row while 
their corresponding reservoirs are in the back row. The webcams normally mounted onto the top viewing 
windows of the aortic chamber have been removed to reveal bioreactor details.[117] 
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During the pumping phase, the curvature of the ventricular chamber and angle of 
media inlets contributes to the circulation of culture medium throughout the chamber. 
Once through the valve, the medium enters the aortic chamber then flows through a 
compliance chamber and into the reservoir. Both the aortic and ventricular chambers have 
multiple ports for easy access of pressure transducers, as inlets and outlets for media 
change, or for other probes. 
Figure 6-1D shows two bioreactors set up in one standard size incubator. The 
clear, flat top of the aortic chamber facilitates the viewing of the functioning of the heart 
valve via the webcam. A permanent fluorescent lamp mounted inside the incubator 
provides lighting. Using websites such as www.livestream.com and others, continuous 
broadcast of the bioreactor and valve performance is possible over the internet, allowing 
the investigators remote viewing of valve performance from any computer and sharing of 
information with collaborators. 
6.1.3 System Limitations and the Need for Further Development 
The manufactured and tested first edition bioreactor system fulfills most of the 
original conditions, including mounting of various types of valves and excellent valve 
opening and closing characteristics. The system ensured good cell and valve viability 
under sterile conditions for extended periods of time and excellent reproducibility. It also 
allowed for implementation of progressive adaptation protocols, ensured perfect visibility 
and the ability to continuously and remotely monitor and record valve function. Many 
successful experiments have been conducted using that edition including cell seeding of 
valves and testing under flow conditions as highlighted in Figure 6-2. 
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Most heart valve 
bioreactors in the literature 
are designed for use with 
only the valve type 
investigated in that 
laboratory. Many facilitate 




However, the Clemson 
heart valve bioreactor is 
able to test all clinically 
relevant sizes and 
variations of stented or 
stentless biological, 
mechanical, or tissue 
engineered valve 
substitutes with multiple 
mounting methods allowing for variations in tissue thickness, engineered material, valve 
diameter, amount of excess tissue, and presence or absence of aortic sinuses. Our 
bioreactor’s mounting design easily facilitates many different valves in a variety of non-
restrictive options. 
 
Figure 6-2: Cell analysis of endothelial cell-seeded valvular scaffolds 
after functioning in the first edition bioreactor 
Representative SEM images showing native cusp surfaces (a, b), at time 
zero (T=0d), i.e. immediately after seeding (c, d) and after 17 days 
(T=17d) in the conditioning system (e-h). 
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Incremental stroke volumes from 4.7 to 22.3 mL were achieved. For the lowest 
stroke volume, the valve was only slightly opening. Under no added pressurization, 
systolic and diastolic pressures had an average value of 40/15 mmHg, respectively. After 
pressurization, these values increased to a stable 80/70 mmHg. Higher pressures could 
be attained, but this halted circulatory flow and the pressures were not stable. The 
pressure limitations were the result of an inability of the system to circulate fluid 
effectively. A very high level of pressure could be reached if the pumping mechanism could 
match and overcome that pressure. By using an alternative pumping mechanism that 
would preserve energy by reducing air compression, modifications could be made to 
increase the flow to match and surpass even high physiological values. The stroke volume 
and pressure of our first edition bioreactor do not yet meet aortic physiological levels and 
as the tissue engineering technology improves and valves get closer to implantation 
stages, we will need to be able to reach those higher values. 
Our heart valve bioreactor system’s primary function is to prepare tissue 
engineered heart valves for animal implantation. Thus, representing the whole spectrum 
of physiological conditions as well as those leading to those conditions and sometimes 
exceeding them is necessary. Although the current system is capable of meeting some of 
those needs independently, improvements were necessary to reach the desired outputs 
and capabilities of the system. Thus, one goal of this research was to modify the heart 
valve bioreactor system to achieve simultaneous physiological levels of flow, pressure, 
and shear stresses while maintaining the independent adjustment of each.  
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6.2 Materials, Methods, and Description 
Incremental improvements have been made to the bioreactor system to reach the 
current capabilities. Each increment (Figure 6-4) added specific value that should not be 
veiled by the consummated design. 
6.2.1 Second Edition Heart Valve Bioreactor 
Aside from the technical capabilities, the largest pitfall of the first edition 
bioreactor was its susceptibility for contamination and cracking of the acrylic material 
around the threaded ports. Not only did this consume a tremendous amount of resources 
to repeat contaminated experiments, it was also very time consuming to assemble in a 
sterile hood. A method of connecting the multiple chambers that did not utilize threaded 
fittings was investigated. A quick connect fitting similar to those available from Colder 
Products Company (Figure 6-3A) was desired, with the only difference being that the 
male end plugged into a bulkhead (the side 
wall of the acrylic chamber) instead of 
another fitting. If the second fitting was 
used, the same problem of connecting that 
fitting to the acrylic chamber would occur. 
After exhausting all known 
distributors and suppliers as well as 
inquiring about custom fittings, a novel 
quick-connect fitting (Figure 6-3B) was 
developed and patented[151] that would 
 
Figure 6-3: Quick connect fittings 
Commercially available (A) quick-connect fittings did 
not resolve existing issues, so new fitings (B) were 
designed to plug into a tank like the bioreactor.[151] 
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maintain a sterile seal and be quick to install without utilizing Teflon tape, threading, or 
difficult to sterilize materials. This quick connect fitting is a male fitting with an actuating 
member that engages with a groove in the wall of the bioreactor to lock it in place. It 
utilizes a reliable o-ring seal to maintain sterility and allow for a quick-connection. 
Additionally, it can be manufactured out of materials that can be cleaned and sterilized 
multiple times or 3-D printed and autoclaved for single uses. 
Although the hospital ventilator was able to fulfill the role of pumping media, the 
controls of this ventilator 
did not provide adequate 
tuning of the conditions 
desired and are often 
difficult and expensive to 
acquire. A custom LabView 
program was written to 
control and monitor custom 
equipment (Figure 6-4B) 
for setting the stroke 
volume, stroke rate, duty 
cycle, trans-valvular 
pressures, and overall flow 
rate. Figure 6-5B 
demonstrates the second 
edition bioreactor’s 
 
Figure 6-4: Editions of the heart valve bioreactor 
The conditioning system (A) consists of a three-chambered heart valve 
bioreactor (1), an optional pressurized compliance tank (2), a reservoir 
tank (3) with sterile filter (4) for gas exchange, one-way valves (5), 
resistance valves (6), pressure transducers (7), a flow meter, a webcam 
(8), and an air supply. External LabView software and custom hardware 
(B) monitor and control the system. The bioreactor has come through 
three iterations (C) with the current design shown here (D). 
Page | 103  
 
attainable pulmonic and aortic 
levels of pressure at 75 beats per 
minute, which is adjustable for all 
relevant values. The new system 
for providing the pumping 
mechanism was powered by a 
standard air compressor instead of 
a hospital ventilator. Bioreactor 
pressures are easily adjusted by 
controlling input air pressure and 
can currently reach any desired level. Maximum stroke volume levels achieved under 
sterile conditions with the second edition bioreactor are roughly 30 mL (70 mL is normal 
average). 
An additional upgrade in this edition was utilizing custom glass-blown bottles as 
compliance chambers and reservoirs. By using standard media bottles with barbed 
attachments, we were able to replace multiple assembly steps. Together, the new bottles 
and fittings were able to drastically reduce system setup time and connection points and 
therefore reduce the opportunity for contamination of the system during initial setup. 
While the first edition took 4-6 hours to set up depending on user skill, the second edition 
took less than 2 hours. More improvements in the third edition bioreactor system would 
further reduce that time to about 30-45 minutes for an experienced user. 
User-friendliness was drastically improved with the second edition bioreactor. As 
a result, it was able to support more valve testing experiments than previously possible, 
 
Figure 6-5: Third edition ioreactor function and capabilities 
Mechanical and bioprosthetic (A) replacement valves in their 
open and closed positions. Screenshot of LabView program (B) 
showing pulmonic and aortic pressures. 
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but at sub-physiological flow rates. Shear stress on the tissue was also low because the 
viscosity of the fluid in the system was much lower than that of blood. As the main 
objective of developing a tissue engineered heart valve progressed, additional 
improvements were desired to reach full physiological conditions, decrease complexity of 
the system, and allow for seamless integration into the entire valve preparation process. 
6.2.2 Third Edition Heart Valve Bioreactor 
The next edition of the heart valve bioreactor had slight modifications to its main 
chambers. It eliminated unnecessary ports; added custom threaded nuts to reduce the 
number of bolts used and eliminate any threading in the acrylic components; and utilized 
a re-designed method of holding the heart valve tissue. This tissue holder (described in 
Chapter 3:) is installed around a fresh heart valve and is used to hold, transport, and seal 
the valve in the various treatments of decellularization, fixation, cell seeding, condition, 
and final preparations for implantation. It provides a no-touch approach to handling the 
valves and fully integrates the entire valve preparation process. Utilizing this valve holder 
significantly reduced the time to install a valve into the bioreactor, which not only 
decreased overall assembly time, but also increased cell viability because of the decreased 
amount of time the cell-seeded valves were outside of culturing media. 
3-D printing technology provided by Clemson University Machining and 
Technical Services (both Printer companies, places) was utilized to reduce the footprint 
and number of bioreactor components and subsequently, those connections. It allowed 
the quick connect fittings to be directly attached to custom-shaped reservoirs and 
compliance chambers. By printing the external modules of the bioreactor in a material 
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that could be autoclaved once, we were able to pre-assemble a majority of the components 
outside of the hood, saving time and decreasing the difficulty of assembling a majority of 
the system in a laminar flow hood.  
The new components and custom shapes also allowed for reduced overall footprint, 
lower media volumes used, and an alternative air filter for gas exchange. Very few filters 
were found that could provide the volume transfer over the low pressure drop provided 
by the bioreactor system. Although two options remained, the large flow filter was 
utilized. 
One of the requirements of this edition of the bioreactor was to reduce complexity 
by utilizing disposable or autoclavable components that could be pre-assembled. Recently 
developed turbine flowmeters (EquFlow, Netherlands) were acquired that could be 
autoclaved, but were also relatively inexpensive and could be discarded if necessary. They 
also acted as a partial constriction valve by their inherent functional properties. 
Alternative disposable pressure transducers were utilized that would connect directly to 
ports on the 3-D printed fittings. Normally utilized for invasive blood pressure 
monitoring, these transducers are very precise. 
Utilization of the new flowmeters and pressure transducers also required an 
upgrade to the hardware and software of our controls devices. A chassis system with 
interchangeable modules (National Instruments) that could support the new systems 
components was utilized. This chassis system allowed for numerous counters for the 
flowmeters and data conditioning required by the pressure transducers. This chassis 
system was also beneficial for use in controlling the other components and devices utilized 
in the valve preparation process. 
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6.2.3 Achieving Physiological Pressure, Flow, and Viscosity with the Third Edition 
Heart Valve Bioreactor (Fourth Edition Bioreactor) 
Although the changes made for the third edition bioreactor enable normal and 
pathological conditions of pressure, flow, and shear stress, further modifications were 
necessary to provide those conditions in a sterile environment and control them 
independently. To modify fluid viscosity, 2.5% dextran (Sigma Aldrich) was added to the 
media to thicken the media. 
As previously described, all normal and pathological levels of pressure can be 
achieved by adjusting the input air pressure pumping the system. By increasing the 
pressure, the flow will also increase. However, the physical components of the previous 
versions have limited the flow to about 30 mL per stroke (normal stroke volume is 70 mL 
per stroke) at physiological pressures and 75 beats per minute (bpm). As a result, larger 
flow paths and different compliance chambers were developed with the goal of achieving 
up to 100 mL per stroke at 75 bpm with physiological pulmonic and aortic pressures. 
After increasing all fluid lines to at least 0.9 inches in diameter, we determined 
that initial air volumes of 8 and 1.5 liters would be necessary for pulmonic and aortic 
conditions, respectively to provide adequate flow. This can be calculated from the 
compression ratio of air from 10 to 25 mmHg and 80 to 120 mmHg for pulmonic and 
aortic pressures, respectively. However, it is also dependent upon having enough time 
and low enough resistance to move the fluid by that amount under those relatively small 
pressure changes  
Since 10 liters is too large of a volume to fit multiple systems into one incubator, 
we investigated alternative methods of creating such a compliance chamber. The 
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approach of using a liquid head of pressure for pulmonic conditions was investigated. 
Since 30 mmHg is equivalent to roughly 40 cm H2O, we determined that a cylinder that 
extended at least 40 cm above the valve would be adequate to create pulmonic pressures. 
Additionally, this configuration would fit inside a standard sized incubator. The final 
approach was to attach a 3-D printed cylinder with specific variances in diameter to the 
fluid circulatory line of the system (Figure 6-6A) to create the appropriate pressure head 
on the valve. During diastole, as the fluid continued to flow out of the compliance chamber 
cylinder and into the reservoir, the fluid level would lower and the pressure would 
decrease. By changing the diameter of the cylinder and varying it along the length, we 
could adjust how fast the fluid dropped, which affected the stroke volume and the diastolic 
pressure. This rapid change in air volume in the system was only possible by allowing 
airflow into and out of the compliance chamber. To accommodate, an air filter was 
 
Figure 6-6: Fourth edition bioreactor CAD and photographs 
Pulmonary (A) and aortic (B) modules are shown. CAD renderings and photographs demonstrate the path 
from design to manufacturing 
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attached to this chamber as well as the reservoir that had a large enough surface area to 
accommodate the rapid change in air over the relatively low pressure changes. 
A two-liter custom glass-blown bottle (Figure 6-6B) was used as a compliance 
chamber for the aortic conditions. This size bottle allowed all ranges of stroke volumes, 
depending on how much air was initially in the system at 80 mmHg. By altering the 
amount of fluid in the bottle (and subsequently, how much air) we could control stroke 
volume of the system independently from pressures. Designs have been made to adjust 
the volume via an external source of fluid while maintaining system sterility. This would 
require the least amount of culture media inside the flow loop to reduce supplies. In 
addition, this bottle has a port through which an initial air pressure can be supplied to 
ensure low media usage. 
Incremental improvements in the bioreactor design have allowed us to control the 
compliance tank size, compliance tank shape, pumping air pressure, media viscosity, 
pumping rate, resistance, and duty cycle. Variations of certain combinations of these 
factors allow for the independent control flow, pressure, and shear stresses applied to the 
valves. Furthermore, each can be controlled while maintaining sterile testing conditions. 
While the current system meets all the research needs, further improvements are 
recommended to aid during assembly by novice users. These can be found in Error! 
Reference source not found.: Error! Reference source not found.. 
6.2.4 Validation of Function Testing 
St. Jude mechanical heart valves used for validation of functions. Viscosity 
adjustments were made in accordance with published results.[152] Performance testing 
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was performed on the benchtop to aid in fluid visualization, but closed systems as those 
seen in sterile experiments were maintained. A custom LabView program was used to 
control pumping and monitor flow and pressure during operation. This software utilized 
a National Instruments cDAQ-9178 chassis and appropriate modules. Bioreactor 
pumping utilized module 9472. 
Flow between the compliance chamber and reservoir was measured by an EquFlo 
turbine flowmeter. In this position, continuous flow occurred with cyclical increases in 
flow rate during systole. All fluid passes through this one constriction point, but it should 
be noted that if any regurgitation occurred, this volume of fluid would not be accounted 
for in the flow calculations. Flow is measured in a turbine by counting the pulses sensed 
from an infrared sensor placed in line with the turbine spokes. As the spokes pass, the 
sensor is blocked and a pulse is generated. A National Instruments cDAQ-9401 module 
was used to count pulses and calculations were made dependent upon each individual 
flowmeter’s pulse/liter rating. 
Pressure was measured by DTX Plus pressure transducers. A National 
Instruments cDAQ-9237 module was used to measure and condition the incoming signals. 
Transducers were located at the level of the valve or the baseline adjusted appropriately. 
Each transducer was zeroed to atmospheric pressure in the software before initial use. 
6.3 Results and Validation of Function 
Overall, the bioreactor system has come through four iterations of design. 
Alternative components (compliance chambers, reservoirs, restrictor valves, etc) were 
developed or acquired to allow for physiological levels of flow at pulmonic and aortic 
pressure conditions while maintaining sterility. The controlling hardware and software 
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was upgraded to allow simultaneous and independent operation of multiple bioreactors 
and accurate monitoring of the flow and pressure conditions. 
Shear stresses were increased by adding dextran to the culture media. Other 
researchers had determined that a concentration of 2.5% Dextran (2x106 MW) in DMEM 
with 10% FBS would result in a fluid viscosity to match that of blood. Their previous 
experimentation to measure fluid viscosity was deemed unnecessary to repeat. 
6.3.1 Pulmonary and Aortic Conditions 
Although stroke rate and duty cycle can be adjusted to all reasonable levels, 
testing was performed at 75 bpm with a systole time of 0.3 seconds and a diastole time of 
0.5 seconds. Dextran can be easily added to thicken the media to the appropriate viscosity. 
Full physiological conditions were met for pulmonic position testing. These included flow 
rates exceeding 75 mL per stroke, and pressures up to 35/20 including the normotensive 
pressure of 25/10 in that position. Figure 6-7 demonstrates a valve in the open and closed 
position being tested in the bioreactor at those pulmonic conditions. Full physiological 
conditions have been met for aortic position testing using non-sterile conditions only. 
The newest updates will allow those conditions to be met while maintaining sterility, but 
the final details to 
accommodate are not yet in 
place. However, using the 
aortic module on the 
benchtop, flow rates can 
reach nearly 100 mL per 
 
Figure 6-7: Valve in the functioning bioreactor at pulmonic 
conditions 
Valves open and close well at both pulmonic and aortic conditions of 
pressure and flow. 
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stroke and pressures can rise well beyond 300 mmHg. Normotensive pressures of 120/80 
mmHg and average flow rates of 70 mL per stoke are also reachable in this configuration. 
However, until final device details are in place, increased amounts of media are necessary 
to reach those conditions. 
6.4 Discussion of Further Potential Uses 
The most recent platform bioreactor system developed has numerous applications 
for tissue engineering, mechanical testing, and pharmacological development. The 
resulting small footprint, ease of assembly, modularity, and means of sterile media 
exchange have led to a truly platform system that can be utilized in many fields. While 
many systems described in the literature or that are commercially available can perform 
a single function well, this system performs multiple functions well with a simple change 
of module when necessary. For instance, it can: 
1) Provide a variety of physiological pulmonary and aortic conditions. 
2) Provide a flow loop condition for the mitral valve. 
3) Maintain a sterile environment or be used on the benchtop. 
4) Precondition a tissue engineered valve. 
5) Mechanically test the opening of a valve. 
6) Allow visualization and capture of cusp movement. 
7) Test the placement and perivalvular leakage of transcatheter-deployment. 
8) Assist in the training of transcather deployment of replacement valves. 
9) Create normal or pathological conditions for use in disease modeling. 
10) Independently control up to four systems inside one cell culture incubator. 
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In all, nearly 100 experiments have been performed with these systems and 
improvements have been made with each through the knowledge learned about the 
system. With the knowledge gained from these experiments, we see an expansive field of 
use for this and future editions of the Clemson heart valve bioreactor. 
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PART 3: RESEARCH AND CLINICAL APPLICATIONS 
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CHAPTER 7: BIOREACTOR VALIDATION CASE STUDIES 
7.1 Introduction to Multiple Uses of the Heart Valve Bioreactor 
Bioreactors have many applications from the bioreactors used for microbial 
expansion to those intended to prepare a tissue for implantation. In the realm of tissue 
engineered heart valves, they have two main purposes: 1) to elucidate the mechanisms  
that influence interactions between cell types or cells and scaffolds and 2) to prepare a 
tissue engineered construct for implantation into a living animal.[118] However, even 
within the application of preparing or testing valve constructs, many various functions 
are performed by bioreactors. From seeding cells, to testing cell retention, to developing 
new extracellular matrix, bioreactors fulfill many purposes that are otherwise unavailable 
with conventional 2D or even some 3D methods. 
Our heart valve bioreactor system’s primary function is to prepare tissue 
engineered heart valves for animal implantation. Thus, representing the whole spectrum 
of physiological conditions as well as those leading to those conditions and sometime 
exceeding them is necessary. However, at other times, our system has been utilized for 
other purposes. Projects from undergraduates, other subprojects, and even other main 
graduate student projects have, at various times, made use of the bioreactor systems 
herein described. Disclosed here are other applications of our platform bioreactor system 
that serve to demonstrate its versatility of uses including testing valve designs, creating 
a diseased condition to evaluate drug treatment regimens, and even differentiating stem 
cells into valvular interstitial cells[78]. It should be noted that with a simple switch of 
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modules, the aortic/pulmonic bioreactor has been adjusted to become a mitral valve 
bioreactor. As this is the focus of another student’s ongoing project, details are withheld. 
7.2 Gelatin-Coated Resorbable Polymer Mesh as a Novel Scaffold for 
Heart Valve Tissue Engineering 
7.2.1 Abstract 
A gelatin coated resorbable polymer scaffold was used to create tissue engineered 
heart valves (TEHV) in order to address the issues associated with the longevity of 
current artificial heart valves. It was hypothesized that the combination of specific 
elements is essential to development of a functional TEHV: biomimetic geometry, flexible 
and durable scaffolds, proper cell seeding, and mechanical stimulation. Testing of this 
hypothesis included iterations of aortic valve scaffold designs to mimic native heart valve 
architecture using stainless steel and bioabsorbable polymer meshes. The functionality of 
the valve was tested with a pulsatile flow bioreactor. Preliminary scaffolds were too rigid 
and displayed only a minimal effective orifice area (EOA) for blood flow through the valve. 
The bioabsorbable polymer mesh provided adequate structural support and greater 
flexibility for the gelatin heart valve when compared to the stainless steel mesh. A new 
suturing technique was then incorporated to increase the EOA. Initial studies 
demonstrated that the new suturing technique allowed for natural movement of the root 
and closure of the cusps. However, improvements are still needed to further increase the 
EOA during valve opening. Future research plans include modification of suturing 
techniques as well as the acquisition of more compliant polymer meshes. The gelatin-
coated scaffolds were also tested for cytotoxicity by seeding with cells. Preliminary 
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results displayed cell attachment, but ingrowth was limited. Long-term goals include 
endothelial cell seeding on the most effective polymer scaffold, which will then be cultured 
in a bioreactor where it will be subjected to mechanostimulation. 
7.2.2 Introduction  
The human heart performs approximately forty million cycles a year – an 
estimated three billion cycles for the lifespan of the average human.[11] However, 
increased applied working loads as a result of patient-dependent factors such as stress, 
high blood pressure, and stenosis can lead to degeneration and premature failure of the 
native valve.[153] Malfunction of heart valves can also be caused by non-patient-
dependent factors such as congenital deformation, inadequate leaflet strength, 
calcification of leaflets causing stenosis, or inflammation of the valve.[11] The 
aformentioned pathologies can 
cause inadequate blood flow 
through the valve when the leaflets 
do not fully open, as well as 
regurgitation when the leaflets do 
not properly seal the pathway upon 
closure[154,155] as shown in 
Figure 7-1. In modern times, an 
increasing lifespan has 
proportionally increased the 
occurrence of degradation in heart 
 
Figure 7-1: Normal vs stenotic valves 
Comparison in orifice area of aortic valve with normal function 
and stenotic aortic valve. 
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valves. This failure has led to an increased demand for heart valve replacement 
surgeries.[156] The aortic and mitral valves are more commonly replaced than the 
tricuspid and pulmonary, with more than 100,000 patients requiring replacement of a 
diseased or dysfunctional valve every year in the United States.[157] 
There are currently two categories of replacement heart valves: mechanical heart 
valves constructed from pyrolitic carbon and bioprosthetic heart valves composed of 
biological tissue.[59] These heart valves ensure an improved quality of life, but are 
hindered by a decrease in their viability over time. Mechanical heart valves are more 
durable, but patients who receive them are administered anticoagulants as long as they 
have the implant. Bioprosthetic valves are made from animal tissues and materials that 
are compatible with the body and therefore do not require the administration of 
anticoagulants post implantation. However, the valves are more likely to degenerate 
leading to patients requiring revision surgeries.[158] To overcome these issues, 
researchers have sought to create an entirely tissue-engineered valve capable of 
integration into the body and remodeling to become living tissue. As a deviation from the 
ideology of mere disease mitigation, tissue-engineered heart valves promise to be the 
ultimate fix, serving as a living replacement for a diseased component of the human 
anatomy.[53] Although several groups have demonstrated the feasibility of this new 
technology using animal studies, there are a number of unmet design problems.[102,159] 
Therefore, it is pertinent for a new aortic valve design to be fabricated. 
The focus of the present study was to create living, tissue engineered heart valves 
which can surpass the longevity of current artificial heart valves and optimize structural 
integrity. It was hypothesized that the combination of specific elements are essential in 
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development of a functional tissue engineered heart valve: biomimetic geometry, flexible 
and durable scaffolds, proper cell seeding, and mechanical stimulation. In this study, 
gelatin-coated polymer mesh sutured to mimic porcine valve geometry was used as a 
flexible scaffold and mechanically stimulated in a pulsatile flow bioreactor. Effective 
orifice area and movement of the root and cusps without cells seeded were assessed. 
Fibroblasts were seeded onto the valve materials and were assesed for reaction and 
ingrowth into the materials. This paper describes the design process in an effort to report 
both successful and unsuccessful methodologies to assist future tissue engineering heart 
valve researchers. The final version of the valve, presented herein, is a result of an 
iterative design process, whereby many fabrication techniques were tested to develop the 
best method for mimicking the functionality of a native heart valve while also providing 
optimal durability and biocompatibility. 
7.2.3 Methods and Materials 
Valve Design Process 
The valve was designed by selecting materials, patterns, and techniques based on 
effectiveness and ease of assembly. In general, the desired cusp and wall shapes were cut 
from a mesh, assembled in the form of a tri-leaflet valve, coated with gelatin, and tested 
to assess valve functionality compared to native valves. The first generation design began 
with the use of a stainless steel mesh (Small Parts, Inc., Miramar, Florida, USA) that was 
cut using the contiguous scalloped leaflet template (Figure 7-2a) and sutured (Ethicon, 
Inc., Somerville, New Jersey, USA) to the valve wall (Figure 7-2b). The sutured mesh was 
then fit onto the silicon mold and coated using a gelatin injection technique (described 
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below). Initial testing in a heart valve bioreactor showed very little cusp movement and 
an opening in the center of the valve where the cusp edges were not large enough to touch 
each other upon closing.  
The second generation valve was constructed using a high-density biodegradable 
polymer mesh sutured together to create the valve scaffold. We used the contiguous 
peaked leaflet template (Figure 7-2c) to allow the cusps to touch in the center, and 
finalized it with the gelatin injection technique. This valve was tested in the heart valve 
bioreactor (see description below) and showed adequate closure. However, cusp 
movement was not ideal due to an accumulation of gelatin at the base of each leaflet. For 
this reason, a gelatin submersion technique (see description below) was developed and 
replaced the injection technique to provide a thinner layer of gelatin that would better 
facilitate cusp movement.  
This new gelatin submersion technique was used in combination with a more 
pliable mesh of the same material that had a lower density (AM6-A) and a new design: 
the individual peaked leaflet template (Figure 7-2d) . This new leaflet template was 
designed to create more freely flowing movement of the valve with the use of individual 
leaflets. After testing, these selections were seen to provide optimal valve function and 
served as the third generation valve. 
To further improve function and ease of assembly, a number of different meshes 
and attachment methods were tested. These included a 19 courses per inch (cpi) low 
tension reverse locknit, a 28 cpi low tension reverse locknit, and a 40 cpi low tension 
tricot (generously donated by Poly-Med, Inc., Anderson, SC). Mesh materials and 
architecture were analyzed for valve functionality as well as cellular compatibility. In 
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addition, the suturing method of assembly was compared with a cauterizing method and 
a combined suturing/cauterizing method.  
Gelation Injection Technique 
For non-sterile studies, Knox 
gelatin (Kraft Foods, Tarrytown, New 
York, USA) was dissolved in boiling water 
on a hot plate at a concentration of 0.1 
g/mL and 2% antibiotic-antimycotic 
solution (Mediatech, Inc., Manassas, 
Virginia, USA) was added after cooling. 
Once the mixture thickened, it was 
injected into a silicone mold containing the 
mesh framework and wrapped in plastic 
piping to prevent gelatin from seeping out. 
The mold was then stored at 4°C in a 
refrigerator for 24 hours to allow thermal 
gelation to occur.  
Gelation Submersion Technique 
Gelatin was prepared in the same 
method as the gelation injection technique. 
Using tweezers to hold the feet of the valve 
wall, the valve was submerged in the 
 
Figure 7-2: Leaflet templates 
(2a, b) Contiguous scalloped leaflet design. (2c) Valve 
root design as used with original continuous 
scalloped leaflet design. (2d) Individual peaked leaflet 
design with valve root and valve wall. 
Page | 121  
 
gelatin (Figure 7-3). After each submersion, a 
paintbrush was used to evenly distribute gelatin 
on the valve and avoid undesirable gelatin 
accumulation at the base of the leaflets. 
Submersion and painting was repeated four times 
and the valve was allowed to set for three minutes. 
After setting, the valve was submerged and 
painted three more times to allow for sufficient 
coverage. The valve was stored in a humidifier box 
at 4°C for 24 hours in an inverted position to 
encourage the leaflets to remain in the closed 
position post thermal gelation.  
Bioreactor Studies 
To effectively reproduce and measure the effects of the human body on the 
proposed tissue-engineered heart valve, a pulsatile flow bioreactor designed for heart 
valves[117] was used. The entire assembly has been tested thoroughly and has 
performed consistently in more than 30 experiments with various valve designs.[78] It 
allowed for testing the opening and closing of leaflets in order to qualitatively assess 
similarities to native leaflet movement.  
The bioreactor was designed to allow for mounting valves of various sizes and 
shapes, as well as allow proper exposure to mechanical stimuli for preconditioning of 
valves. To mount a valve in this bioreactor, the valve base must be clamped between two 
 
Figure 7-3: Gelatin submersion technique 
Photograph of gelatin submersion technique 
employed for a polymer mesh scaffold. 
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o-rings. For these experiments, the valve design consists of a valve wall with attachment 
feet (Figure 7-4) that allow for easy installation into this bioreactor. 
Manual Heart Valve Tester 
This novel tester is intended for quick assembly and testing of valves to assess 
integrity and function. By requiring fewer steps during its assembly than the bioreactor 
(described above), it provides a faster alternative when evaluating new valve designs. As 
shown in Figure 7-5, the primary components in the design are: a ventricular chamber, 
bracing rings, an aortic chamber, and a cap. The aortic chamber is attached to the 
ventricular chamber via three adjustable draw latches that can quickly secure the two 
chambers while allowing for adjustments in height for different valve designs. For 
convenience, the tester was designed to utilize the same set of bracing rings as used in 
the bioreactor described by Sierad, et al., which are placed between the two chambers. 
Three screws are used to ensure the cap stays in the correct position and a seal is 
maintained. To manipulate the valve, the user operates two bellows so that when the 
 
Figure 7-4: Dipped mesh scaffold 
Apical view (left) and basal view (right) of valve scaffold after dipping showing feet in basal view. 
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ventricular bellow is squeezed (collapsed), fluid moves through the valve into the aortic 
chamber and the valve opens. The user then collapses the aortic bellow to shut the valve 
and the fluid travels through the external tubing to return to the ventricular chamber. 
The components of the tester in contact with fluid are made entirely from clear acrylic 
and are easy to sterilize. This allows the valve being tested to be clearly viewed from all 
angles.  
Analysis of Effective Orifice Area 
One important measure of valve functionality is the effective orifice area (EOA). 
EOA is the area between the leaflets when a valve is in the open position. EOA relates to 
 
Figure 7-5: Manual heart valve tester 
This tester can be very quickly assembled and is used for quick valve testing. Valves are placed between the 
bracing rings and the metal latched hold all other components together with a quick latch. The two rubber 
bellows are used to pump fluid through the valve to evaluate opening and closing. 
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the amount of work it takes for the heart to push blood through the valve. The larger the 
orifice, the more blood can go through with one pump of the heart and the less work 
required when compared to a smaller opening.  
Effective orifice area was calculated using ImageJ software (National Institutes of 
Health) for valves consisting of high-density bioabsorbable polymer mesh sutured using 
the contiguous scalloped leaflet template (second generation valves) and the thin mesh 
sutured using the individual peaked leaflet template (third generation valves). The EOA 
for an aortic porcine valve was calculated as a control comparison. Images were taken of 
the valves during testing in the pulsatile flow bioreactor. From a series of images taken, 
images of the valve when open were collected and analyzed using ImageJ. The images 
were made binary and inverted so that the valve opening was black. A freehand selection 
drawing was made around the opening and the ‘analyze particles’ command was used to 
calculate the amount of black space in the freehand selection. The particle size was set to 
50-infinity pixels2 and the circularity was 0-1.00. The area reading was recorded. The 
oval selection command was used to evaluate the maximum effective orifice area possible 
if the leaflets were fully open (the inner diameter of the valve). This evaluation was 
performed using the ‘measure’ 
command. The effective orifice area 
was divided by the total area 
possible and multiplied by 100. In 
this study, EOA is represented as a 
percentage of the total possible 
opening of the valve. 
 
Figure 7-6: Mesh valve study design 
12- well plate used for cell study showing rows for Live/Dead 
Assay, H&E staining, and the control. 
Page | 125  
 
Cell Study 
To test cytotoxicity and cell integration of the low-density bioabsorbable polymer 
mesh coated with gelatin (used in the third generation valves), a 3-week cell study was 
performed. 12 samples of the mesh were cut into 1 cm2 pieces, sterilized with ethylene 
oxide, and coated with gelatin using the gelatin submersion technique. Once coated, the 
samples were placed in a 12-well plate, one sample per well (Figure 7-6). After thermal 
gelation, the gelatin coated mesh samples were crosslinked using 0.075% glutaraldehyde 
in 0.1 M Hepes buffered saline at pH 7.4 for 24 hours. The glutaraldehyde was then 
removed and replaced with a 1:1 ratio of Fetal Bovine Serum (FBS) to Dulbecco’s 
Modified Eagle’s Medium (DMEM) for 24 hours for neutralization of glutaraldehyde 
residues. After the allotted time, the FBS/DMEM was removed and the mesh was coated 
in glycine for 2 hours. 3T3 fibroblasts were seeded at a seeding density of 100,000 
cells/well in DMEM/10%FBS media. After 3, 7, 14, and 21 days, samples were examined 
using the Live/Dead assay (Invitrogen) and Hematoxylin and Eosin staining. Samples 
without cells served as a control. 
7.2.4 Results  
Effective Orifice Area 
Figure 7-7 shows one of the initial valves mounted in the bioreactor. Looking 
closely, you can see spaces between the cusps, showing the inability of the initial valves 
to completely coapt. For the low-density bioabsorbable polymer mesh valve made using 
the individual peaked leaflet template (third generation valve), the average percent 
opening was 16.6% for the images from the first day and 15.7% for the second day. A 
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student’s T test determined 
that there was no 
significant difference in 
EOA between the first and 
second day. This shows 
consistency in the valve 
over the course of the time 
spent in the bioreactor. The 
average percent opening for 
the high-density 
bioabsorbable polymer 
mesh valve made using the contiguous scalloped leaflet template (second generation valve) 
was 6.6%. The average percent opening for the decellularized porcine valve was 15.4%. 
There was no significant difference in average percent opening between the low-density 
bioabsorbable polymer mesh valve (third generation valve) and the porcine valve. These 
results reveal that the EOA of the low-density bioabsorbable polymer mesh valve (third 
generation valve) is comparable to that of the porcine valve and there is a significant 
difference between the high-density bioabsorbable polymer mesh valve (second 
generation valve) and the porcine valve showing a large increase in valve functionality in 




Figure 7-7: Bioreactor testing of mesh valves 
Apical view of the second and third generation valves in the bioreactor, 
showing the inability of the initial valves to fully close and open. 
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Cell Study 
The results of the 
LIVE/DEAD Viability 
study are shown in Figure 
7-8. The images are 
overlays of the green and 
red fluorescent images 
created using ImageJ 
software. The results of 
Day 3 and Day 7 showed 
only a few dead cells and a 
large amount of live cells surrounding the low-density bioabsorbable polymer mesh. Day 
14 and Day 21 had an increased amount of dead cells, but still showed an abundance of 
live cells surrounding and incorporating within the mesh fibers.  
The results of the hematoxylin and eosin stains are shown in Figure 7-9. The 
controls and samples were stained and observed under bright field microscopy. The 
results of cellular integration with the mesh were inconclusive, but the images depict the 
gelatin in purple integrating throughout the circular polymer mesh fibers. 
7.2.5 Discussion 
Analysis of Valve Efficacy 
The first iteration of the valve, constructed with a stainless steel scaffold, was 
tested in a pulsatile flow bioreactor for 3 days. This valve exhibited a small effective orifice 
 
Figure 7-8: Cell coverage on the scaffold 
Live/Dead Images at (clockwise from top left) 3 Days, 7 Days, 14 Days, 
and 21 Days. 
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area. Bioreactor testing showed that motion was hindered by an accumulation of gelatin 
at the base of each leaflet. Further, complete coaptation was not evident and the leaflets 
did not display biomimetic motion. These problems can be attributed to the choice of 
material and the template used to make the valve. Understanding that this valve exhibited 
poor compliance to flow lead to the development of a new valve design that more 
accurately mimics the native valve. 
In the second iteration, the high-density bioabsorbable polymer scaffold used a 
contiguous peaked architecture that attempted to better represent native leaflets. This 
valve, however, showed poor movement due to an accumulation of gelatin at the base of 
each leaflet, preventing proper motion in vitro. It was determined that the gelatin 
injection technique applied more gelatin than desirable for effective leaflet motion.  
In comparison with the stainless steel scaffold, the second iteration using the high-
density bioabsorbable polymer scaffold appeared to allow sufficient motion, but valve 
architecture was still a hindrance to valve movement and coaptation. It was determined 
that a contiguous design was preventing valve responsiveness to flow and leading to 
fabrication of a stenotic valve. With these results in mind, alternatives for gelatin coating, 
as well as polymer mesh density and leaflet architecture were considered. A gelatin 
submersion technique, as 
well as a single peaked 
leaflet design and use of 
more porous polymers were 
developed for the third 
iteration of the valve. 
 
Figure 7-9: Gelatin integration around scaffold 
Hematoxylin & Eosin sample showing gelatin integration at 100x (left) 
and 200x (right). 
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In the third iteration valve using low-density bioabsorbable polymer scaffold, each 
leaflet was constructed with a mesh of different courses per inch (cpi), allowing for 
monitoring of individual leaflet motion. Bioreactor analysis suggested that improvements 
were made by switching from the stainless steel to a polymer mesh, but more 
improvements are necessary to reach a fully functional tissue-engineered heart valve.   
The third valve, a low-density bioabsorbable polymer scaffold, addressed the 
issues discussed above and the tests were more successful. The results of testing in the 
bioreactor showed an increase in the EOA of the valve during opening. The low-density 
bioabsorbable polymer scaffold leaflets presented mechanical properties similar to native 
heart valve leaflets, as a result of their compliance to flow. Tight closure of the leaflets 
was observed with little or no backflow.  
7.2.6 Conclusions 
Our data suggests that by using the individual peaked leaflet design, the geometry 
and movement of our valve more closely mimicked that of a native human aortic valve. 
Combining a low-density, bioabsorbable mesh with a gelatin submersion technique 
allowed for an increased EOA as well as more natural and flexible physiological motion 
of the scaffold. Further advancements should include modification of suturing techniques 
and improved gelation techniques to produce a more compliant scaffold while maintaining 
structure integrity, thus increasing EOA.  
Growth of fibroblast cells on the gelatin and mesh scaffold demonstrated that the 
chosen materials could foster the growth of tissue. The growth of new tissue in parallel 
with scaffold degradation will allow for preservation of the original valve architecture 
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and ensure normal blood flow. Future work includes the growth of endothelial cells, the 
native blood contacting surface, on the low-density bioabsorbable polymer scaffold and 
exposing this construct to mechanical stimulation in the bioreactor. Mechanostimulation 
is known to promote the growth of cells, and would lead to an improved design. 
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7.3 Toward an Endothelial-Cell Covered Mechanical Valve; Surface Re-
Engineering and Bioreactor Testing of Mechanical Heart Valves 
7.3.1 Abstract 
Mechanical valve replacements for diseased heart valves have excellent long-term 
durability, but necessitate a lifetime anticoagulation regimen. We aimed to create a more 
hemocompatible device by modifying the leaflet surfaces to promote adherence and 
retention of endothelial cells under physiological shear forces. 
St. Jude Medical mechanical valves were autoclaved, plasma treated, coated with 
a collagen/fibronectin solution, and seeded with porcine aortic endothelial cells. The next 
day, the valves were placed in a custom-made bioreactor where pressures were gradually 
increased until pulmonary or aortic pressures were reached.  Conditioning continued for 
7 days. Cellular retention, viability, and morphology were investigated using 
Live/DEAD® staining, immunofluorescence for CD-31, and scanning electron 
microscopy. 
Results demonstrated successful adhesion of the collagen/fibronectin substrate to 
the pyrolytic carbon surface. Complete endothelial coverage of the leaflet surface in the 
static control group indicates that our surface modification approach created a suitable 
environment for the cells to attach, proliferate, and remain viable. Moreover, after 7 days 
of dynamic conditioning at pulmonary pressures, a significant portion of the endothelial 
cells remained adherent to valve surfaces, improved cell coverage over static controls, 
remained viable, increased cell-cell interactions, and maintained expression of CD31. 
Similar results were seen at aortic pressures but with increased cell removal due to higher 
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shear stresses. Further work is needed to improve cell retention in areas of high shear 
stress, but surface modification and endothelial cell coating may ultimately aid in limiting 
coagulation and reduce the need for anticoagulation medication in patients receiving 
mechanical heart valve implants. 
7.3.2 Introduction 
The overall prevalence of heart valve disease, adjusted to the US 2000 population, 
was 2.5%[160] with about 99,000 heart valve operations yearly.[157] Most of these 
procedures were directed at repairing or replacing the mitral or aortic valve with either 
a bioprosthetic or mechanical valve. Whereas the bioprosthetic valves function well with 
usually no medication needed, many fail within 15 years of implantation.[56] The 
mechanical valves have several positive attributes to their structure including strength, 
durability, and ease of operation. However, they initiate thrombosis within the blood 
stream because of the foreign surface as well as high shear forces.[161–163] To prevent 
this process, the patient must be medicated with anticoagulants and blood-thinning 
medication for their remaining lifespan. Even with the prescription of anticoagulants, the 
patient is still at high risk for blood clots, which can cause stroke, myocardial infarction, 
or pulmonary embolism.[164,165] Thrombosis can also cause the heart valve to 
malfunction, requiring the patient to reenter surgery for repairs. Even if the anticoagulant 
regimen successfully prevents clotting, there is still the increased risk of hemorrhages 
associated with blood thinning medication.[166]  
Endothelialization of blood-contacting surfaces with autologous cells to reduce 
the implants thrombogenicity is a common procedure in the literature. For example, 
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vascular grafts have been seeded with endothelial cells to improve hemocompatibility, 
showing successful attachment of cells to vascular prostheses where the surface had been 
modified using ePTFE and a collagen matrix.[167–169] Studies have also been 
conducted to analyze the morphology of endothelial cells attached to vascular 
prosthesis[114,170] as well as heart valves.[15,93,171] 
Previous work has been performed with the idea of modifying a mechanical valve 
surface to reduce or eliminate the amount of anticoagulants patients would need to 
take.[169] In that experiment, researchers modified mechanical valves by seeding a 
confluent layer of cells on the surfaces. The valves were then implanted into the mitral 
position in pigs for one hour. Although cells initially attached to these leaflets, no cells 
remained attached after explantation, possibly due to the shear forces of the blood on the 
cells and their lack of initial attachment to the surfaces. A drastic improvement in cellular 
retention under physiological shear forces is needed for this method of valve 
improvements to be successful. 
The long-term goal of the present study is to prevent thrombosis in patients with 
mechanical heart valves by improving previous methods[169] of reducing the amount of 
coagulation-causing factors and more specifically by generating endothelial cell-covered 
mechanical valves. For this study, we hypothesized that surface modification will enhance 
initial endothelial cell coverage and further retention under dynamic flow conditions.  To 
test this hypothesis, mechanical heart valves were treated with plasma for surface 
activation, coated with a type I collagen/fibronectin matrix, seeded with endothelial cells 
and maintained in static cell culture. Endothelial cell-seeded mechanical valves were then 
subjected to flow and simulated pulmonary and aortic pressure conditions using our 
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custom-made heart valve bioreactor. Viability tests, scanning electron microscopy and 
immunofluorescence of dynamically challenged cell seeded valves showed that surface-
bound endothelial cells remained attached to the modified valves, proliferated and 
maintained their endothelial phenotype.  
7.3.3 Materials and Methods 
Overall, we first modified the surfaces of isolated leaflets from St. Jude Masters 
Series mechanical heart valve via plasma treatment and matrix attachment. The modified 
surfaces were analyzed with Coomassie Blue staining and scanning electron microscopy 
to confirm matrix attachment and uniformity. Initial cell viability studies were performed 
with fibroblasts. Endothelial cells were then used to further investigate the most effective 
surface modification combination for this application. Cellular analyses were performed 
by Live/DEAD® staining.  
After obtaining the desired surface modification method and confirming its 
cellular compatibility, we cultured and attached porcine aortic endothelial cells on the 
outflow surface of intact St. Jude Master Series mechanical heart valves. These cell-seeded 
valves were then dynamically tested under pulmonic and aortic pressures for seven days 
using a previously described heart valve bioreactor.[117] Valves kept under static 
conditions overnight and for 7 days were used as controls. We analyzed the cells via 
Live/DEAD® imaging, scanning electron microscopy, and immunofluorescence for 
morphology, coverage, and expression of the endothelial cell marker, CD-31 (PECAM), 
respectively. 
Surface Modification 
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Sterilization, Surface Modification, & Matrix Attachment 
Whole valves or individual leaflets removed from St. Jude Medical (St. Paul, MN) 
Masters Series (AJ25) mechanical heart valves ( 1A) were sterilized via steam autoclaving. 
After allowing the valves/leaflets to completely cool and dry, they were plasma treated 
for 5 minutes using a Expanded Plasma Cleaner (PDC-001) from Harrick Plasma (Ithica, 
NY) at 50 mTorr to modify the valve surfaces and promote protein attachment.[172] 
Immediately after plasma treatment, the valves were placed in a sterile 6-well plate and 
immersed in a collagen solution. The collagen solution was prepared by mixing (on ice) 
4 parts 3.1 mg/mL PurCol type I collagen solution (Advanced Biomatrix, San Diego, CA), 
4 parts ddH2O, 1 part 10X phosphate buffered saline (PBS) (Mediatech, Manassas, VA) 
and 1 part 0.1M NaOH (Fisher Scientific). After matrix deposition was confirmed, 100 uL 
of 1 mg/mL fibronectin (Sigma-Aldrich) were added to 7.5 mL of each collagen batch to 
complete the collagen/fibronectin solution. The whole valves or individual leaflets were 
then placed in a cell culture incubator (37oC, 5% CO2) overnight.  
Quantification of Protein Adhesion   
Individual leaflets (n=6) were autoclaved and distributed evenly into the following 
treatment groups: Group 1 – with plasma, with collagen; Group 2 – no plasma, with 
collagen; Group 3 – with plasma, no collagen. Leaflets were modified as above and rinsed 
three times with 1X PBS. Following rinsing, 200 µL of Coomassie Blue stain solution (1% 
Coomassie Blue R-250 in 10% methanol, 80% ddH2O, 10% acetic acid) was placed on the 
leaflets for five minutes at room temperature. Leaflets were then rinsed with ddH2O and 
three times with Coomassie Blue wash solution (38% methanol, 60% ddH2O, 2% acetic 
acid) before adding 250 µL eluent solution (50% ethanol, 50% 50mM NaOH). After 30 
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minutes, 200 µL of the eluent solution was transferred to a 96 well plate and absorbance 
was measured in a Biotek plate reader at 620 nm with a reference of 450 nm. Eluent 
solution was used as a blank.  
SEM Analysis of Modified Surface 
Scanning electron microscopy (SEM) was used to visualize the level of 
homogeneity of the collagen solution on the leaflet surface. After sterilization, two leaflets 
were plasma treated, coated with collagen solution as described above, and allowed to dry. 
One additional leaflet was used as a control with no further modification after sterilization. 
For SEM analysis, the leaflets were fixed in Karnovsky’s fixative (2.5% glutaraldehyde, 
2% formaldehyde in 0.1 M cacodylate buffer, pH 7.4) for at least 24 h. Samples were 
dehydrated in increasing ethanol concentrations until absolute alcohol was reached, then 
stored in 100% ethanol for up to 12 hours. Following immersion in hexamethyldisilazane 
(Polysciences, Inc., Warrington, PA) for 15 min, samples were left to air dry. Samples 
were then coated with platinum for 2 min (Hummer 6.2, Anatech LTD, Union City, CA) 
before imaging with a Hitachi S4800 or TM3000 Tabletop scanning electron microscope 
(Clemson University Electron Microscope Facility, Anderson, SC).  
Cellular Attachment 
Initial Cell Viability Static Test using 3T3 Fibroblasts 
Three leaflets were sterilized and plasma treated before applying the collagen 
solution as described above. 3T3 fibroblasts (Cell Applications Inc, San Diego, CA) were 
expanded in DMEM (Mediatech, Manassas, VA) with 10% FBS (Atlanta Biologicals, 
Lawrenceville, GA) and 1% Antibiotic-Antimycotic (Ab/Am) Solution (Mediatech, 
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Manassas, VA) and 80,000 cells were seeded onto each leaflet for 20 minutes before 
adding additional media to each well to minimally cover the leaflet. Media was changed 
ever 3-4 days for 21 days before analyzing with Live/DEAD® stain for viability as 
described below.  
Endothelial Cell Culturing 
Porcine aortic endothelial cells (pAEC; Cell Applications Inc, San Diego, CA) were 
cultured on cell-culture flasks coated with 50 µL/cm2 fibronectin solution (1 mg/mL; 
Sigma-Aldrich) in a 20 µg FN/mL dilution. Cell culturing media consisted of MCDB-131 
(Mediatech, Manassas, VA) with 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 1% 
Antibiotic/Antimycotic (Mediatech, Manassas, VA), and 0.36 g/L of L-Glutamine 
(Fisher Scientific) and passaging occurred at 80-90% confluence.  
Live/DEAD® Imaging 
Presence of live cells on valves and leaflets was analyzed using Live/DEAD® stain 
(Invitrogen, Eugene, Oregon) according to manufacturers’ directions, using 20 µL of 
EthD-1 and 5 µL of Calcein-AM in 10 mL of 1X PBS. The Live/DEAD® solution was 
added to cover each sample and covered with foil at room temperature for 30 minutes 
before fluorescent imaging with an inverted microscope.  
Dynamic Bioreactor Conditioning 
Mechanical Valve Seeding 
The aortic surfaces of sterilized, plasma-treated, and matrix-coated valves were 
aseptically seeded with porcine aortic endothelial cells (1,250,000 per leaflet) in 500 µL 
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media in a 6-well plate. If any suspension flowed through, it was re-pipetted over the 
valve. This process was repeated for 20 minutes. Valves and leaflets were submerged in 
culture media (about 10 mL for valves and about 3 mL for individual leaflets) before 
placing them in an incubator for overnight attachment. The next day, the valves were 
processed according to dynamic and static conditions below. Media was prepared using 
MCDB-131 with 10% FBS, 2% Ab/Am, 0.36 g/L L-Glutamine, and 0.2% Gentamycin 
(50mg/mL, Sigma-Aldrich).  
Dynamic Conditioning 
The previously described Clemson Heart Valve Bioreactor[117] was used to 
simulate the dynamic conditions placed on the valve. The entire assembly has been tested 
thoroughly and has performed consistently in more than 35 experiments with various 
reported[78] and unreported valve designs. The bioreactor was designed to allow for 
mounting valves of various sizes and shapes, as well as allow proper exposure to 
mechanical stimuli for preconditioning of valves.  
Three valves tested under dynamic conditions were split between high (aortic 
pressures of 120/80 mmHg, one valve) and low (pulmonary pressures of 40/25 mmHg, 
two valves) pressure conditions. The valves were inserted into the bioreactor where 1.2 
L of media was circulated through the system at 60 beats per minute, and roughly 20 mL 
(1200 mL/minute) or roughly 10 mL (600 mL/minute) stroke volume for high and low 
pressures, respectively. Both low and high pressure valves began at a pressure of 7 mmHg. 
For progressive conditioning, systolic pressure was increased to 20 mmHg after 3.5 hours, 
to 30 mmHg after 6.5 hours, and to 40/25 mmHg after 15.75 hours. The valve at low 
pressure condition was left at this pressure until 7 days passed. The valve at high pressure 
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continued to undergo pressure increases to 64/43 mmHg after 19.83 hours, 85/60 mmHg 
after 24.72 hours, 100/75 mmHg after 27.12 hours, and 120/80 mmHg after 47.17 hours, 
where it remained until seven days had passed. Media was changed after three days in all 
bioreactor studies. On the seventh day, all the valves were removed and prepped for 
Live/DEAD® imaging (one low pressure valve) or immunofluorescence (one low pressure 
valve and the high pressure valve). After Live/DEAD® imaging, valves were fixed for 
SEM as indicated below. 
Static Controls 
One valve and leaflet were processed after an overnight incubation under static 
conditions. After overnight cell attachment, the valve was prepped for Live/DEAD® 
imaging and SEM and the leaflet was prepped for immunofluorescence imaging. Another 
valve and leaflet were placed in a 6-well plate with 10 mL and 3 mL of media, respectively. 
The media was changed every 24 hours for seven days. The valve was then prepped for 
Live/DEAD® imaging and SEM and the leaflet was prepped for immunofluorescence 
imaging.  
Immunofluorescence 
Valves or leaflets for immunofluorescence imaging were rinsed with 10 mL of 
warm 1X PBS 2 to 3 times and fixed for 30 minutes at room temperature in 4% 
formaldehyde (BDH Chemicals). Following rinsing with 1X PBS, the bottom of the valves 
was sealed with parafilm and placed into a custom made, pre-formed, silicone mold 
(CopyFlex Liquid Silicone, Culinart, Inc.) to minimize volume needed for staining (Figure 
7-10B). Samples were then blocked using 5% Bovine Serum Albumin (Rockland 
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Immunochemicals, 
Gilbertsville, PA) with 
0.05% Triton (BDH 
Chemicals) in 1X PBS for 2 
hours at room temperature. 
The blocking solution was 
removed and 1000 µL (250 




Littleton, CO) in blocking 
solution (1:2 dilution) was added for 1.5 hours at room temperature. The primary 
antibody was removed before rinsing 4 times with 1X PBS. The secondary antibody, 
Alexa Fluor® 594 Donkey Anti-Mouse IgG (Invitrogen, Grand Island, NY) diluted in 
blocking solution (1:2 dilution) was added for 1 hour at room temperature in the dark 
followed by 4 rinses with 1X PBS. Finally, 500 µL DAPI stain (Sigma-Aldrich) was added 
to each leaflet for 5 minutes at room temperature in the dark before fluorescent imaging. 




Figure 7-10: Mechanical heart valves and testing methods 
A) Masters Series mechanical heart valves provided by St. Jude Medical 
showing the Dacron sewing rings, the inflow side (upper left), the 
outflow side (upper right), and isolated leaflets (bottom). B) Silicone 
mold used to minimize volume needed for staining during 
immunofluorescence. Liquid silicone was poured into the wells and 
covered with plastic wrap before pressing a closed valve into the 
silicone. After curing, the valve and plastic wrap was removed to create 
custom formed wells for mechanical heart valves and leaflets. C) 
Absorbance readings of Coomassie Blue staining for proteins on 
surface-modified mechanical heart valves. ECM = extracellular matrix. 
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The combination of autoclave 
sterilization, plasma treatment, and 
submersion in the collagen/fibronectin 
solution proved to be an effective method 
to attach a cell-friendly matrix to the inert 
surface of a mechanical heart valve. 
Coomassie Blue elution analysis showed 
that collagen indeed attached to the 
surface while confirming the necessity to 
use the combination of both plasma treatment and matrix submersion rather than either 
one alone (Figure 7-10C). Plasma alone and ECM coating alone resulted in negligible 
readings, whereas the combination of the two gave an expected reading for the presence 
of proteins, demonstrating that significant levels of collagen had strongly bonded to the 
pyrolytic carbon surface and were not rinsed away during the coomassie blue procedure. 
SEM analysis (Figure 7-11) provided further visual evidence that a collagen-based matrix 
formed on the leaflet surfaces in a fairly homogeneous distribution after plasma treatment 
and submersion in the collagen solution whereas unmodified leaflets were still smooth. 
Cellular Attachment 
Initial cell attachment and viability tests using fibroblasts cultured on the leaflets 
for three weeks demonstrated that the matrix-coated leaflet was well accepted by the cells 
and did not appear to detach from the leaflet surface. Cells had proliferated to become 
nearly 100% confluent in most areas (Figure 7-12). Under these static culture conditions, 
 
Figure 7-11: SEM of leaflet surfaces 
Scanning electron microscope images of untreated 
(A, B) and ECM-treated (C, D) leaflets at low (A, B) and 
high (C, D) magnifications. 
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over 99% of the cells remained viable, demonstrating excellent cellular compatibility of 
the re-engineered mechanical valve surfaces.  
Dynamic Bioreactor Conditioning 
In order to evaluate the ability of the re-engineered, endothelial cell seeded 
mechanical valve surfaces to withstand dynamic conditions, we subjected valves to 
conditioning in a valve bioreactor, with valves and leaflets incubated in static conditions 
serving as controls. The bioreactor setup seen in Figure 7-13 served to supply and 
simulate physiologic pressures and shear stresses on the mechanical heart valves, causing 
them to fully open and close (Figure 7-13). 
Static Controls 
The valve processed after overnight attachment provides a control from which to 
gauge cellular changes after seven days on the surface of the valve in the flow and non-
flow conditions. Live/DEAD® (Figure 7-14A-C), SEM (Figure 7-15A-C), and 
immunofluorescence (Figure 7-16A, B) 
imaging of the valve under static 
conditions revealed the successful 
attachment of endothelial cells onto the re-
engineered surfaces. The Live/DEAD® 
stain showed the majority of the cells 
fluorescing green rather than red, showing 
excellent initial cell viability. Endothelial 
cell attachment was successful on all areas 
 
Figure 7-12: Fibroblast coverage of leaflets 
Live/DEAD® staining (live=green, dead=red) of 
fibroblasts seeded on the surface of a mechanical 
heart valve leaflet after 21 days in static culture 
conditions. A) shows cells on the rounded edge of the 
leaflet, B) in a central region and C) on the straight 
edge. 
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of the valves, with cells 
appearing as spindle to 
triangular shaped and 
exhibiting no uniformity in 
cellular alignment. A nearly 
confluent layer of cells was 
present on the static valves 
after overnight incubation. 
However, small void spots 
were still present, which 
apparently left room for cell 
proliferation to provide 
almost complete coverage of the valve, which was seen after seven days (Figure 7-14D-
F, Figure 7-15D-F, and Figure 7-16B). Most of the cells retained their spindle shape and 
exhibited tendency to align in swirl patterns, but noticeable distinctions are seen between 
cellular alignment and morphology between time points, especially in the higher 
magnifications. These results indicate that the extracellular m atrix created through our 
resurfacing protocol is a suitable environment for the cells to proliferate and survive. The 
positive CD-31 staining (Figure 7-16A, B) demonstrates the ability of our matrix to 
facilitate a monolayer coverage of anti-thrombotic endothelial cells, which is a key 
component to our objective of reducing thrombogenicity of mechanical heart valves. 
 
 
Figure 7-13: Bioreactor system and valve opening 
A) Overview of the bioreactor system used for testing endothelial cell-
seeded mechanical valves under dynamic pulmonary and aortic 
pressures. The pneumatically driven, pressure controlled valve 
bioreactor 18 is housed inside the cell culture incubator and controlled 
remotely by LabView via a custom made electronics box utilizing the NI-
6008 controller connected to a desktop computer. B,C) An endothelial 
cell-seeded mechanical valve in open (B) and closed (C) positions during 
dynamic testing. 
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Dynamic Testing 
The imaging of the dynamic seven day valves under pulmonic pressures revealed 
three distinct zones of cell coverage (Figure 7-14G-I). The first region is the edge of the 
valves, where most cells were no longer present after seven days of dynamic conditioning. 
This region composed roughly only 10% of the total leaflet area. Moving inward from the 
edges, region two is described as the area of slightly less dense cell coverage than the 
central regions (region three). In these slightly less dense regions, the cells apparently 
 
Figure 7-14: Cell coverage of leaflets after testing by Live/Dead 
Live/DEAD® staining (live=green, dead=red) of aortic endothelial cells on the surface of modified 
mechanical heart valves in static overnight group (A, B, C), static seven day group (D, E, F) and dynamic 
pulmonary seven day group (G, H, I). The upper row (A, D, G) shows the middle of the valve where the two 
leaflets join together. The middle row (B, E, H) shows the hinge or edge of the valve where the leaflet inserts 
into the outer ring. White lines in G and H show the edges of the leaflet. H shows the central region (right) 
as well as the edge region of the leaflet (left). 
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exhibit a larger surface area with a more rectangular morphology than the spindle shape 
seen in the central regions. In this third region (about 85% of the leaflet area), the spindle 
shaped cells do not exhibit a complete uniformity of alignment, but long bands of 10-30 
cells in width are conforming to a single alignment in swirling patterns across the leaflet.  
Compared to the static valves, the pulmonic pressure valves had more complete 
cell coverage of the pyrolytic carbon. The small gaps that existed after static conditions 
were not present in the dynamic valves. This could be seen in the Live/DEAD® images 
in Figure 7-14F and Figure 7-15I, but was more clearly noticed in the SEM images in 
 
Figure 7-15: Cell coverage of leaflets after testing by SEM 
Scanning electron microscopy images of aortic endothelial cells on the surface of modified mechanical heart 
valves in static overnight group (A, B, C), static seven day group (D, E, F), and dynamic pulmonary seven day 
group (G, H, I). Note that under dynamic pulmonary conditions endothelial cells are forming a flat sheet 
with numerous cell-cell junctions that makes it difficult to distinguish the individual cellular boundaries (I). 
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Figure 7-15F and Figure 7-16I where the cells formed more complete junctions almost 
appearing as a cell “sheet” with fewer spaces in the dynamic conditions than in the static 
conditions. The SEM images in Figure 7-15 also revealed that in both static and dynamic 
conditions, the cells appear to be quite flattened on the pyrolytic carbon surface. 
Bioreactor conditioning under pulmonic pressures apparently resulted in stronger, 
more consistent CD-31 expression than under static conditions (Figure 7-16B, D). Under 
aortic pressures, cells remained attached to the valve and continued to express CD-31 
(Figure 7-16, F).  
Conditioning under aortic pressure conditions had similar results to that of 
pulmonary conditions, but fewer cells apparently remained attached to the mechanical 
valve surfaces. Lower cell retention was expected for the dynamic valve under high 
 
Figure 7-16: Cell coverage of leaflets after testing by immunofluorescence 
Immunofluorescence images for CD-31 marker (red) and dapi stain for nuclei (blue) of aortic endothelial 
cells on the surface of modified mechanical heart valves in static overnight group (A), static seven day group 
(B), dynamic pulmonary pressures seven day group (C, D), and dynamic aortic pressures seven day group 
(E, F). Inserts in A, and B are immunofluorescence negative controls. 
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pressure because of the greater shear force and stress. Overall, we noted good cell viability, 
retention, and CD-31 expression (Figure 7-16E, F) for the cells under aortic conditions.  
7.3.5 Discussion 
Surface Modification & Cellular Attachment 
The objective of the present study is to modify the surface to allow for complete 
endothelial cell coverage of the pyrolytic carbon mechanical heart valve leaflets and 
enhanced retention under shear forces. A collagen/fibronectin matrix was used for leaflet 
re-engineering because of their biocompatibility and documented facilitation of cell 
attachment[167] as well as cellular integrin’s ability to strongly bind to the RGD 
sequences found on the fibronectin strand.[173,174] These features allow strong initial 
attachment of cells and subsequent extracellular matrix formation.  
We successfully attached our collagen/fibronectin matrix to the autoclaved leaflet 
surfaces after modifying the pyrolytic carbon surface through plasma treatment, which 
proved to be necessary for the matrix to attach. Plasma treatment uses free radical 
chemistry to clean, micro-etch, crosslink, and surface activate the material. This 
treatment can result in a 2 to 10 fold increase in protein adhesion.[172] From our initial 
data, it is apparent that the collagen matrix completely and evenly bonded to the surface 
of the pyrolytic carbon through functional groups. Whereas Bengtsson and associates 
have previously demonstrated complete endothelial cell coverage on pyrolytic carbon 
through manual seeding with no surface modification,[169] our studies show that not 
only do both fibroblasts and endothelial cells attach to the collagen/fibronectin coated 
valves, but that the matrix actually promotes a more complete cell coverage of the valve 
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over non-altered valves at these seeding densities (data not shown). Although not the aim 
of this particular study, we speculate that fibroblast pre-seeding, as a preamble to 
endothelial cell seeding, might further improve the stability of the ECM bound to the 
pyrolytic carbon surface.   
Successful seeding of endothelial cells on to the modified mechanical valve was 
demonstrated by the results of immunofluorescent and SEM imaging. Images of the 
overnight time point under static conditions suggest that the seeding method used was 
sufficient in creating an even layer of cells on the entire leaflet. After seven days of growth 
in static conditions, a nearly confluent endothelial monolayer was achieved on the 
mechanical valve, but small gaps still appeared between cells, possibly signifying a lack 
of cell-cell interactions that was present in the dynamic conditions. A more spindle shaped 
than triangular shape was also seen after seven days in static conditions. This shape 
reduces cell area, and since cell coverage appeared to be similar or greater after seven 
days, suggesting that cell spreading, rearrangement, and ultimately proliferation is 
taking place. Thus, imaging of the static valves supports the hypothesis that the 
collagen/fibronectin matrix bound to plasma-activated pyrolytic carbon surfaces is not 
cytotoxic.  
Bioreactor Conditioning 
Subjecting the cells to mechanical conditions in the heart valve bioreactor was 
necessary to demonstrate the ability of the matrix modified leaflet to retain cells under 
native conditions before further animal testing. It was also important to test their ability 
to maintain their phenotype in dynamic conditions to ensure a non-thrombogenic surface. 
The heart valve bioreactor previously developed by our lab,[117] which creates nutrient 
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transfer and pressures similar to that of the heart, was utilized to simulate dynamic 
conditions. Valves conditioned using the bioreactor showed a difference in cell coverage, 
cell morphology and alignment, cell-cell interactions, and CD-31 expression compared to 
valves in static conditioning.  
The valve under pulmonic pressures of 40/25 mmHg exhibited better cell 
coverage in the central 90% of the leaflet compared to valves under static conditions 
overnight, as the cells closed the gaps between cells that were present in the static valves. 
The outer 10% of leaflet area, especially around the hinges, contained very few cells 
possibly due to the shear forces on the cells.[175–177] A further increase of shear forces 
on the cells under aortic pressures of 120/80 was correlated to a decrease in final cell 
coverage. The large numbers of cells present on the surfaces after 7 days of exposure to 
aortic pressures indicate that our approach could yield non-thrombogenic mechanical 
valves. However, since mechanical heart valves are already known to cause hemolysis due 
to high shear forces around the leaflet edges and hinges, these areas vacant of cell 
coverage pose an obstacle to reducing hemolysis. Ideally, full coverage of the leaflets is 
desired, especially around the areas with higher shear stress to mitigate the risk of 
hemolysis and the resulting cascade of health issues. 
Cell morphology, orientation, and alignment under dynamic conditions was 
similar to that in static conditions after seven days, but the attached cells appeared longer, 
more flattened, and had a larger surface area under the dynamic conditions. The complete 
coverage in dynamic conditions also leads us to believe that the cells are proliferating, as 
in the static conditions.  
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SEM imaging suggested that the cells are not only flattening out, but also 
interacting with one another more under dynamic conditions than static conditions. This 
might be promising for the creation of a continuous monolayer of cells to reduce 
thrombogenic effects of the foreign surface. The expression of the endothelial cell marker, 
CD-31, under both static and dynamic conditions demonstrates that the cells appear to 
retain their endothelial phenotype and therefore their anti-thrombotic function while 
attached to the surface of the mechanical heart valve. Clinically, this means that an 
autologous endothelial-cell coated mechanical heart valve would create a non-
thrombogenic surface, thus possibly limiting coagulation occurring in patients receiving 
mechanical heart valve implants.  
Challenges in Heart Valve Recellularization 
Providing a confluent endothelial cell surface on any blood-contacting surface is 
a common objective among regenerative medicine cardiovascular implants. Achieving 
such is not simple. We have faced many obstacles and questions in the search for a method 
to do this with a mechanical heart valve. Bonding a matrix to the pyrolytic carbon for 
improved cell attachment may be one breakthrough in this challenging task. However, 
this study has several limitations and opens avenues for further studies with every 
question we face. 
First, what treatment to the valve surface would facilitate a more complete cell 
coverage and stronger bond for the cells upon subjection to shear stresses, especially on 
the inflow side where larger forces are seen than on the outflow side of the valve? 
Alternative matrix components or concentrations could yield results that are more 
favorable.  
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Second, what progressive mechanical conditioning regime would allow more cells 
to remain attached? Further studies should examine incubating the cell-seeded valves 
under static conditions for several days before subjecting the valves to dynamic conditions 
and/or slowing the rate of increase in progressive adaptation to reach physiologic 
pressures. Our studies progressed to aortic conditions over two days whereas recent 
experiments indicate that progression lasting up to three weeks may be necessary.  
Third, if cells can be retained to reach physiological conditions, how would they 
phenotypically and morphologically respond to appropriate conditions of shear and valve 
opening/closing speeds? Studying cellular response with appropriate flow rates and after 
adding a thickening agent such as dextran to the media may help answer these questions.  
Finally, will the layer of endothelial cells on a mechanical valve leaflets 
functionally reduce thrombogenicity of mechanical heart valves? It is well documented 
that high shear forces around the valve – not contact with the pyrolytic carbon surface – 
is responsible for hemolysis leading to clotting. Functional thrombogenicity in in vitro 
testing with whole blood or purified platelets, as well as in vivo large animal implantation 
as valve substitutes are required for validation of this mechanical heart valve re-surfacing 
and re-engineering approach.     
7.3.6 Conclusions  
Surface modification of mechanical heart valves via plasma treatment facilitates 
attachment of a cell-friendly surface layer of matrix proteins, which supports endothelial 
cell attachment, spreading, and proliferation in static conditions. In short-term dynamic 
conditioning under physiologic pressures, the new endothelial monolayer maintains 
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viability, cell-cell interactions, and endothelial phenotype. Although the cell retention in 
these studies is promising, improvements are greatly needed when subjecting the cells to 
physiologic shear stress, especially in areas around the edges and hinges of the leaflets. 
This is intensified when considering that the preservation of the endothelial coating on 
the leaflet in areas subjected to high shear forces will determine the success of reducing 
thrombogenic effects caused by mechanical heart valves. Work is needed to develop a 
progressive pre-conditioning regime that maintains cell attachment before steady 
subjection to pulmonic or aortic pressures and flow. Additionally, further in vitro and in 
vivo testing is necessary to demonstrate the decreased thrombogenicity of endothelium-
covered mechanical heart valves. Success of such advances could ultimately aid in 
reducing the need for anticoagulation medication in patients receiving mechanical heart 
valve implants. 
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7.4 Discussion of Bioreactor Applications 
The bioreactor systems developed have numerous applications for tissue 
engineering, mechanical testing, and pharmacological development. In all, dozens of 
experiments have been performed with these systems and improvements have been made 
with each through the knowledge learned about the system. The resulting small footprint, 
ease of assembly, modularity, and means of sterile media exchange have led to a truly 
platform system that can be utilized in many fields.  
Beyond tissue engineering and testing heart valves, the platform bioreactor 
system has great potential for developing in vitro models for comparing drugs and 
screening potential treatments for diseases. Animal models do not fully reproduce human 
pathology and are difficult to combine multiple risk factors seen in dialysis-sustained 
ESRD, besides their restrictive cost considerations. A testing platform to would assist in 
the development of such a pharmacological treatment for aortic valve disease. 
While many systems described in the literature or that are commercially available 
can perform a single function well, this system has been shown to perform multiple 
functions well with a simple change of module when necessary. It can provide a variety 
of normal and pathologic physiological conditions including those for aortic and mitral 
valves while maintaining a sterile environment to precondition a tissue-engineered valve. 
These conditions can also be made to mimic diseased states for evaluating drug treatment 
regimens. It can be used on the benchtop to test the opening of a valve, TAVR valve 
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placement, and perivalvular leakage. It can assist in the training of transcatheter 
deployment of replacement valves and allows visualization and video capture of cusp 
movement regardless of location. Furthermore, it is compact enough to fit four 
independently controlled systems inside a standard cell culture incubator. The described 
experiments have demonstrated the utility of this system and are but a sampling of its 
capabilities. 
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CHAPTER 8: TISSUE ENGINEERED HEART VALVE 
CONDITIONING 
8.1 Introduction 
The key to achieving an implant capable of repairing itself in response to micro 
tears is the presence of cells to remodel the matrix as necessary.[35,37] In cases where 
the valve implant does not have the adequate mechanical properties to function properly 
upon implantation, in vitro cellular remodeling must prepare the valve scaffold prior to 
implanting.[89–91] Multiple groups have demonstrated cell seeding on the exterior 
surface of valve cusps and some have even achieved some interstitial seeding, though full 
revitalization has not been realized.[92–94] The surfaces of some valves have even been 
repopulated after implantation in animal models,[95,96] but the same is not guaranteed 
in the human system. Even if the valve can be initially covered with cells,[73,97,98] it is 
likely that these cells will need some sort of progressive conditioning to remain attached 
after implantation since application of sudden shear forces can detach cells. Overall, more 
progress is needed to achieve full and consistent external and internal recellularization of 
the cusps and to determine what methods are needed to allow the cells to remain, but 
autologous adult stem cells provide a promising source for this application.[99,100] 
8.2 Materials and Methods 
8.2.1 Study Overview 
Fresh porcine aortic valve roots were collected, cleaned, and prepared as described 
in section 3.3.1. Aortic roots were decellularized by 16-day perfusion as in section 4.2.3 
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or in the case of one valve, by 8-day immersion as in section 4.2.2. All valves were then 
crosslinked with PGG as in section 4.2.4. Prior to seeding, valves were neutralized for 
18-24 hours in DMEM with 50% FBS and 1% Antibiotics/Antimycotics at 37°C. Stem 
cells were cultured as in 5.2.2. Many cell-seeded valves were tested for this compilation 
study, but due to device failures, data for only 13 valves will be reported. Additionally, 
valves evaluated for initial cell placement (internal and external) have been reported in 
Chapter 5: and details will not be repeated here. 
One valve was externally seeded with 16 million cells by method 1 of section 5.2.6 
before being placed in the bioreactor for progressive conditioning and testing. Results 
from this trial indicated that additional preconditioning was necessary. Following the 
first experiment, 10 more valves were internally seeded with 4 million cells at passage 6 
per cusp as in section 5.2.5. Six of those valves were also externally seeded with 30 million 
cells at passage 6 by method 2 of section 5.2.6. Furthermore, three of the latter group 
were seeded as above and successively seeded with an additional 30 million cells at 
passage 7 by method 3 of section 5.2.6. A summary of the cell-seeded valves can be seen 
in Table 8-1. 
Initially seeded valves were described in Chapter 5:. Internally and externally 
seeded valves were investigated for each group, but are often contained in the same valve, 
leading to a seemingly high total sample size. Final test groups can be seen in Table 8-2 
and include: 
1) Static controls (ST): Valves kept in the incubator with media changes every 
two days, daily, or 2 hours as necessary. 
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2) Rotationally conditioned (RC): Valves conditioned by the seeding chamber 
frame described in section 5.2.3. 
3) Rotationally and bioreactor conditioned (RCBR): Valves rotationally 
conditioned then bioreactor conditioned with the third (section 6.2.2) or fourth 
(section 6.2.3) edition bioreactor. 
4) Bioreactor conditioned (BR): Valves conditioned in the third (section 6.2.2) 
edition bioreactor immediately after cell seeding.  
After appropriate conditioning, valves were analyzed for cellular attachment, 
spreading, retention, alignment, and viability using the Live/DEAD® assay, scanning 
electron microscopy (SEM), histology, or immunohistochemistry as appropriate for each 
group. 
8.2.2 Static Controls 
For the static valves, sterile filters were attached to the needleless ports in the lid 
of the chambers and the seeding chambers remained in the cell culture incubator for 13-
15 days. Media was changed every two days, daily, or12 hours as necessary based on pH 
colorimetric indicators in the media. 
Table 8-1: Summary of cell-seeded valves 
Number 
of Valves Internal Seeding Primary External Seeding Secondary External Seeding 
1 0 Method 1: 16e6 cells, p5 0 
6 4e6 cells/cusp, p6 0 0 
3 4e6 cells/cusp, p5/p6 Method 2: 30e6 cells, p5/p6 0 
2 4e6 cells/cusp, p5/p6 Method 2: 30e6 cells, p6 Method 3: 26e6 cells, p7 
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8.2.3 Pulmonic Bioreactor Conditioning and Testing without Rotational Conditioning 
After external seeding, distal aortic root stabilizers (section 3.2.5) were added to 
each valve root for support during bioreactor conditioning and testing. The valves were 
transferred to the pre-assembled third edition bioreactor, where pressure was increased 
every 12 hours until final pulmonic parameters were reached, as seen in Figure 8-1. 
Upon reaching final pressures of 40/25 mmHg and flow of roughly 30 mL per 
stroke at 75 beats per minute (bpm), valves were tested for an additional 13 days before 
analysis for a total of 17 days in the bioreactor. Media was changed every 3.5 days (twice 
per week) throughout conditioning and testing. 
8.2.4 Rotational Conditioning 
After the desired internal and external seeding, valves were conditioned further 
in the rotating chambers. The end-over-end rotating chamber holding plate was attached 
to the frame and needleless ports were attached to each seeding chamber. The chambers 
were placed into the chamber holder plate. Rotating and orbital conditions progressively 
increased every 12 hours until a shaker speed of 40% and rotational speed of 4 rpms were 
achieved for short-term conditioning. Long-term conditioning followed the schedule seen 
in Table 8-3 with media changes occurring during every adjustment (roughly every 12 
Table 8-2: Test groups for valve seeding experiments 
Group Number Internal Seeded Vavles Days 
Number External 
Seeded Valves Days 
Initially Seeded 2 0 2 0 
Static (ST) 1 13 1 13 
Rotationally Conditioned (RC) 
1 13 1 13 
3 23-25 1 25 
Rotationally and Biroeactor 
Conditioned (RCBR) 
1 8 1 8 
1 29 1 29 
Bioreactor Conditioned (BR) 2 23 1 17 
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hours) after day 3. Position 
A (holder orientation) from 
previous rotation angles 
was not monitored from 
this point on. After 13-15 
(short term) or 23-25 (long 
term) days of rotational 
conditioning, valves were 
analyzed or transferred to the bioreactors for adaptive conditioning and testing. 
Media was changed every two days, daily, or every 12 hours as necessary based 
on pH colorimetric indicators in the media. For these changes, the chambers were 
removed from the frame and drained by vacuum through a needleless port with an empty 
50 mL syringe attached to the other port to allow sterile air into the system. Following 
draining, about 130 mL of cell culture media was added to each chamber (until the media 
just covered the stainless steel mounting rings). The syringes were removed and the 
chambers placed back into the chamber holders with the 0° mark aligning with the set 
mark on the holding plate and rotated. 
 
Figure 8-1: Bioreactor preconditioning without rotation conditioning 
This trial reached pressures of 40/25 within 4 days. 
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8.2.5 Pulmonic Bioreactor Conditioning and Testing with Rotational Conditioning 















0° on set mark 16:00 1 10% 2 1800 540 1000 
0° on set mark 05:20 1 20% 3 1800 540 1000 
0° on set mark 13:40 2 25% 4 1800 360 1000 
0° on set mark 22:15 2 25% 5 1800 360 1000 
0° on set mark 10:05 3 25% 6 1800 180 1000 
0° on set mark 23:15 3 25% 7 1800 180 1000 
0° on set mark 14:00 4 25% 8 1800 0 1000 
0° on set mark 20:32 4 25% 9 1800 0 1000 
0° on set mark 11:35 5 25% 10 1800 0 1000 
0° on set mark 21:45 5 25% 11 1800 0 1000 
0° on set mark 11:25 6 25% 12 1800 0 1000 
0° on set mark 23:45 6 25% 13 1800 0 1000 
0° on set mark 13:00 7 25% 14 1800 0 1000 
0° on set mark 22:45 7 25% 15 1800 0 1000 
0° on set mark 11:00 8 25% 16 1800 0 1000 
0° on set mark 22:00 8 25% 17 1800 0 1000 
0° on set mark 13:30 9 25% 18 1800 0 1000 
0° on set mark 04:30 9 25% 19 1800 0 1000 
0° on set mark 20:30 10 25% 20 1800 0 1000 
0° on set mark 11:45 10 25% 20 1800 0 1000 
0° on set mark 20:00 11 25% 20 1800 0 1000 
0° on set mark 16:30 11 25% 20 1800 0 1000 
0° on set mark 13:00 12 25% 20 1800 0 1000 
0° on set mark 21:00 12 25% 20 1800 0 1000 
0° on set mark Missed 13 25% 20 1800 0 1000 
0° on set mark 18:45 13 25% 20 1800 0 1000 
0° on set mark 12:00 14 25% 20 1800 0 1000 
0° on set mark 22:30 14 25% 20 1800 0 1000 
0° on set mark 14:00 15 25% 20 1800 0 1000 
0° on set mark 22:00 15 25% 20 1800 0 1000 
0° on set mark 12:00 16 25% 20 1800 0 1000 
0° on set mark 23:30 16 25% 20 1800 0 1000 
0° on set mark 20:00** 17 25% 20 1800 0 1000 
0° on set mark 12:45 17 25% 20 1800 0 1000 
0° on set mark 02:00 18 25% 20 1800 0 1000 
0° on set mark 20:00 18 25% 20 1800 0 1000 
0° on set mark 10:50 19 25% 20 1800 0 1000 
0° on set mark 23:00 19 25% 20 1800 0 1000 
0° on set mark 17:30 20 25% 20 1800 0 1000 
0° on set mark 09:00 20 25% 20 1800 0 1000 
0° on set mark 20:00 21 25% 20 1800 0 1000 
0° on set mark 14:00 21 25% 20 1800 0 1000 
0° on set mark 22:45 22 25% 20 1800 0 1000 
0° on set mark 17:30 22 25% 20 1800 0 1000 
0° on set mark 10:30 23 25% 20 1800 0 1000 
0° on set mark 23:45 23 25% 20 1800 0 1000 
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After 5 or 25 days of the above rotational conditioning, distal aortic root 
stabilizers (section 3.2.5) were added to each valve root for support during bioreactor 
conditioning and testing. The valves were transferred to pre-assembled third (for 5 day 
conditioned valves: “short pre-conditioned”) or fourth (for 24 day conditioned valves: 
“long pre-conditioned”) edition bioreactors (see section 6.2.3 for details of this system). 
The short pre-conditioned valve was increased to 25/15 mmHg at 75 bpm and a 
stroke volume of 35 mL over the course of eight days (Figure 8-2). Increases in pressure 
occurred every 12 hours. At each increase, systolic pressure was increased by 0.5 mmHg 
each time for the first five days and 4 mmHg each time for the final 3 days. Media was 
changed every 3.5 days (twice per week) throughout conditioning. Upon reaching final 
pressures of 25/15 mmHg and flow of 35 mL per stroke, valves were analyzed by 
Live/DEAD, histology, and immunohistochemistry. 
8.2.6 Live/DEAD® Imaging 
Presence of live cells on tissue surfaces was analyzed using Live/DEAD® stain 
(Invitrogen, Eugene, 
Oregon) according to 
manufacturers’ directions, 
using 20 µL of EthD-1 and 
5 µL of Calcein-AM in 10 
mL of 1X PBS. The 
Live/DEAD® solution was 
added to cover each sample 
 
Figure 8-2: Bioreactor preconditioning without rotation conditioning 
This trial reached pressures of 25/15 within 7 days after rotation 
conditioning for 5 days. 
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and covered with foil at 37°C for 20 minutes before fluorescent imaging with an inverted 
microscope. 
8.2.7 Histology and Immunohistochemistry 
For histology studies, samples collected from the aortic wall, sinus, cusp and 
muscle were fixed in 10% formalin, embedded in paraffin, sectioned at 5 µm (3 µm for the 
aorta), and stained with DAPI for nuclei, Hematoxylin & Eosin (H&E), and Movat’s 
Pentachrome.  
Immunohistochemistry (IHC) was performed to detect remaining components 
after decellularization. Biotinylated Griffonia simplicifolia (GS) lectin was used to detect 
Gala1–3Gal (a-Gal), the main porcine antigen responsible for acute rejection of 
xenotransplants. IHC for laminin, and type IV collagen was also performed. Tissue 
samples were rinsed with 1X PBS fixed at room temperature in 4% formaldehyde (BDH 
Chemicals). Following rinsing samples were blocked using 5% Bovine Serum Albumin 
(Rockland Immunochemicals, Gilbertsville, PA) with 0.05% Triton (BDH Chemicals) in 
1X PBS for 2 hours at room temperature. The blocking solution was removed and 250 
µL primary CD-31/PECAM1 Antibody (VM64) (NBP1-42152; Novus Biologicals, 
Littleton, CO) in blocking solution (1:2 dilution) was added for 1.5 hours at room 
temperature. The primary antibody was removed before rinsing 4 times with 1X PBS. 
The secondary antibody, Alexa Fluor® 594 Donkey Anti-Mouse IgG (Invitrogen, Grand 
Island, NY) diluted in blocking solution (1:2 dilution) was added for 1 hour at room 
temperature in the dark followed by 4 rinses with 1X PBS. Finally, 500 µL DAPI stain 
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(Sigma-Aldrich) was added to each slide for 5 minutes at room temperature in the dark 
before fluorescent imaging. Primary antibody was omitted for staining negative controls. 
8.3 Results and Discussion 
8.3.1 External Cell Response 
As shown previously and repeated in Figure 8-3, initial cellular attachment to the 
cusp surfaces was very successful with method 1. However, the surfaces of the sinus and 
aortic wall required additional seeding. Utilizing methods 2 and 3 have resulted in 
excellent initial cell coverage of those areas as well. 
Cell-seeded valves were placed directly into the bioreactor for 17 days. As a result 
some cells remained attached to the valve and were further spread and aligned than static 
controls and initial time points. However, many of the cells had been removed from the 
scaffolds, presumably because of the applied shear stresses. We believed that a gentler 
pre-conditioning regimen, including more time in the rotating seeding chambers, would 
increase cellular retention. Studies were performed to evaluate the effect of increasing the 
cell quantity, rotational conditioning time, and the time it took for the bioreactor to reach 
full pulmonic conditions. A summary of this data can be seen in Figure 8-3. 
Valves conditioned in the rotating conditioner for 13 days are subjected to lower 
shear stresses than those in the bioreactor and thus, they retained full cell coverage on 
both sides of the cusp with similar, but less noted spread and alignment compared to 
bioreactor valves. This indicates that a substantial layer of cells was growing on the 
surface of the cusps prior to bioreactor conditioning. 




Figure 8-3: External and Internal cell seeding and retention 
Live/DEAD® and H&E imaging of fresh valve cusps (A-C) in comparison to valves initially seeded (D-
E), static for 13 days (G-I), bioreactor conditioned for 13 days (J-L), rotating conditioned for 13 (M-
N, R), 15 (O), and 24 (S) days, and rotating conditioned for 5 days then bioreactor conditioned for 
8 days (P-Q). (R) is internally and externally seeded. 
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Valves were placed in rotational conditioning regimens for 5 and 25 days prior to 
being placed into the bioreactor. Once in the bioreactor conditions were slowly increased 
until 25/15 mmHg at 75 bpm was reached. The first set of valves achieved 35 mL per 
stroke and was cultured in the bioreactor for a total of 8 days. The second set of valves 
achieved 70 mL per stroke and 2.5% dextran and was cultured in the bioreactor for a total 
of 29 days. Surface imaging indicated that the 5-day rotational pre-conditioning was 
inadequate. Similar or fewer cells remained on the valve surfaces for this experiment than 
the previous bioreactor experiment having no rotational conditioning. The second set of 
valves took that into consideration and had an extensive rotational conditioning step 
before being placed into the bioreactor. 
Unfortunately, during the rotational conditioning, it is likely that many of the 
cells died due to a pH imbalance. As the conditioning progressed, the pH in the media 
inside the seeding chambers was dropping, as indicated by the phenol red indicator 
turning orange faster and faster). At one point, an extended period elapsed between media 
changes (indicated by ** in Table 8-3). After this time point, the media did not change to 
orange nearly as fast. Initial evaluations of the valves indicated that most of the cells had 
been removed from the scaffold surfaces. Despite this, one valve was placed in the 
bioreactor in case external cells remained on that valve or the internally seeded cells were 
still viable. 
Overall, additional rotational conditioning is necessary for cell retention once the 
valves are placed in the bioreactors. However, improved devices, methods of gas exchange, 
and protocols must be investigated to reduce the chances of the seeded cells dying during 
this phase.  
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8.3.2 Internal Cell Response 
Internal seeding of hADSCs into porcine aortic valve cusps yielded promising 
results. Initial cell placement was concentrated in boluses at the injection sites with 
improved initial distribution near the base of the cusps. Static and short-term rotational 
conditioning yielded little to no cellular migration. However, after 24 days in rotational 
conditioning and bioreactor conditioning, cells were beginning to migrate into the 
surrounding tissue layers (see especially Figure 8-3O). Although slow and not ideal, this 
method of repopulating the internal areas of the aortic cusps has yielded promising results. 
Immunohistochemistry (Figure 8-4) of the injected cells immediately after 
injection and after 24 days in the rotating conditioner or bioreactor conditioner 
 
Figure 8-4: Immunohistochemistry of conditioned internal cells 
Slides stained for Vimentin, alphs-SMA, and P4HA3 immediately after injection and after 24 days in the 
bioreactor or rotating conditioner.[140] 
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demonstrated some changes in marker expression. Notably, alpha-smooth muscle actin 
had a higher expression after bioreactor conditioning than rotating conditioning. The 
expression of this marker indicates a myofibroblast-like phenotype typical of cells that 
are remodeling their matrix. 
Further IHC analysis suggests that the cells undergoing rotational conditioning 
resemble q-VICs. There is strong expression of vimentin and little to no true staining for 
α-SMA and prolyl-4-hydroxylase. These reports are promising, as the goal of achieving 
a quiescent-VIC phenotype is ideal prior to further mechanical conditioning. 
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CHAPTER 9: ANIMAL IMPLANTS OF TISSUE ENGINEERED 
HEART VALVES 
9.1 Introduction 
Laboratory research is often disconnected from clinical practice. One day, we may 
be able to develop a functional tissue engineered valve, but if the technology cannot be 
utilized in a clinical setting, it may be necessary to revise the technology from a 
fundamental level. If we can adapt our laboratory practices to consider clinical 
requirements during the research and development stage, translation into clinical practice 
will be more easily realized. Initial animal trials must be performed to reveal hurdles we 
will need to overcome in our process of translating tissue engineered heart valves into 
clinically relevant products. We will then be able to adapt our laboratory practices to 
consider clinical requirements during the research and development stage. 
Our initial investigations into animal implantation revealed a necessity for many 
of the specific features of the devices described in previous chapters. For example, it was 
vital to have a user-friendly valve mounting system that will be used to house the valve 
from initial cleaning to just before implantation with minimal to no handling of the valve 
itself. This chapter will describe the experiments made possible by the technologies and 
research previously described. Herein, we aim to generate implantable tissue engineered 
heart valves by optimal integration of three main factors: acellular heart valve root 
scaffolds, autologous stem cells, and construct preconditioning in a bioreactor. As the 
study continues, additional translational challenges will inevitably necessitate further 
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alterations to our laboratory protocols for valve preparation as we translate the 
laboratory research into a clinical setting 
By implanting these tissue engineered heart valves, we will be implanting the first 
stem cell seeded heart valve in an animal model to eliminate the risk of immune response 
due to remaining cells. These studies will also help to demonstrate that translational 
regenerative medicine is feasible with autologous stem cells for tissue engineering 
replacement therapy – a vital stage in the ability to remove barriers in commercializing 
tissue engineered products.[68,123–125] 
9.2 Materials and Methods 
The research team in Targu Mures, Romania has prepared acellular porcine valve 
scaffolds using the devices and methods developed in chapters 3 and 4. They will isolate 
adipose derived stem cells from sheep, multiply them in culture, and use them to 
repopulate the acellular scaffolds as in chapter 5. They will then precondition the cell-
seeded scaffolds using rotational conditioning methods developed in chapter 8. After 
preconditioning, the surgical team will implant the autologous cell-seeded tissue-
engineered valves in a right ventricle to pulmonary artery shunt in the young adult sheep 
from which the cells were originally taken. Future studies will analyze these valves at 6- 
and 12-month time points at the macroscopic and microscopic level for calcification, 
necrosis, structural damage, cell infiltration, and cell retention. 
9.2.1 Primary Stem Cell Isolation and Culture 
Sheep adipose-derived stem cells (sADSCs) were isolated (Figure 9-1) from well-
vascularized, soft subcutaneous fat samples in the rear subscapular region under sterile 
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conditions and anesthesia from 
individual animals. Established 
collagenase digestion 
protocols[178] were used to 
isolate the stem c ells, which 
involved cutting the tissue 
fragments into small pieces and 
digesting with 20 mL/50 mL tube 
collagenase type I (Sigma) 
1mg/mL 1% BSA, PBS at 37°C, 1 
hour with agitation in the water 
bath. Tissue digest was filtered through 100 µm sieves into new 50 mL tubes and 
centrifuged at 1000 rpm for 5 minutes before aspirating the supernatant. The cell pellet 
was resuspended in 155 mM NH4Cl with 0.1 mM EDTA in PBS and incubated 5-10 
minutes at room temperature to lyse red blood cells. After another centrifugation at 1000 
rpm for 10 minutes, the supernatant was aspirated and the pellet was resuspended in 
DMEM with 10% FBS and 2% Antiobiotics/Antimycotics and plated. Media was changed 
every 3-4 days and passaged with trypsin at 70% confluence 
9.2.2 Scaffold Preparation 
Fresh porcine aortic valve roots were collected, cleaned, and prepared as described 
in section 3.3.1 with the restriction that the donor pigs weigh between 45-50 kg. Aortic 
roots were decellularized by 16-day perfusion (section 4.2.3) techniques, crosslinked with 
 
Figure 9-1: Stem cell isolation from sheep 
After cleaning and antiseptic treatment (A), fat tissue is 
collected from subcutaneous, highly vascularized subscapular 
regions (B), and transported to the lab for immediate stem cell 
isolation (C) before the wound is closed and treated with local 
antiseptic (D). 
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PGG as in section 4.2.4 (later trials also utilized RapidGlut as in section 4.2.5), and 
neutralized for 18-24 hours in DMEM with 50% FBS and 1% Antibiotics/Antimycotics 
at 37°C. 
9.2.3 Stem Cell Seeding 
Stem cells were isolated from sheep and cultured as described above. Each primary 
source of cells was tracked and a single source of cells was used to seed valve scaffolds 
internally with 4-6 million cells per cusp as in section 5.2.5. The remaining cells from the 
culturing were is suspension, but the valve position was not controlled during rotation 
and pausing.  
9.2.4 Valve Conditioning and Preparation for Implantation 
After seeding, the valves were conditioned further in the rotating chambers by 
simple rotation in the incubator. Media was changed every two days until implantation. 
Each valve was tracked for final implantation into the same sheep from which the cells 
came for an autologous tissue engineered implant. 
Before implantation, conduits of decellularized bovine pericardium were attached 
to the proximal and distal segments of the valve root by a continuous suture (Figure 9-2A 
& B). This created a pipeline for the valve that will be intercalated between implant 
locations for routing of the host circulation. 
9.2.5 Surgical Procedure: Right Ventricle to Pulmonary Artery Conduit Implant 
Juvenile male sheep (5-6 months, 35-40 kg) are chosen for these studies because 
of several benefits including growing in size, similar anatomy and hemodynamic 
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parameters to young adults, and 
prior testing of heart vavle 
bioprostheses degeneration and 
calcification.[179] Animals were 
obtained from the local Animal 
Research Station and the sheep 
were housed under optimal 
conditions and monitored pre and 
post-operatory for general health, 
food intake, behavior, and blood 
tests.  
Animal implantation 
protocols were approved by the 
Institutional Review Board of the 
University of Medicine and 
Pharmacy of Târgu Mureş. The shunting procedure (Figure 9-2C&D) involves attaching 
pericardial tubes to each side of the valve (Figure 9-2A&B) then attaching those tubes to 
their respective portions of the right ventricle or pulmonary artery. Animals were set 
under general anesthesia with controlled ventilation and continuous monitoring of ECG, 
arterial pressure, pulse-ox, and temperature.  Surgical procedure generally followed the 
steps here: 
1. Access via left thoracotomy at the level of the 4th intercostal space. 
2. Incision of the parietal pleura and pericardium.  
 
Figure 9-2: Tissue engineered valve preparation, 
implantation, and follow up 
Pericardium tubes are attached to the valve (A&B) before 
implanting the conduit between the right ventricle and 
pulmonary artery (C-D). Postoperative housing is indoors  (F) 
before longer term outdoor housing. (F) Echocardiogram and 
other methods are used for follow up. 
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3. Lateral clamping of the right ventricle followed by a 3 cm long 
ventriculotomy.  
4. The proximal end of the valved conduit was anastomosed to the ventricle 
at this level using a continuous suture (Surjet with Prolene 5.0), 
strengthened by Teflon pledgets where needed.  
5. The pulmonary trunk was then clamped and the distal end of the valved 
conduit was sutured to the pulmonary trunk with same suturing method. 
6. After declamping, the pulmonary trunk was ligated shut at 1-2 cm above 
the level of the pulmonary valve.  
7. After hemostasis and checking sutures and conduit for leaks, the 
pericardium and pleura were left open to prevent tamponade.  
8. Finally, cavities were drained and the thoracic cavity was closed with 
Dexon 2.0. Closing  was in layers and isolated sutures at the tegument. 
9.2.6 Postoperative Care 
Following surgery, the sheep are temporarily placed in indoor monitoring 
facilities (Figure 9-2E) before being released to their outdoor living spaces until explant 
and analysis. Animals are cared for by standard techniques concerning monitoring, 
supervision, pain killer medication, X-ray monitoring of the chest, laboratory tests and 
food, with the consultation of a veterinarian, surgeon, anesthesiologist and cardiologist. 
Animals will be monitored post-op for respiration (frequency, thoracic X-ray, blood 
gases), cardiac frequency, hydration status, pH equilibrium, nutrition, hematology 
(hemoglobin, hematocrit and electrolytes). Sheep will be sacrificed at 6 months (n=6) and 
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12 months (n=6). At explanation, valves will be analyzed for morphology and function. 
Those future studies will analyze these valves at the macroscopic and microscopic level 
for calcification, necrosis, structural damage, cell infiltration, and cell retention. 
9.3 Results and Discussion 
9.3.1 Scaffold Preparation 
Aortic valves were harvested from pigs of various ages and weights to assess the 
anatomical details of the aortic valve (size, diameter, and position) that best corresponds 
to implantation in sheep hearts in the pulmonary position. The optimum weight was 
identified at 45-50 kg to obtain an aortic valve corresponding to the size of the sheep 
pulmonary tract. Additional modifications to the research protocol were necessary to 
accommodate the surgical setting. One such change has been the method of valve cleaning 
and mounting during decellularization to allow pericardial tubes to attach to the valve. 
The resultant conduit is necessary for the current placement of the valves and gives 
relevant information about the ability to suture the resulting valve root scaffold. 
9.3.2 Preliminary Sheep Results 
Progress has been made toward testing a revitalized valve root in an ovine right 
ventricle to pulmonary artery shunt model. Three surgeries have been performed with 
glutaraldehyde treated valves to increase familiarity with the surgical procedure before a 
tissue-engineered valve is utilized. The first resulted in animal death due to anesthesia 
difficulties. The animals survived both the second and third procedures and operating 
time decreased for each case. 
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In all, at least 25 surgeries have been performed and they are still ongoing. More 
recent trials utilizing tissue-engineered valves have had varied success. Surgical 
procedures are still being adjusted to meet the needs of the sheep. Initial trials with valves 
crosslinked only with PGG indicated that the valves were deteriorating more rapidly than 
expected. This has also led to the modification of our research protocols as seen in the 
addition of RapidGlut crosslinking treatment to later valve trials. 
Overall, the implantation of tissue-engineered valve implants seeded with 
autologous stem cells is one of the first such trials being performed in large animals. As 
the teams become more familiar with the procedures and modifications are made to 
improve outcomes, the advancement of a clinically relevant product will take great strides. 
The knowledge gained by these studies will contribute important information for a 
commercial valve replacement product. 
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PART 4: CONCLUSIONS AND REFLECTIONS 
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CHAPTER 10: DISCUSSION, CONCLUSIONS, AND FUTURE 
WORK 
10.1 Conclusions of Research and Recommendations 
The advance of heart valve replacements is moving in the direction of tissue-
engineered devices. This research has shown how core devices are a vital part to 
developing and commercializing valve replacements. This research has also served to 
progress the field of tissue-engineered heart valves forward by means of the novel devices 
as well as scientific findings. 
10.1.1 Valve Holding Device 
A tool to handle a scaffold for a tissue-engineered product is integral to the many 
components and processes used for developing those products. Without appropriate 
handling, the scaffold could be damaged or even unable to transition between the various 
treatments involved in developing these products. The valve holder developed through 
this research provides an excellent hold on the tissue during assembly and use, provides 
a reliable seal around the tissue in all processes, and is easy to use with many versatile 
applications. 
Recommendations 
• The distal root stabilizer currently utilizes sutures to hold the root up during 
bioreactor functioning. This method is very versatile, but can also be time consuming, 
even with the relatively few sutures needed. A means of quickly attaching the distal 
aortic root to the stand and stabilizer would prevent the valve and cells from drying 
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out during valve preparation and would also greatly decrease the time necessary to 
prepare a valve for bioreactor functioning. Initial designs and prototypes have utilized 
an internal retaining spring that can be applied with plier tools. Concave grooves in 
the upper ring or stand itself would help seat the retaining spring and prevent 
dislocation during valve functioning. 
• Nonmetal materials should be sourced for the potential use of the valve in an MRI 
device or for disposability. However, care should be taken to ensure chemical 
compatibility with all decellularization, crosslinking, and culturing solutions. An inert 
ceramic or plastic that would provide adequate strength would serve well.  
10.1.2 Perfusion Decellularization Method and Device 
Immersion decellularization techniques are inadequate for whole-root 
decellularization. The thick, elastin-rich areas require a more robust method of 
decellularization. The perfusion system designed for this research is the first of its kind 
for heart valve roots. Its capabilities to treat individual components of the valve root with 
independent conditions allows it to be rigorous enough to decellularize the aortic root 
while gentle enough not to destroy the cusps. Any scaffold to be implanted must be free 
of all animal cells and the valve root is no exception. Each area of cusp, sinus, aorta, and 
muscle must be free of native cells. However, we are currently unaware of the effects of 
this process on the mechanical durability of the valve root components. 
Recommendations 
• The current device uses nearly 4 liters of fluid for each media change. While an 
adequate fluid-to-tissue ratio is necessary, this system is excessive and potentially 
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wasteful. A main chamber that reduces the area around the valves should be built. 
This chamber would essentially be contoured to the shape of the valve roots while 
allowing adequate circulation. Alternatively, individual chambers or a reduced 
number of valves could be processed with the above in mind. 
• Future versions of the system should be manufactured with slight variances to the 
layers and materials to ease assembly and reduce components. For instance, the 
central holding plate (layer 3) can be combined with the main chamber portion (layer 
4) and the material should be a rigid plastic such as Delrin. Additionally, by thickening 
the other layer that holds the valves (layer 2), a dampening section can be dug out of 
that layer along one side. That dampening section would be full of air while not 
increasing the volume of solution used to eliminate the dampening bottle. 
• Individual chambers could also allow the valves to be crosslinked inside the system 
without the need for packing the cusps with cotton balls. By reversing the flow, a 
slight pressure gradient can be created to crosslink the valves in the naturally position. 
• Upgrades to the software should include connecting the peristaltic pump to the 
computer so it can be monitored and controlled via a feedback loop by the software. 
The pump includes that capability and software, but LabView programming and 
potentially another piece of hardware will be necessary to provide the interface. 
• Mechanical evaluation should be performed on the valve roots. Compliance data can 
be obtained through the clear wall of the system by inserting a ruler into the main 
chamber of the decellularization system and diameters measured at varying pressures 
using the existing setup. Biaxial or uniaxial testing should be performed on the aortic 
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root to determine if excessive damage is being done to the elastic properties and 
strength of the native tissue. 
• The decellularization protocol may also be optimized. A shorter time for various steps 
of the process could reduce the overall time required to achieve full decellularization. 
10.1.3 Cell Seeding by Injection and Rotational Seeding and Conditioning Device 
Cell seeding by injection is much more effective than relying on cellular migration, 
but it is not the optimal means of revitalizing a tissue because of its damaging and 
inconsistent aspects. It is also technically difficult and reproducibility is user-dependent. 
The rotational seeding device works well, but requires routine user input and observance. 
The optimal methods of achieving a confluent layer of cells on all surfaces of the valve 
root are also deficient. Current methods achieve the goals, but may be using too many 
cells and supplies. 
Recommendations 
• A new method of recellularizing the internal portions of valve cusps is necessary. This 
method should provide more uniform coverage and result in less tissue damage. Other 
methods currently being investigated in the lab are promising. Details are 
purposefully omitted to maintain confidentiality. 
• External seeding could be optimized by clamping the distal aorta with existing 
equipment and sealing the inflow with o-rings as done in other places. This would 
localize the cell seeding solution within the valve lumen to allow a much higher 
concentration of cells to attach to the valve, resulting in higher seeding densities with 
fewer cells used. Care should be taken to ensure that the devices fit inside the chamber 
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and that the external surfaces of the root maintain moisture, although concern for the 
second point is minimal given the small air volume in the system. 
• Seeding protocols should also be optimized. A combination of method 2 and 3 should 
be compared with method 3 alone to determine the most efficient means of fully 
recellularizing all of the aortic root surfaces. Reducing the number of cells or 
repetitions could also yield results that are just as effective. 
• Improvements to the frame and software should allow monitoring of rotation angles 
to enable pausing at specified angles. Automated control of the speed of the shaker 
plate should also be incorporated into the controls of the system. The seeding method 
and regimen should be entered into LabView in “spreadsheet style” instead of “on/off” 
style. These upgrades will allow complete customization of rotational scenarios. Bob 
Teague is currently working on automated control of the shaker plate and Charlie 
McDonald is currently working on spreadsheet style of entering data into LabView. 
• Gas exchange inside the seeding chambers needs immense improvement. Securing the 
lids and flowing appropriately mixed gases through the ports and sterile filters by 
pressure or vacuum would improve this, but must be compatible with the rotation of 
the system. Preliminary designs have been discussed that involve routing a 
pressure/vacuum line through the axle of the chamber holder and incorporating a gas 
line inside the holding plate that would protrude next to each chamber position. 
Hydrophobic sterile filters could be attached to the system to allow gas movement 
and timing could be aligned appropriately with the placement of the gasses near the 
ports if necessary. 
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10.1.4 Fourth Edition Heart Valve Bioreactor Device 
The fourth edition of the bioreactor is a sophisticated system that provides 
capabilities not seen in most other systems in the research or commercially available. In 
addition, its small footprint, relatively simple assembly, and ability to fine-tune make it a 
valuable component to the laboratory’s research. The current edition is nearing 
completion to provide pulmonic or aortic conditions of flow, pressure, and viscosity, but 
additional improvements and modifications are necessary to reach those conditions or 
improve ease of use. 
Recommendations 
• The first objective should be to finalize the size and shape of the bottle used as an 
aortic compliance chamber. The means of providing an internal balloon membrane 
should also be finalized. A component of this chamber will include an input pressure 
regulator and filter to control the internal air pressure of the chamber without 
opening it to non-sterile air or using excessive amounts of fluid. 
• The quick-connect latches of the quick-connect bioreactor fittings should be adjusted 
to function with the 3-D printed materials. Although the o-rings provide a reliable 
seal, there is potential risk that the fittings could slide out of the main bioreactor 
chamber without the latches in place. External design services of the inventors can be 
sourced for this task. 
• Additional tools should be developed to assist in the assembly of the bioreactor. These 
include a membrane cutting and placement tool, a camera holder, a pressure 
transducer holder, and any required supports for the modules. 
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• As with all future devices made of a clear plastic, future versions of the chambers 
should be machined out of polysulfone rather than acrylic. This material is semi-
transparent and can be sterilized by autoclave. 
• A manifold system should be developed inside the incubator that allows the small 
through-wall port of the incubator to provide enough real-estate to service four or 
more bioreactors within the same incubator. 
• A more aseptic method of adding media to the bioreactor should be developed. 
Current methods work well, but have risks of contamination. If media could be 
delivered by attaching bagged media to the bioreactor through one of the needleless 
ports and applying a small vacuum force to the main chambers, the media could be 
added very quickly without drying out the valve sample. 
• Studies should be performed to evaluate the cytotoxicity of all printed or other 
materials on cells. While no effects have been seen, validation of the appropriate choice 
of material should be performed. 
• Additional modules should be developed to provide capabilities to test mitral valves 
and transcatheter implantations. The validation an in vitro system for creating 
diseased states and testing drug treatments is still a possible use for the bioreactor 
systems that should not be abandoned. 
• Living aortic valves should be collected from the slaughterhouse and mounted into 
the bioreactor. The bioreactor should be run for at least four weeks to demonstrate 
its capabilities to provide a healthy, native environment to heart valves. This scientific 
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evidence will be the bedrock to support claims that this bioreactor system can 
adequately prepare a tissue-engineered valve for implantation. 
• Additional case studies should be performed to widen the applicable uses of the heart 
valve bioreactor. From providing physiologically relevant flow to enabling another 
technology, the bioreactor system is truly a platform system that can be applied in 
many areas. 
10.1.5 Tissue-Engineered Heart Valve Conditioning and Animal Implants 
Progressive adaptation regimens to allow seeded cells to remain attached to 
scaffold surfaces are vital to a valve’s self-modulation of the repair of the cusps. Included 
studies have shown that this progressive adaptation is necessary for cell retention and a 
select few trials have been performed to develop the appropriate protocol. Factors of other 
systems (gas exchange in the seeding chambers, etc) have prevented further study herein.  
Autologous stem cell-seeded scaffold being implanted into large animals is new in 
this field. Many hurdles have been faced in translating this research project into clinical 
applications, but the animal studies have revealed very important aspects of our research 
that must continuously be adapted to fit the need. 
Recommendations 
• Trials should be performed to determine the necessary pre-conditioning regimens for 
adequate cell retention after reaching pulmonary and aortic conditions. A period of 
gentle conditioning followed by more rigorous conditioning in the seeding 
chambers/rotating frame before transferring the valves to the bioreactor has shown 
great promise, but needs to be optimized and validated. 
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• Cell staining (such as for focal adhesion kinases, FAK) to observe the cell-cell 
interactions as well as the cell-matrix interactions should be performed to evaluate 
cellular attachment to the scaffolds. 
• Overall, fewer cells should be used to revitalize the scaffold. Current methods employ 
more cells than reasonably collected from a patient without in vitro culturing.  
• One ongoing question is if externally seeded cells are necessary for these implants. 
After pre-conditioning regimens are developed to retain cells at physiological 
conditions, trials should be performed using externally seeded valves. 
10.2 Final Discussion of Progress 
The field of heart valve devices has come far since the advent of mechanical valves 
in the middle of last century. There have been improved hinge designs, alternative 
bioprosthetic materials, minimally invasive implantation procedures, and even animal 
trials with decellularized or tissue-engineered valve replacements. As our understanding 
of this complex and astounding structure increases, we will continue to develop better 
replacement products that perform closer and closer to the way the valve was designed 
to work in a healthy person. There is much work to be done, but we stand on a hill of 
giants gone already deeply entrenched and dedicated to its progress. We look forward to 
where our future innovations, learning, worldwide need, and even funding will lead us. 
There is no doubt that a robust tissue-engineering replacement heart valve will soon be 
available to improve lives all around the world. 
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